<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Neurosci</journal-id><journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1662-4548</issn><issn pub-type="epub">1662-453X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5732983</article-id><article-id pub-id-type="doi">10.3389/fnins.2017.00663</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neuroscience</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>And Then There Was Light: Perspectives of Optogenetics for Deep Brain Stimulation and Neuromodulation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Delbeke</surname><given-names>Jean</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/168394/overview"/></contrib><contrib contrib-type="author"><name><surname>Hoffman</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/434133/overview"/></contrib><contrib contrib-type="author"><name><surname>Mols</surname><given-names>Katrien</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Braeken</surname><given-names>Dries</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Prodanov</surname><given-names>Dimiter</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/2068/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>LCEN3, Department of Neurology, Institute of Neuroscience, Ghent University</institution>, <addr-line>Ghent</addr-line>, <country>Belgium</country></aff><aff id="aff2"><sup>2</sup><institution>Neuroscience Research Flanders</institution>, <addr-line>Leuven</addr-line>, <country>Belgium</country></aff><aff id="aff3"><sup>3</sup><institution>Life Science and Imaging</institution>, <addr-line>Imec, Leuven</addr-line>, <country>Belgium</country></aff><aff id="aff4"><sup>4</sup><institution>Environment, Health and Safety</institution>, <addr-line>Imec, Leuven</addr-line>, <country>Belgium</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Diana Deca, Norwegian University of Science and Technology, Norway</p></fn><fn fn-type="edited-by"><p>Reviewed by: Stefano Vassanelli, Universit&#x000e0; degli Studi di Padova, Italy; Anton Ilango, University of Magdeburg, Germany</p></fn><corresp id="fn001">*Correspondence: Dimiter Prodanov <email xlink:type="simple">dimiterpp@gmail.com</email>; <email xlink:type="simple">Dimiter.Prodanov@imec.be</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Neural Technology, a section of the journal Frontiers in Neuroscience</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>11</volume><elocation-id>663</elocation-id><history><date date-type="received"><day>31</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Delbeke, Hoffman, Mols, Braeken and Prodanov.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Delbeke, Hoffman, Mols, Braeken and Prodanov</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Deep Brain Stimulation (DBS) has evolved into a well-accepted add-on treatment for patients with severe Parkinsons disease as well as for other chronic neurological conditions. The focal action of electrical stimulation can yield better responses and it exposes the patient to fewer side effects compared to pharmaceuticals distributed throughout the body toward the brain. On the other hand, the current practice of DBS is hampered by the relatively coarse level of neuromodulation achieved. Optogenetics, in contrast, offers the perspective of much more selective actions on the various physiological structures, provided that the stimulated cells are rendered sensitive to the action of light. Optogenetics has experienced tremendous progress since its first <italic>in vivo</italic> applications about 10 years ago. Recent advancements of viral vector technology for gene transfer substantially reduce vector-associated cytotoxicity and immune responses. This brings about the possibility to transfer this technology into the clinic as a possible alternative to DBS and neuromodulation. New paths could be opened toward a rich panel of clinical applications. Some technical issues still limit the long term use in humans but realistic perspectives quickly emerge. Despite a rapid accumulation of observations about patho-physiological mechanisms, it is still mostly serendipity and empiric adjustments that dictate clinical practice while more efficient logically designed interventions remain rather exceptional. Interestingly, it is also very much the neuro technology developed around optogenetics that offers the most promising tools to fill in the existing knowledge gaps about brain function in health and disease. The present review examines Parkinson's disease and refractory epilepsy as use cases for possible optogenetic stimulation therapies.</p></abstract><kwd-group><kwd>viral vectors</kwd><kwd>biosafety</kwd><kwd>optogoenetics</kwd><kwd>deep brain stimulation</kwd><kwd>neural prosthesis</kwd><kwd>Parkinson's disease</kwd><kwd>epilepsy</kwd><kwd>neuromodulation</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Fonds Wetenschappelijk Onderzoek<named-content content-type="fundref-id">10.13039/501100003130</named-content></funding-source><award-id rid="cn001">G.0C75.13N</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="7"/><equation-count count="0"/><ref-count count="242"/><page-count count="20"/><word-count count="18831"/></counts></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Therapeutic use of electricity dates back to antiquity. Deep Brain Stimulation (DBS) originates from the advancement of the sterotactic surgical techniques, which allowed the transition from lesional to stimulating technique of the deep nuclei of the brain for therapeutic purposes. Readers are directed to the historical survey by Sironi (<xref rid="B193" ref-type="bibr">2011</xref>) for further information. At present, DBS is an established therapeutic option for a variety of neurological diseases, such as Parkinson's disease (Beitz, <xref rid="B9" ref-type="bibr">2014</xref>), essential tremor (B&#x000f8;rretzen et al., <xref rid="B23" ref-type="bibr">2014</xref>), dystonia (Lumsden et al., <xref rid="B121" ref-type="bibr">2013</xref>) and obsessive-compulsive disorder (Greenberg et al., <xref rid="B66" ref-type="bibr">2010</xref>). Closely related to DBS is another electrically-based therapy called neuromodulation. Applied to peripheral (Bhadra and Peckham, <xref rid="B15" ref-type="bibr">1997</xref>) or cranial nerves (Ben Menachem and French, <xref rid="B10" ref-type="bibr">2005</xref>), the spinal cord (Francois et al., <xref rid="B58" ref-type="bibr">2017</xref>), the cochlea (Rajguru et al., <xref rid="B170" ref-type="bibr">2010</xref>), the retina (Nirenberg and Pandarinath, <xref rid="B154" ref-type="bibr">2012</xref>) as well as to the brain (Rossi et al., <xref rid="B176" ref-type="bibr">2016</xref>). This technique is used to treat many conditions and for theses indications it can already be classified as a well&#x02013;accepted clinical treatment.</p><p>Using light to control neural activity holds promises for much improvement since genetics has developed the tools to make specific structures light sensitive. Under appropriate conditions, the action potential, an all-or-nothing phenomenon seen as the neural information carrier, can be triggered by light<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref> as well as by electrical stimulation. The use of light for brain stimulation is a disruptive advancement for both neuromodulation and DBS. This entirely different stimulation modality is brought about by a critical mass of innovations in molecular genetics and virology. Towne and Thompson (<xref rid="B209" ref-type="bibr">2016</xref>) define optogenetics as &#x0201c;<italic>a method that uses light to control cells in living tissue, typically neurons, that have been modified to express light-sensitive ion channels and pumps</italic>.&#x0201d; The foundation of optogenetics is a combination of genetic manipulations, which renders identified populations of neurons sensitive to the action of light. Development of optogentics would not have been possible without the research conducted on light sensitive algae by Nagel et al. (<xref rid="B146" ref-type="bibr">2002</xref>). The optogenetic approach was further championed by Deisseroth, Boyden, Miesenb&#x000f6;ck and Haegemann and has led to an explosive proliferation of different variants of light-sensitive ion channels, G protein-coupled receptors and ion pumps (Boyden et al., <xref rid="B21" ref-type="bibr">2005</xref>; Lima and Miesenb&#x000f6;ck, <xref rid="B111" ref-type="bibr">2005</xref>). In the last 8 years, optogenetics has become an established research tool for studying brain function. In fact, results obtained so far indicate that optogenetics provides unprecedented control and granularity of stimulation (Boyden et al., <xref rid="B21" ref-type="bibr">2005</xref>).</p><p>So far optogenetics has been used predominantly as a research tool in animals, however applications in humans are not deemed impossible. There are patents in this direction filed by Boyden et al. (<xref rid="B20" ref-type="bibr">2012</xref>) and Deisseroth et al. (<xref rid="B45" ref-type="bibr">2015</xref>, <xref rid="B44" ref-type="bibr">2016</xref>) to name but a few. Orphan status was recently granted to a viral-vector-based optogenetic therapy (from the company RetroSense Therapeutics) for retinitis pigmentosa, and initial clinical trials to evaluate safety are underway (Yun and Kwok, <xref rid="B237" ref-type="bibr">2017</xref>). Microbial opsins do not possess toxic properties <italic>per se</italic>, therefore, applications in humans appear feasible from this perspective. Safety of the resulting therapy is, therefore, expected to depend mostly on the long-term properties of the genetic vector together with the safety of the implant. As such, safety aspects of the implants can be optimized to a sufficient extent based on the abundant experience with various types of DBS and other electrodes applied to neuromodulation and neuroprosthetics.</p><p>In this review, we will focus on <italic>Parkinsons disease</italic> with its local degenerative changes inducing a profound motor control disorder and <italic>refractory epilepsy</italic> as an example of a more distributed network disease, although often triggered by a focal lesion. Parkinson's disease and epilepsy can be taken ins some sense as extreme cases, since the acceptance criteria for eventual optogentics therapies can be very different. Both diseases get increasing attention in the literature as potential applications (see Figure <xref ref-type="fig" rid="F1">1</xref>). In Parkinson's disease, a loss of dopaminergic neurons leads to the loss of inhibitory gamma aminobutyric acid-sensitive input to the <italic>subthalamic nucleus</italic>. While there is no generally-accepted definition of refractory epilepsy (French, <xref rid="B59" ref-type="bibr">2006</xref>), this term generally designates a spectrum of pathologies characterized by recurrent seizures, which respond poorly or not at all to conventional medicines. Clinical evidence indicates that some of these patients will actually benefit to some extent from add-on treatments while maintaining the antiepileptic drugs unchanged. At present, the main treatment options for refractory epilepsy are brain surgery (i.e., temporal lobe localized neocortical resection) and vagus nerve stimulation, which is a variety of neuromodulation (review in Cox et al., <xref rid="B41" ref-type="bibr">2014</xref>). More recently, researchers started to explore possible optogenetic approaches as well (Wykes et al., <xref rid="B228" ref-type="bibr">2016</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Articles published for the period 2005&#x02013;2015. Articles published in Medline for the period 2005&#x02013;2015; keywords: deep brain stimulation and optogenetics, epilepsy and optogenetics. Data were analyzed using the Medline trends tool (Corlan, <xref rid="B39" ref-type="bibr">2004</xref>).</p></caption><graphic xlink:href="fnins-11-00663-g0001"/></fig><p>Neuromodulation, defined as as &#x0201c;the alteration&#x02014;or modulation&#x02014;of nerve activity by delivering electrical or pharmaceutical agents directly to a target area<xref ref-type="fn" rid="fn0002"><sup>2</sup></xref>,&#x0201d; will be considered in some alternative realizations. At present, clinically accepted neuromodulation and DBS therapies are still open-loop. However, the importance of simultaneous stimulation and recording from the neural tissue should not be overlooked. There are several reasons for this, including the possibility to better titrate the therapy and also to ensure appropriate timing of stimuli according to the state of the neural target. The sensing branches can control the stimulation regimen, adapt it to the state and needs of the neural system itself (Krook-Magnuson et al., <xref rid="B102" ref-type="bibr">2013</xref>) or lock the activation under a given safety limit. In &#x0201c;controlled therapy,&#x0201d; sensing is essential to use physiological signals for triggering the therapeutic device (Zrenner et al., <xref rid="B242" ref-type="bibr">2016</xref>). This is particularly important for epilepsy (Sorokin et al., <xref rid="B197" ref-type="bibr">2017</xref>). Contrarily to electrical stimulation, optogenetics has the great advantage not to interfere with the recording of the tiny neural electrical signals. Already existing systems combine optogenetic activation with electric feedback loops (Emiliani et al., <xref rid="B53" ref-type="bibr">2015</xref>; Yang et al., <xref rid="B232" ref-type="bibr">2016</xref>).</p><p>The present review will not consider issues related to the optimizations and efficiency of light-sensitive ion channels and ion pumps, where there is a steady progress. Interested readers are directed to recent overviews by Wietek and Prigge (<xref rid="B224" ref-type="bibr">2016</xref>) and Deisseroth (<xref rid="B43" ref-type="bibr">2015</xref>) on opsin technology. Instead, we will address clearly unresolved issues, among which the biosafety of viral vectors.</p></sec><sec id="s2"><title>2. A note on the mechanisms of DBS</title><p>The clinical use of DBS is mostly empirical, based on decades of experience with surgical ablative therapies. It must be emphasized that historically the major findings in both DBS and neuromodulation fields rest on serendipity and empirical observations because fundamental knowledge about the brain is still far from allowing complete understanding of patho-physiology as would be required to design optimal therapies. There are numerous historical examples ranging from the Renaissance era observations of Galvani to mid twentieth (Sironi, <xref rid="B193" ref-type="bibr">2011</xref>) discovery of positive reinforcement by electrical stimulation (Olds and Milner, <xref rid="B158" ref-type="bibr">1954</xref>).</p><p>It is an accepted clinical observation that both DBS (expected to stimulate the immediate target) and a lesion (silencing the same target) do alleviate symptoms of motor disorders despite their apparently opposite actions. In contrast, local stimulation leads to neuronal excitation and DBS affects symptoms on varying timescales and involving structures at different levels of organization.</p><p>To the present date, the mechanisms underlying the therapeutic effects of DBS remain insufficiently understood to predict applications in new therapeutic domain (recent reviews in Chiken and Nambu, <xref rid="B31" ref-type="bibr">2016</xref>; McIntyre and Anderson, <xref rid="B135" ref-type="bibr">2016</xref>). Even after 25 years of continuous application and research the circuit-level mechanisms of DBS remain elusive. While early hypotheses focused on the analogy between effects of ablation and those of stimulation, recent hypotheses on the mechanisms of DBS have shifted toward network-based theories, forgoing a direct link between lesioning and stimulation, and focusing instead on stimulation-induced disruption of pathological network oscillations (Johnson et al., <xref rid="B87" ref-type="bibr">2008</xref>; McIntyre and Hahn, <xref rid="B136" ref-type="bibr">2010</xref>; McIntyre and Anderson, <xref rid="B135" ref-type="bibr">2016</xref>). It can even be conceived that DBS interferes with certain communication channels of the brain and thus disrupts pathological patterns of activity. The simplistic view of an imbalance between excitatory and inhibitory pathways must be complemented to take into account phenomena, such as retrograde activation, synchronicity in specific cells, interference with spontaneous (rhythmic) activity (Tass et al., <xref rid="B206" ref-type="bibr">2012</xref>) and cell type activated (Witt et al., <xref rid="B225" ref-type="bibr">2013</xref>). The role of astrocytes is well recognized but still difficult to integrate in our models (Kovacs and Pal, <xref rid="B98" ref-type="bibr">2017</xref>). More and more, it is the limitations in physiological knowledge that impedes an optimal exploitation of techniques, such as optogenetics in the clinical world (Karas et al., <xref rid="B91" ref-type="bibr">2013</xref>). On the other hand, optogenetics offers the new tools needed to further explore the brain and that is indeed what most application papers are about today (Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref>).</p></sec><sec id="s3"><title>3. A multidisciplinary context</title><p>In this review, we argue that a number of independent technologies must converge to implement optogenetics as an effective therapy. We discern six major steps, which will be discussed in more details in subsequent sections:</p><list list-type="order"><list-item><p>The recombinant genetic technology required to develop a gene encoding the desired photosensitive ion-channel or any other desired protein.</p></list-item><list-item><p>The transfection technology required to introduce the new gene into target cells.</p></list-item><list-item><p>The genomic know-how needed to assure that the newly inserted gene gets activated.</p></list-item><list-item><p>The stereotaxic surgery which can play an essential role in the transfection by injecting agents into the appropriate target and by implanting the light stimulation device as required.</p></list-item><list-item><p>The engineering know-how of designing and producing an implantable optical stimulator is also significant and it represents a clearly distinct field of expertise, itself subdivided in several disciplines.</p></list-item><list-item><p>The clinical application of the optogenetic system involves the clinical and physiological knowledge, which is necessary to personalize parameter settings and optimize the clinical protocol.</p></list-item></list><p>Steps 1&#x02013;3 are specific to optogenetics, while 4&#x02013;6 are more generic.</p><p>It should be stressed that each technological domain listed above can also develop some forms of treatment on its own. Gene therapy (Collins and Thrasher, <xref rid="B37" ref-type="bibr">2015</xref>) for example has been attempted long before optogenetics was even conceived. Direct insertion of functional proteins (Lin et al., <xref rid="B114" ref-type="bibr">2017</xref>) or optic control of these proteins (Brechun et al., <xref rid="B22" ref-type="bibr">2016</xref>) have also been suggested. The observation of Parkinson symptoms improvement after a localized brain lesion (Dubois et al., <xref rid="B50" ref-type="bibr">1986</xref>) inspired the use of stereotactic brain surgery in patients. This old technique of stereotactic surgery (Lehman and Augustine, <xref rid="B106" ref-type="bibr">2013</xref>) is facing a recent revival through the availability of new technological improvements (Starr et al., <xref rid="B199" ref-type="bibr">1998</xref>). The effect of electrical stimulation used for anatomical guidance during ablative surgery finally resulted in the replacement of the brain lesion by a reversible DBS system (Benabid et al., <xref rid="B11" ref-type="bibr">1996</xref>) and brain stimulators for human clinical use are now common. Hitherto, history of therapeutic progresses has very much resulted from serendipity and empirical findings rather than physiological knowledge based design. In addition to the need for more basic science, multi-disciplinarity characterizes modern brain therapies (Rossi et al., <xref rid="B176" ref-type="bibr">2016</xref>). Genetics, pharmacology, photo-chemistry, cellular biology, surgery, neuroscience, optics, electronics, material science and various medical clinical specialties, to name but the most evident domains will have to collaborate. Unfortunately, there is often a significant tension between the required scientific freedom to transgress discipline boundaries on one hand and the institutional organization for teaching and employment of academics on the other hand (Osborne, <xref rid="B159" ref-type="bibr">2015</xref>). Today, this constraint still represents a major challenge in a field, such as optogenetics, creating an urgent need for experts with overlapping skills and knowledge and, perhaps further thoughts about transdisciplinarity (Mittelstrass, <xref rid="B139" ref-type="bibr">2011</xref>).</p></sec><sec id="s4"><title>4. Light vs. electrical current</title><sec><title>4.1. Electrical stimulation for DBS</title><p>Electrical activation of voltage sensitive channels is controlled by the voltage difference across the cell membrane, which drives ion currents. Sodium transient channel opening is activated by a membrane depolarization, thus by an inward current through the neural membrane. Other voltage sensitive channels have different responses to voltage and are more or less specific to other ions. The seven nanometer-thin lipid cell membranes form a relatively large electrical capacitance, requiring current to flow for some time before the activation threshold voltage can be reached. This explains the main part of the strength-duration relationship between activation threshold and stimulation pulse duration (Bostock, <xref rid="B19" ref-type="bibr">1983</xref>). Assuming that the membrane conductivity is negligible compared to the extracellular space, Kirchoff's laws indicate that the current through the membrane is roughly proportional to the Laplacian (second spatial derivative) of the voltage along the membrane and a constant resistive factor. In peripheral nerves, the differential equations can be approximated by difference equations spanning over anatomically-defined distances determined by the nodes of Ranvier. These are considered as the only active spots along myelinated axons (Stephanova and Bostock, <xref rid="B201" ref-type="bibr">1995</xref>). More complex volume conductor models have been developed for complex dendritic trees of the neurons in the central nervous system (Ranck, <xref rid="B171" ref-type="bibr">1975</xref>). Not all identical neural structures are activated simultaneously but their recruitment depends on the anatomical position of the stimulation electrodes, the electrical properties (conductivity) of the intervening tissue and the anatomy of the neural structure itself. Variation of the waveform's shape can be used to improve the selectivity of stimulation in the peripheral nervous system by recruiting different groups of fibers. Readers are referred to the recent review of Grill et al. (<xref rid="B67" ref-type="bibr">2009</xref>) for update on the topic. Recent modeling studies point out some possibilities in the central nervous system in terms of neuromodulation by AC currents (Mahmud and Vassanelli, <xref rid="B123" ref-type="bibr">2016</xref>).</p><p>Magnetic stimulation can be compared to electrical stimulation in the sense that the extracellular current generated by a pair of electrodes is now replaced by an induced current by a varying magnetic flux (Silva et al., <xref rid="B191" ref-type="bibr">2007</xref>). In both cases, the extracellular current generates an extracellular potential field which induces the trans-membranous current. When that current has loaded the membrane capacitance up to a threshold potential, the voltage sensitive channels set up an all-or-nothing action potential.</p><p>Variables determining DBS outcome are the stimulation parameters and the positioning of the electrode. The stimulation parameters include the amplitude (current of voltage), frequency, and pulse width. These parameters play a role defining the volume of tissue activated (VTA) and in the therapeutic effectiveness of DBS (Butson et al., <xref rid="B25" ref-type="bibr">2007</xref>). Typical clinically effective parameters for monopolar DBS are presented in Table <xref ref-type="table" rid="T1">1</xref>.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Typical clinically effective stimulation parameters in DBS.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Voltage [V]</bold></th><th valign="top" align="center" colspan="2" rowspan="1"><bold>Pulse width [</bold><italic><bold>&#x003bc;s</bold></italic><bold>]</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1.3&#x02013;4.4</td><td valign="top" align="center" rowspan="1" colspan="1">60&#x02013;120</td><td valign="top" align="center" rowspan="1" colspan="1">130&#x02013;160</td><td valign="top" align="left" rowspan="1" colspan="1">Kuncel et al., <xref rid="B103" ref-type="bibr">2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2.2&#x02013;3.6</td><td valign="top" align="center" rowspan="1" colspan="1">60&#x02013;90</td><td valign="top" align="center" rowspan="1" colspan="1">130&#x02013;185</td><td valign="top" align="left" rowspan="1" colspan="1">Moro et al., <xref rid="B142" ref-type="bibr">2002</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1.0&#x02013;3.0</td><td valign="top" align="center" rowspan="1" colspan="1">60&#x02013;120</td><td valign="top" align="center" rowspan="1" colspan="1">130&#x02013;185</td><td valign="top" align="left" rowspan="1" colspan="1">O'Suilleabhain et al., <xref rid="B160" ref-type="bibr">2003</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1.0&#x02013;3.5</td><td valign="top" align="center" rowspan="1" colspan="1">60&#x02013;210</td><td valign="top" align="center" rowspan="1" colspan="1">100&#x02013;185</td><td valign="top" align="left" rowspan="1" colspan="1">Volkmann et al., <xref rid="B215" ref-type="bibr">2002</xref></td></tr></tbody></table><table-wrap-foot><p><italic>Typical monopolar DBS parameters used to treat patients can range from 1 to 4.4 V for the stimulation amplitude, 60 to 450 &#x003bc;s for the pulse width and from 90 to 185 Hz for the stimulation frequency</italic>.</p></table-wrap-foot></table-wrap><p>VTA in human subjects has been estimated in computational models (Maks et al., <xref rid="B125" ref-type="bibr">2009</xref>). The more complete versions use patient specific imaging data that enrich the models with anatomical information. They also incorporate electrical characteristics, such as impedance and anisotropy, of the different brain parts surrounding the electrode. The study by Maks et al. (<xref rid="B125" ref-type="bibr">2009</xref>), found volumes varying from 30 to 116 mm<sup>3</sup> with an average of 71 mm<sup>3</sup> (i.e., 5 mm diameter). The results from this study further suggest that smaller stimulation volumes in the subthalamic nucleus (STN) are better at alleviating Parkinson's symptoms. The model was experimentally verified indirectly by estimating the stimulation volume spreading into the <italic>capsula interna</italic> for different voltages and comparing this to muscle twitching of the arm or leg by patient stimulation of the <italic>corticospinal tract</italic> (Butson et al., <xref rid="B25" ref-type="bibr">2007</xref>). Other studies from this laboratory measured the voltage spread in the brain of a rhesus monkey and compared it to the one predicted by the model (Miocinovic et al., <xref rid="B138" ref-type="bibr">2009</xref>). The study found that the model accurately predicted the voltage distribution observed <italic>in vivo</italic>.</p></sec><sec><title>4.2. Light stimulation and opsins</title><p>Within the tissue, photons interact with biological matter via various processes, which can be broadly categorized into scattering and absorption. An accessible overview on current photonics medical applications is given in Yun and Kwok (<xref rid="B237" ref-type="bibr">2017</xref>). Light works in a different way upstream of the activation of the membrane ion channels. Here, it is the optical properties of light across the tissues that will determine the threshold and target selectivity. In the case of the well-studied ion channel ChR2, the blue light will cause all-<italic>trans</italic>-retinal to isomerize to 13-<italic>cis</italic>-retinal, and so a conformational change in the protein will open the ChR2 channel to allow cations to enter and depolarize the cell. Switching the light off again will cause the 13-<italic>cis</italic>-retinal to revert to its original state closing the channel and thereby repolarizing the cell. These ion channels do not close spontaneously (as the voltage sensitive sodium channel does) and the resulting response dynamics is in the first place dependent on the opto-chemical properties and density of the photosensitive channels. The strength-duration relationship or the significance of the stimulus duration is now entirely different despite still linked to electrical charges on the membrane capacitance. When open, these charges depolarize the membrane by providing a leakage current. Only then the membrane capacitance starts loading and the density of the available channels is thus much more a limiting factor. The strength-duration relationship still corresponds to a membrane capacitance being loaded, but no longer through the same current.</p><p>It should be noted that even if the stimulus does not produce an action potential, a membrane potential shift occurs, such that very long stimulus pulses will modulate spontaneous activity. New phenomena can thus be expected to occur (Grossman et al., <xref rid="B69" ref-type="bibr">2011</xref>). For example, on striatal brain slices, dopamine release (which is an effect pursued in treating Parkinson's disease) appears to be stable when electrically stimulated while a rundown effect is observed with optical stimulation (O'Neill et al., <xref rid="B156" ref-type="bibr">2017</xref>). Once the membrane depolarization voltage has reached the threshold value, however, the same voltage-controlled mechanism as described for electrical stimulation will launch a propagated action potential. Activation selectivity still depends on the geometry and intervening tissues. However, whereas electrical stimulation is controlled by the electrode position, the membrane ion channel distribution and roughly constant resistivity, here, source orientation, source optic features (color, polarization), optic characteristics of intervening tissues, channel density and opto-sensitivity, are the key parameters defining the threshold, selectivity and recruitment.</p><p>Selectivity also arises from the use of cell-specific promoters, which drives the expression of the protein in the cells. The opsin is placed downstream of a strong promoter such as synapsin, CMV or CAG. This will lead to strong expression of the opsin in almost all of the cells where the construct is present. Alternatively, one can opt to target cell-specific promoters such as alpha-calcium/calmodulin-dependent kinase II (&#x003b1;-CamKII), which is expressed in forebrain pyramidal neurons. Where electrical stimuli can in some conditions block the propagation of action potentials, similar effects are now obtained with infra-red pulses (Walsh et al., <xref rid="B216" ref-type="bibr">2016</xref>). Some opto-sensitive channels can work as cell silencers, which is not the same as the selective activation of inhibitory pathways, which both techniques could in principle achieve (Malyshev et al., <xref rid="B126" ref-type="bibr">2017</xref>). Through color selectivity, a single optic device could now selectively inhibit or activate the same cells.</p><p>Geometric or anatomical selectivity is in principle available to optic stimulation as well as to electrical micro-electrodes (McCreery et al., <xref rid="B133" ref-type="bibr">2006</xref>). Activating light oriented toward a specific points is a realistic goal in examples, such as the retinal prosthesis (Soltan et al., <xref rid="B196" ref-type="bibr">2017</xref>). Optical techniques are being developed that could achieve similar or better selectivity and parallelism than the electrical equivalent (McAlinden et al., <xref rid="B131" ref-type="bibr">2015</xref>; Conti et al., <xref rid="B38" ref-type="bibr">2016</xref>). It should be emphasized that the placement of electrodes is entirely dependent on the surgery. Electrode placement is also a selectivity factor in the frame of optogenetics but selective transfection is another possibility so that only the targets are made photo-sensitive. Selective activation of specific cells, as can be achieved in the frame of optogenetics, could become a key to a successful therapy (Yekhlef et al., <xref rid="B233" ref-type="bibr">2017</xref>). However, the impact on the therapeutic effect cannot yet be established on the basis of the rather preliminary information available today.</p></sec><sec><title>4.3. Functionality</title><p>The architecture of the brain nuclei poses a problem for purely electrical stimulation because electrodes are relatively indiscriminate with regards to the underlying physiology of the neurons that they stimulate. Typically, physical proximity of the stimulating electrode contact to the neuron is often the determining factor as to which neurons will be stimulated (Deisseroth et al., <xref rid="B46" ref-type="bibr">2014</xref>). Accordingly, it is not considered feasible to restrict stimulation to a single class of neurons with electrical stimulation while optogenetics promises to do just that and even to activate specific channels within the same neurons.</p><p>In optogenetics, the volume of tissue that gets activated is also determined by the interaction of several processes. Neuronal activation depends on the absolute amount of light that reaches the neurons, the efficiency of the transfection and the sensitivity of the opsin. Besides these, neuronal physiological properties and the network in which the neuron is embedded also influence how effectively light can control the activity. The propagation of light in the brain is determined by the light absorption and scattering (Vo-Dinh, <xref rid="B214" ref-type="bibr">2003</xref>). How far light reaches inside the brain can be estimated using Monte Carlo simulations. Different studies have calculated that the light intensity drops to 1% at a distance 1 mm away from the emission point (Bernstein et al., <xref rid="B13" ref-type="bibr">2008</xref>; Chow et al., <xref rid="B34" ref-type="bibr">2010</xref>; Stujenske et al., <xref rid="B202" ref-type="bibr">2015</xref>). Additionally, these simulations show that the light distribution inside the brain has an ellipsoidal shape depending on the wavelength, the size and type of light source and the emission aperture angle (i.e., numerical aperture). The simulations also show that a portion of the light back scatters and illuminates the tissue behind the optical fiber. This effect gets exacerbated at higher emission powers to the point that, in some cases, the tip of the fiber is at the center of the illuminated volume. Regarding the sensitivity, studies in acute slices and <italic>in vitro</italic> show that maximal channel activation for different channelrhodopsin 2 (ChR2) variants is achieved at a power density of 10 mW/mm<sup>2</sup>, with only 50% of the channels getting activated at 1 mW/mm<sup>2</sup> (Wang et al., <xref rid="B218" ref-type="bibr">2007</xref>; Lin et al., <xref rid="B113" ref-type="bibr">2009</xref>). If an optgenetic DBS would deliver light through an optical fiber with a core diameter of 200 &#x003bc;m and a numerical aperture of 0.22, the data obtained by (Stujenske et al., <xref rid="B202" ref-type="bibr">2015</xref>) can be used to estimate the power required to achieve an activation volume similar to electrical DBS (i.e., 5 mm sphere). For maximal neuronal acativation, a total of 1.5 W would be required to obtain a power density larger than 10 mW/mm<sup>2</sup> within the illumination volume. Assuming that the tip is indeed at the center. The required power gets exponentially higher if it is not. If the criteria are relaxed and only a power density of 1 mW/mm<sup>2</sup> is provided at the end of the volume only 150 mW should be delivered. The first value is prohibitively high and would probably create some direct damage in the brain. The second is also quite high, although the brain might be able to withstand it. However, a portable device that has to deliver that amount of power would probably not be practical. Tapered fibers have been tested recently by Pisanello et al. (<xref rid="B164" ref-type="bibr">2017</xref>) who showed that varying tapering angle allows for obtaining selectivity of stimulation in vertical direction. Authors claim that achieving uniform effective illumination of large brain structures with minimal invasiveness and light power. In addition, tapering permits smooth insertion into the brain, which also minimizes tissue reaction.</p><p>So-stated arguments indicate that stimulation paradigm with ChR2 analogous to DBS might not be the best approach with common ChR2 variants. An alternative could be to use recent variants like ChR2-XXL, which is 10,000 times more sensitive with the disadvantage that it is slower (Dawydow et al., <xref rid="B42" ref-type="bibr">2014</xref>). However, this approach does not take advantage of the capabilities of the optogenetical tools for specific cell type stimulation. Selectivity of stimulation has been tested in rodent models with some positive results (Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref>). As an alternative, the inhibition modality of optogenetics could be used. A widely accepted hypothesis of DBS for Parkinson's disease is that excitatory neurons in the STN are inhibited (Shin et al., <xref rid="B188" ref-type="bibr">2007</xref>; Sutton et al., <xref rid="B205" ref-type="bibr">2013</xref>). This hypothesis has been tested by two different groups in rodent models of Parksinosn's disease (Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref>; Yoon et al., <xref rid="B236" ref-type="bibr">2014</xref>, <xref rid="B235" ref-type="bibr">2016</xref>). Unfortunately, the results obtained by each group contradict the other, although Yoon et al. (<xref rid="B236" ref-type="bibr">2014</xref>) attribute the difference to the animal model and the test used to evaluate Parksinosn's disease improvement by the other group. Tables <xref ref-type="table" rid="T2">2</xref>, <xref ref-type="table" rid="T3">3</xref> show the efficacy of applying optogenetic stimulation or inhibition to rodent models in different studies. The tables have a line-to-line correspondence to facilitate comparison. Although, there is yet no definitive conclusion regarding the use of optogenetics of the treatment of Parkinson's disease, these studies demonstrate that optogenetics would be an indispensable tool to better understand mechanisms of Parksinosn's disease and DBS.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Summary of the efficacy of applying optogenetics in Parksinosn's disease rodent models, I.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Cell type</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Wavelength</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Opsin</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Frequency (Hz)</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">561</td><td valign="top" align="left" rowspan="1" colspan="1">eNpHR</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Astroglia</td><td valign="top" align="left" rowspan="1" colspan="1">473</td><td valign="top" align="left" rowspan="1" colspan="1">ChR2</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">473</td><td valign="top" align="left" rowspan="1" colspan="1">ChR2</td><td valign="top" align="left" rowspan="1" colspan="1">130</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">473</td><td valign="top" align="left" rowspan="1" colspan="1">ChR2</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Afferent axons</td><td valign="top" align="left" rowspan="1" colspan="1">473</td><td valign="top" align="left" rowspan="1" colspan="1">ChR2</td><td valign="top" align="left" rowspan="1" colspan="1">130</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Afferent axons</td><td valign="top" align="left" rowspan="1" colspan="1">473</td><td valign="top" align="left" rowspan="1" colspan="1">ChR2</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Projection neurons</td><td valign="top" align="left" rowspan="1" colspan="1">473</td><td valign="top" align="left" rowspan="1" colspan="1">ChR2</td><td valign="top" align="left" rowspan="1" colspan="1">130</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Projection neurons</td><td valign="top" align="left" rowspan="1" colspan="1">473</td><td valign="top" align="left" rowspan="1" colspan="1">ChR2</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr style="border-top: thin solid #000000;"><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">590</td><td valign="top" align="left" rowspan="1" colspan="1">NpHR</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Yoon et al., <xref rid="B236" ref-type="bibr">2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">590</td><td valign="top" align="left" rowspan="1" colspan="1">NpHR</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Yoon et al., <xref rid="B236" ref-type="bibr">2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">590</td><td valign="top" align="left" rowspan="1" colspan="1">NpHR</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Yoon et al., <xref rid="B236" ref-type="bibr">2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">590</td><td valign="top" align="left" rowspan="1" colspan="1">NpHR</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">Yoon et al., <xref rid="B235" ref-type="bibr">2016</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Medium spiny neurons</td><td valign="top" align="left" rowspan="1" colspan="1">473</td><td valign="top" align="left" rowspan="1" colspan="1">hChR2(H134R)</td><td valign="top" align="left" rowspan="1" colspan="1">CW</td><td valign="top" align="left" rowspan="1" colspan="1">Hern&#x000e1;ndez et al., <xref rid="B56" ref-type="bibr">2017</xref></td></tr></tbody></table><table-wrap-foot><p><italic>I, intermittent stimulation</italic>.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Summary of the efficacy of applying optogenetics in Parksinosn's disease rodent models, II.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Cell type</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Effect</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Model</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Test</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Success</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition</td><td valign="top" align="left" rowspan="1" colspan="1">Rat, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">Amphetamine/Rotation</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Astroglia</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition</td><td valign="top" align="left" rowspan="1" colspan="1">Rat, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">Amphetamine/Rotation</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">Activation</td><td valign="top" align="left" rowspan="1" colspan="1">Rat, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">Amphetamine/Rotation</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">Activation</td><td valign="top" align="left" rowspan="1" colspan="1">Rat, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">Amphetamine/Rotation</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Afferent axons</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition</td><td valign="top" align="left" rowspan="1" colspan="1">Mouse, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">Amphetamine/Rotation</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Afferent axons</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition</td><td valign="top" align="left" rowspan="1" colspan="1">Mouse, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">Amphetamine/Rotation</td><td valign="top" align="left" rowspan="1" colspan="1">Worsen</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Projection neurons</td><td valign="top" align="left" rowspan="1" colspan="1">Stimulation</td><td valign="top" align="left" rowspan="1" colspan="1">Mouse, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">Amphetamine/Rotation</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Projection neurons</td><td valign="top" align="left" rowspan="1" colspan="1">Stimulation</td><td valign="top" align="left" rowspan="1" colspan="1">Mouse, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">Amphetamine/Rotation</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref></td></tr><tr style="border-top: thin solid #000000;"><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition</td><td valign="top" align="left" rowspan="1" colspan="1">Rat, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">Stepping</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Yoon et al., <xref rid="B236" ref-type="bibr">2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition</td><td valign="top" align="left" rowspan="1" colspan="1">Rat, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">Cylinder</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Yoon et al., <xref rid="B236" ref-type="bibr">2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition</td><td valign="top" align="left" rowspan="1" colspan="1">Rat, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">Apomorphine/Rotation</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Yoon et al., <xref rid="B236" ref-type="bibr">2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excitatory glutamatergic</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition</td><td valign="top" align="left" rowspan="1" colspan="1">Rat, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">Apomorphine/Rotation</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Yoon et al., <xref rid="B235" ref-type="bibr">2016</xref></td></tr><tr style="border-top: thin solid #000000;"><td valign="top" align="left" rowspan="1" colspan="1">Medium spiny neurons</td><td valign="top" align="left" rowspan="1" colspan="1">Stimulation</td><td valign="top" align="left" rowspan="1" colspan="1">Rat, 6-OHDA</td><td valign="top" align="left" rowspan="1" colspan="1">stereotypic behavior</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Hern&#x000e1;ndez et al., <xref rid="B56" ref-type="bibr">2017</xref></td></tr></tbody></table><table-wrap-foot><p><italic>The studies used different power settings: Gradinaru et al. (<xref rid="B61" ref-type="bibr">2009</xref>) used 10/200 &#x003bc;m fiber core; Yoon et al. (<xref rid="B236" ref-type="bibr">2014</xref>, <xref rid="B235" ref-type="bibr">2016</xref>) used 1.1/200 &#x003bc;m core fiber; Hern&#x000e1;ndez et al. (<xref rid="B56" ref-type="bibr">2017</xref>) used 10 mW output power</italic>.</p></table-wrap-foot></table-wrap><p>We have seen that electrical currents and light do not necessarily activate the same structures. In addition, photosensitive channels have been developed for specific ions and superposition of different light wavelengths allows for activation/inhibition combinations that are not possible with electrical stimuli. However, once action potentials are launched, they can no longer be distinguished on the basis of the triggering event. Parameters, such as pulse frequency, train duration, train rate, treatment session duration, duration of the therapy, event-triggering of the therapy and so on are expected to yield the same effects if the same structures were activated and, this is where a serious word of caution is warranted. In addition, the neural system is an adaptive network. Plasticity, as a general phenomenon can completely modify long-term effects.</p><p>Long-term consideration is thus not only important to check the lifetime of implanted device or to evaluate unwanted side effects but also to ensure effectiveness of the treatment strategy (Jarvis and Schultz, <xref rid="B85" ref-type="bibr">2015</xref>). As &#x0201c;accelerated aging&#x0201d; methods do not work here, chronic studies and high sensitivity detection seem to be the only alternative.</p></sec></sec><sec id="s5"><title>5. Optogenetics</title><p>At present, optogenetic ion channels are designed routinely on the basis of the family of the bacterial opsins. In hindsight is seems surprising that applications in the neural system took as long as 40 years after the initial isolation of the halobacterial rhodopsin. Only, by 2010, the major classes of ion-conducting microbial opsins have been demonstrated to be able to excite neurons (Yizhar et al., <xref rid="B234" ref-type="bibr">2011</xref>). Optogenetic proteins can be classified into several overlapping groups by the mode of their actions (i) fast-inhibiting; (ii) fast exciting; (iii) step function opsins (i.e., bi-stable); (iv) modulated biochemically (review in Yizhar et al., <xref rid="B234" ref-type="bibr">2011</xref>). A large variety of channels with different absorption spectra and kinetics have been designed. The temporal precision based on the use of custom opsin designs offers unprecedented opportunity for modulation of defined neuronal populations. Such perspective is in a sharp contrast with the relatively &#x0201c;broad&#x02013;band&#x0201d; electrical stimulation traditionally employed in DBS.</p><sec><title>5.1. Variants of optogenetic approaches</title><sec><title>5.1.1. Overwhelming possibilities</title><p>In addition to forms sensitive to different wavelengths, the classical opsins such as DNA/channelrhodopsin 2 (ChR2) have been complemented with Halorhodopsin (NpHR) that hyperpolarizes the Cl- pump (Klapper et al., <xref rid="B94" ref-type="bibr">2016</xref>) and Archaerhodopsin-3 (Arch) that forms a light sensitive proton pump (Mantoan Ritter et al., <xref rid="B129" ref-type="bibr">2014</xref>). As already mentioned, combining these makes it possible to control different effects using different light colors (Stark et al., <xref rid="B198" ref-type="bibr">2012</xref>). More recently, several cellular control methods have been developed around the possibility to modulate G-proteins (Kleinlogel, <xref rid="B96" ref-type="bibr">2016</xref>) thus opening a new branch of optogenetics with new applications in perspective. Alternatively, genes for endo-cellular molecules (for example genes expressing fluorescent proteins for bio-sensing Enterina et al., <xref rid="B55" ref-type="bibr">2015</xref>) as well as various ion channels can be integrated in the cell genome. For example, intracellular calcium can be specifically controlled (Mager et al., <xref rid="B122" ref-type="bibr">2017</xref>). Key chemicals controlling cellular biology (precursors, enzymes, neurotransmitters and their agonists, sensors or signaling molecules (Smedemark-Margulies and Trapani, <xref rid="B194" ref-type="bibr">2013</xref>), can be delivered to the brain in an inactive form (drug-encapsulating liposomes, caged molecules or photosensitive inactivating bounds) and activated under light control (Nakano et al., <xref rid="B147" ref-type="bibr">2016</xref>). In other applications, optochemistry uses photosensitive uncaging (glutamate release in acute experiments) (Venkataramani et al., <xref rid="B213" ref-type="bibr">2007</xref>). There are also examples of photoreceptors that can be used as &#x0201c;optogenetic switches&#x0201d; (Salinas et al., <xref rid="B179" ref-type="bibr">2017</xref>). Astrocytes can be selectively activated by light-activated Gq protein-coupled opsins (Mantoan Ritter et al., <xref rid="B129" ref-type="bibr">2014</xref>). Among the non-neuronal cells that can be activated, oligodendrocytes might also become important therapeutic targets (Lee et al., <xref rid="B105" ref-type="bibr">2016</xref>). The new possibility to modify synapses (Sinnen et al., <xref rid="B192" ref-type="bibr">2017</xref>) could become a major tool in correcting or adjusting neural pathway balances. Even unexpected possibilities, such as controlling cell mechanical interactions, might become possible (Valon et al., <xref rid="B211" ref-type="bibr">2017</xref>).</p></sec><sec><title>5.1.2. Limitations</title><p>As a rule, the introduced foreign proteins trigger a foreign body immune reaction. In addition, proteins tend to be catabolized so that only gene modifications can enable a chronic effect. Direct introduction of functional proteins seems limited to acute experiments.</p></sec><sec><title>5.1.3. Possible applications</title><p>All monogenic diseases are in principle candidates for gene therapy. Many clinical trials have already taken place in various diseases outside the neural system: myopathies, haemophilia, retinitis pigmentosa are just a few examples (Collins and Thrasher, <xref rid="B37" ref-type="bibr">2015</xref>). Genetically encoded sensors have become essential research tools and might later offer perspectives for &#x0201c;closed loop systems&#x0201d; (Emiliani et al., <xref rid="B53" ref-type="bibr">2015</xref>; Yun and Kwok, <xref rid="B237" ref-type="bibr">2017</xref>). Bioluminescent indicators for voltage and various ion sensors are commercially available (Inagaki et al., <xref rid="B83" ref-type="bibr">2017</xref>).</p></sec></sec></sec><sec id="s6"><title>6. Viral vectors</title><p>From the point of view of biotechnology, viruses are almost perfectly evolved nano-machines for gene delivery. Viruses can infect host cells and completely overtake their metabolism reprogramming it to serve only for their replication. Outside the host cell, the nucleic acid (i.e., DNA or RNA) forming the genome is encapsulated in a protected shell called <italic>capsid</italic> forming a particle with dimensions in the range of 20&#x02013;200 nm. The particle itself is called <italic>virion</italic>. The proteins on the surface of the capsid are responsible for the target specificity and incorporation in the cell.</p><p>Rapid development of viral vector biotechnologies allows for selective modification of the wild type virus properties. Viral genomes can be edited and the genes, encoding pathogenic functions, can be removed and replaced by different genes allowing for engineering of the target cell's function. Such engineered construct is called a <italic>viral vector</italic> and it has important differences by design compared to the native prototype (i.e., the wild type virus).</p><list list-type="bullet"><list-item><p>The most important difference is that by design, viral vectors do not replicate. This feature is achieved by deliberately removing all replication-specific genes from the prototype viral genome. This has impact on the production of the vector. Often the viral genome is segregated into 2&#x02013;4 different plasmids.</p></list-item><list-item><p>Viral vectors retain their invasiveness. They can infect host cells and inject their genetic material in the cytoplasm and in some cases integrate in the eukaryotic genome.</p></list-item><list-item><p>Viral vectors are selected for their specificity.</p></list-item></list><p>Many viruses have been used as prototypes of viral vectors, however only few types are considered suitable for human application. Readers are directed to the recent reviews of Gray et al. (<xref rid="B65" ref-type="bibr">2010b</xref>), Lentz et al. (<xref rid="B107" ref-type="bibr">2012</xref>), and Kantor et al. (<xref rid="B89" ref-type="bibr">2014</xref>) for specific gene-therapy and production aspects of viral vectors. Since the envisioned genetic manipulation making the brain susceptible for optogenetics aims to treat specific diseases one has to consider it as a type of gene therapy. Therefore, all safety and ethical properties of such therapies should apply in further analysis. We give an initial consideration of the issues in the subsequent sections.</p><sec><title>6.1. Safety of gene therapy and viral vectors</title><p>Gene transfer experiments in humans started in 1990s but were hampered by initial failures and serious adverse effects, which occurred in the early trials. By present, viral vector technology advanced substantially because of the substantial improvement of our understanding of how different viruses interact with the organism and how their genomes can be designed to reduce biohazard and improve efficiency.</p></sec><sec><title>6.2. Adenovirus vectors</title><p>Historically, the first applications of gene therapy used adenoviruses and retroviruses. An adenovirus is a non-enveloped particle of size ranging between 70 and 100 nm. Adenoviruses (AV) have been isolated from a large number of species and tissue types, and in humans, they cause mild respiratory illnesses and gastroenteritis. The virus genome consists of linear double stranded DNA of approximately 36 kbp. An AV particle enters a cell via receptor-mediated endocytosis. The virus escapes the endosome and translocates to the nucleus where it delivers its DNA, which stays <italic>episomal</italic>. AV can efficiently infect a wide variety of cell types independent of the phase of the cell cycle (Harui et al., <xref rid="B77" ref-type="bibr">1999</xref>).</p><p>While adenovirus vectors are very efficient at delivering genes, adenovirus vectors can cause toxic effects that limit their efficiency and safety. AV are highly immunogenic. Upon contact with the virus, the human immune system mounts a full-scale assault, including CD4+ T-helper cells, CD8+ cytotoxic-T cells, and NK cells, in order to clear the virus (Xu et al., <xref rid="B230" ref-type="bibr">2010</xref>). Intravenous AV vector delivery for gene transfer purposes, especially at high doses, stimulates strong innate and adaptive immune responses and can be fatal for the host as notoriously found out in the first clinical trials. Further deletions of the adenoviral genes have yielded helper-dependent adenovirus (HD-Ads) or &#x0201c;gut-less&#x0201d; vectors (Kochanek et al., <xref rid="B97" ref-type="bibr">2001</xref>), which are completely devoid of viral protein coding sequences. This has decreased immunogenicity and also prolonged transgene expression.</p><p>In systemic application AV are sequestrated by the liver Kupffer cells and cause toxic effects there. AV vectors also activate the complement system (Manickan et al., <xref rid="B127" ref-type="bibr">2006</xref>; Tian et al., <xref rid="B207" ref-type="bibr">2009</xref>). In addition, high doses of adenovirus vectors rapidly induce a burst of platelet activating factor <italic>in vivo</italic> that can lead to shock.</p><p>From this overview it can be concluded that AV vectors are sub-optimal for gene delivery in the brain due to their immunogenicity (i.e., possibility ot trigger gliosis and neurodegeneration) and low specificity.</p></sec><sec><title>6.3. Adeno associated virus (AAV) based vectors</title><p>AAV forms small, non-enveloped virions with icosahedral symmetry. AAV belongs to the Parvoviridae family and has single-stranded DNA (see Table <xref ref-type="table" rid="T5">5</xref>). Multiple serotypes of AAV have been described (AAV1&#x02013;AAV9) with distinct tissue tropism and transduction efficiency (see Table <xref ref-type="table" rid="T4">4</xref>). AV can not replicate by itself and is not related to any known human pathology. AAV can replicate only in co-infection with helper viruses, such as AV, HSV or papiloma virus (HPV) (Weitzman and Linden, <xref rid="B222" ref-type="bibr">2011</xref>). For example, the adenovirus acts as a helper virus by supplying the E1a, E1b, E2a, E4orf6 and viral-associated RNA genes.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Some properties of AAV serotypes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Serotype</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Receptors</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">AAV1</td><td valign="top" align="left" rowspan="1" colspan="1">N-linked &#x003b1;2, 3/&#x003b1;2, 6-Sialic acid</td><td valign="top" align="left" rowspan="1" colspan="1">Wu et al., <xref rid="B227" ref-type="bibr">2006</xref>; Ng et al., <xref rid="B151" ref-type="bibr">2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AAV2</td><td valign="top" align="left" rowspan="1" colspan="1">Heparan sulfate, Integrins &#x003b1;/&#x003b2;5/&#x003b1;5&#x003b2;1, FGFR1, HGFR, laminin receptor</td><td valign="top" align="left" rowspan="1" colspan="1">Summerford and Samulski, <xref rid="B203" ref-type="bibr">1998</xref>; Qing et al., <xref rid="B168" ref-type="bibr">1999</xref>; Akache et al., <xref rid="B1" ref-type="bibr">2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AAV3</td><td valign="top" align="left" rowspan="1" colspan="1">Heparan sulfate, FGFR1, HGFR, laminin receptor</td><td valign="top" align="left" rowspan="1" colspan="1">Rabinowitz et al., <xref rid="B169" ref-type="bibr">2002</xref>; Akache et al., <xref rid="B1" ref-type="bibr">2006</xref>; Blackburn et al., <xref rid="B17" ref-type="bibr">2006</xref>; Ling et al., <xref rid="B115" ref-type="bibr">2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AAV4</td><td valign="top" align="left" rowspan="1" colspan="1">O-linked &#x003b1;2, 3-Sialic acid</td><td valign="top" align="left" rowspan="1" colspan="1">Kaludov et al., <xref rid="B88" ref-type="bibr">2001</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AAV5</td><td valign="top" align="left" rowspan="1" colspan="1">N-linked &#x003b1;2, 3-Sialic acid, PDGFR</td><td valign="top" align="left" rowspan="1" colspan="1">Kaludov et al., <xref rid="B88" ref-type="bibr">2001</xref>; Walters et al., <xref rid="B217" ref-type="bibr">2001</xref>; Di Pasquale et al., <xref rid="B47" ref-type="bibr">2003</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AAV6</td><td valign="top" align="left" rowspan="1" colspan="1">N-linked &#x003b1;2, 3/&#x003b1;2, 6-Sialic acid, heparan sulfate, EGFR</td><td valign="top" align="left" rowspan="1" colspan="1">Wu et al., <xref rid="B227" ref-type="bibr">2006</xref>; Ng et al., <xref rid="B151" ref-type="bibr">2010</xref>; Weller et al., <xref rid="B223" ref-type="bibr">2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AAV7</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AAV8</td><td valign="top" align="left" rowspan="1" colspan="1">Laminin receptor</td><td valign="top" align="left" rowspan="1" colspan="1">Akache et al., <xref rid="B1" ref-type="bibr">2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AAV9</td><td valign="top" align="left" rowspan="1" colspan="1">N-linked &#x003b2;1, 4-Galactose, Laminin receptor</td><td valign="top" align="left" rowspan="1" colspan="1">Akache et al., <xref rid="B1" ref-type="bibr">2006</xref>; Shen et al., <xref rid="B187" ref-type="bibr">2011</xref></td></tr></tbody></table><table-wrap-foot><p><italic>The table is based on Kantor et al. (<xref rid="B89" ref-type="bibr">2014</xref>). FGFR, fibroblast growth factor receptor; HGFR, hepatocyte growth factor receptor; PDGFR, platelet-derived growth factor receptor; EGFR, epidermal growth factor receptor</italic>.</p></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Virus-derived characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"><bold>Adenovirus (AV)</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Lentivirus</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>AAV</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>HSV</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Particle size</td><td valign="top" align="left" rowspan="1" colspan="1">70&#x02013;90 nm</td><td valign="top" align="left" rowspan="1" colspan="1">80&#x02013;120 nm</td><td valign="top" align="left" rowspan="1" colspan="1">18&#x02013;26 nm</td><td valign="top" align="left" rowspan="1" colspan="1">120&#x02013;300 nm</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Genome size</td><td valign="top" align="left" rowspan="1" colspan="1">37.7 kbp</td><td valign="top" align="left" rowspan="1" colspan="1">9.7 kbp</td><td valign="top" align="left" rowspan="1" colspan="1">4.7 kbp</td><td valign="top" align="left" rowspan="1" colspan="1">150 kbp</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nucleic acid type</td><td valign="top" align="left" rowspan="1" colspan="1">DNA</td><td valign="top" align="left" rowspan="1" colspan="1">RNA</td><td valign="top" align="left" rowspan="1" colspan="1">DNA</td><td valign="top" align="left" rowspan="1" colspan="1">DNA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Genome structure</td><td valign="top" align="left" rowspan="1" colspan="1">ds linear</td><td valign="top" align="left" rowspan="1" colspan="1">ss linear (+)</td><td valign="top" align="left" rowspan="1" colspan="1">ss linear (+/&#x02212;)</td><td valign="top" align="left" rowspan="1" colspan="1">ds linear</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Envelope</td><td valign="top" align="left" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1">VSVG glycoprotein</td><td valign="top" align="left" rowspan="1" colspan="1">None</td><td valign="top" align="left" rowspan="1" colspan="1">Glycoproteins</td></tr></tbody></table><table-wrap-foot><p><italic>ss, Single strand; ds, double strand</italic>.</p></table-wrap-foot></table-wrap><p>The AAV genome consists of two 145 base-pair inverted terminal repeats (ITR), <italic>rep</italic> and <italic>cap</italic> genes. The ITRs form loop structures and are the only cis-acting elements that are necessary for genome replication, integration and packaging in the capsid (Kantor et al., <xref rid="B89" ref-type="bibr">2014</xref>). The wild type AAV genome encodes four rep proteins&#x02014;Rep 78, 68, 52, and 40; three viral structure proteins forming the capsid&#x02014;VP1, 2 and 3; assembly activating protein, which is involved in the translocation to the nucleolus&#x02014;AAP (review in Smith, <xref rid="B195" ref-type="bibr">2008</xref>).</p><p>The capsid determines the tissue specificity or tropism of a given virus by regulating the immediate cellular response to the virus, mediating pathways for internalization into the cell, and functions in the uncoating process within the nucleus. Specific regions of the capsid proteins interact with receptors and co-receptors on the host cellular surface to mediate the viral infection process and serotypes can differ with respect to the receptors that they bind to. AAV infects a host cell through receptor-mediated endocytosis.</p><p>Approximately 80% of the population is seropositive for anti-AAV antibodies (review in Weitzman and Linden, <xref rid="B222" ref-type="bibr">2011</xref>). Also approximately 60% of the population has neutralizing antibodies at age 10, which persists into adulthood. Nevertheless, surprisingly little is known about the life cycle of AAV in humans.</p><p>The AAV vectors can stably transfect tissues in different species, including humans. Reports demonstrate durations of such tranfections of at least 6 years in primates (Rivera et al., <xref rid="B173" ref-type="bibr">2005</xref>), 8 years in dogs (Niemeyer et al., <xref rid="B153" ref-type="bibr">2009</xref>) and more that 10 years in the human brain (Leone et al., <xref rid="B108" ref-type="bibr">2012</xref>).</p><p>AAV is unique among mammalian viruses in that it integrates into a distinct region of the human chromosome 19, the so called AAV integration site AAVS1 (review in Smith, <xref rid="B195" ref-type="bibr">2008</xref>). The site-specific integration of AAV requires the presence of two viral elements: the inverted terminal repeats (ITRs) and nonstructural proteins Rep78/68. Accordingly, all current AAV vectors lacking the <italic>rep</italic> gene lack the capacity for site-specific integration. Wild-type AAV sequences are integrated into the host cell genome as tandem, head-to-tail repeats linked to genomic DNA sequences by the viral inverted terminal repeat elements (or ITRs). Specificity is achieved through the interaction of a glycine-rich loop that binds the major groove and an &#x003b1;-helix that interacts with a downstream minor groove on the same face of the DNA. In contrast, the integration of recombinant AAV genomic sequences in the absence of the AAV Rep proteins is inefficient and is not limited to chromosome 19. It is estimated that only about 10% of recombinant AAV sequences integrate into the host cell genome, thus indicating that the majority of vector genomes persist in an extrachromosomal form <italic>in vivo</italic> (Smith, <xref rid="B195" ref-type="bibr">2008</xref>).</p></sec><sec><title>6.4. Herpes simplex virus (HSV) derived vectors</title><p>HSV is a member of the <italic>Herpesviridae</italic> family. There are two main viral types&#x02014;HSV-1 and HSV-2. While HSV-1 causes orolabial lesions and resides in the trigeminal ganglion, HSV-2 causes genital lesions and resides in the sacral ganglia. About 40% of the adult population is seropositive for HSV-1 in the developed countries (review in Kantor et al., <xref rid="B89" ref-type="bibr">2014</xref>). The HSV particles have icosahedral capsid covered by a lipid bilayer envelope. The envelope includes glycoproteins, which are essential for the viral entry into the cell. The viral genome consists of dsDNA of 152 kb (see Table <xref ref-type="table" rid="T5">5</xref>). The life cycle of HSV is particular: the cycle has two alternative phases&#x02014;lytic and latent. The lytic pathway leads to viral proliferation, emission and imminent cell death, while the latent pathway causes the virus to form an episomal particle within the nucleus in a dormant state. The latent viral particle is capable of lytic transformation upon the action of physical factors (i.e., cold, heat shock etc.). Viral replication is a multistage process, controlled by many genes, which can be removed from the genetic backbone of the vector. This ensures large packaging capacity of up to 125 kbp. What makes HSV suitable for CNS and PNS applications are the following properties: (i) the wild type virus propagates trans-synaptically in both anterograde and retrograde directions; (ii) the wild type virus is neurotropic and (iii) stability of the latent phase.</p><p>Infection with HSV typically occurs at the cutaneous or mucosal epithelium where replication of the virus is initially lytic. The virus can also invade axons of sensory neurons in the affected area and undergo retrograde transport to the dorsal root ganglia where it can switch to a latent phase.</p><p>Once the virus has reached the nucleus of a cell, the linear genome circularizes and is maintained as an episome with minimal integration (Lentz et al., <xref rid="B107" ref-type="bibr">2012</xref>). HSV vectors demonstrate extensive host cell range, high efficiency gene transfer, and enhanced safety, as persistence of the genome as an episome decreases the likelihood of insertional mutagenesis (Shayakhmetov et al., <xref rid="B186" ref-type="bibr">2010</xref>). Due to cytotoxicity associated with viral gene expression non-replicating and <italic>amplicon</italic> vectors have been developed. HSV amplicons are eukaryotic expression vectors that harbor the HSV origin of replication and cleavage/packaging signals. HSVs do not require pseudotyping to increase neurotropism, as these viruses are inherently neurotropic. HSV-mediated gene expression has a rapid onset (&#x0003c; 1 day) (Penrod et al., <xref rid="B162" ref-type="bibr">2015</xref>). Transgene expression mediated by HSV vectors has been demonstrated to persist for up to 7 months in the rat brain, but may not be stable (Zhang et al., <xref rid="B238" ref-type="bibr">2000</xref>; Sun et al., <xref rid="B204" ref-type="bibr">2003</xref>).</p><p>Replication-attenuated and replication-deficient HSV vectors have the transgene of interest inserted into the viral genome, with targeted deletion of specific immediate early (IE) genes to disable the lytic cycle and render these vectors non-toxic (Wu et al., <xref rid="B226" ref-type="bibr">1996</xref>; Krisky et al., <xref rid="B101" ref-type="bibr">1998</xref>).</p></sec><sec><title>6.5. Lentriviral vectors</title><p>Lentivirial vectors are derived from the HIV genome and there is abundant literature about their properties and safety. Interested readers can consult the recent review of Kantor et al. (<xref rid="B89" ref-type="bibr">2014</xref>). Lentriviral vectors lead to permanent genetic modification, which may not be desirable in all cases. Since neurons in the majority of brain areas do not divide, there is a little justification, from medical ethics perspective, why a permanent genetic modification of the patient's brain tissue is desirable.</p></sec><sec><title>6.6. Gene therapy in CNS related to the applications</title><p>The CNS has proven quite permissive to viral vector gene transfer and expression for many of the conventional delivery vectors. AAV, lentiviral, and to a lesser extent HSV vectors, are the most frequently utilized agents for brain and spinal cord gene delivery. At present, AAV vectors are the leading platform for gene delivery in CNS. Beyond the large number of preclinical and basic mammalian studies involving AAV delivery to the brain and/or spinal cord, the large majority (approximately 75%) of clinical trials that have been initiated for CNS gene therapy have utilized AAV, as contrasted to trials utilizing adenovirus (6%), lentivirus (12%) or retrovirus (6%) (Gray et al., <xref rid="B64" ref-type="bibr">2010a</xref>).</p><p>In a recent clinical trial, 12 patients with advanced Parkinson's disease had an application of an AAV vector carrying a transgene encoding glutamic acid decarboxylase (GAD) (Kaplitt et al., <xref rid="B90" ref-type="bibr">2007</xref>). The therapy was well tolerated, with no adverse effects attributable to gene therapy noted for any of the patients. Observed improvement in motor activity lasted for at least 1 year. The trial using AAV-GAD did not establish adverse effects for up to 12 months (Feigin et al., <xref rid="B57" ref-type="bibr">2007</xref>). Another trial for Parkinson's disease using AAV-hAADC vector for dopamine replacement established favorable safety profile (<italic>n</italic> = 5 patients) but low efficacy (Christine et al., <xref rid="B36" ref-type="bibr">2009</xref>). Similar safety profiles have been established in another trial (Muramatsu, <xref rid="B144" ref-type="bibr">2010</xref>). A phase 2 study using 45 patients and AAV-GAD did not establish serious adverse affects attributed to the treatment (LeWitt et al., <xref rid="B109" ref-type="bibr">2011</xref>). So-reported results demonstrate that AAV is a sufficiently safe vector for applications in the brain. In summary, the recombinant AAV vectors have emerged as a viable delivery method for human gene therapy as they can be designed to meet the precise treatment needs of a given disease by delivering a gene to specific cell types within the affected tissues with a minimal immune response.</p></sec><sec><title>6.7. Assessing the risks of the genetic modification</title><p>Genetic modification has some inherent risks. A comprehensive treatment of the principles of risk assessment will require a dedicated publication. Interested readers can consult Baldo et al. (<xref rid="B8" ref-type="bibr">2013</xref>) for treatment of gene therapy cases. Briefly, the methodology of risk assessment consists of the following steps:</p><list list-type="bullet"><list-item><p>hazard identification;</p></list-item><list-item><p>hazard characterization;</p></list-item><list-item><p>risk estimation, i.e., risk band estimation;</p></list-item><list-item><p>evaluation of risk management options based on the assigned risk band.</p></list-item></list><p>Considering viral vector applications the following principal hazards can be identified:</p><list list-type="bullet"><list-item><p>Immune system reaction</p></list-item><list-item><p>Pleiotropic effects due to low specificity</p></list-item><list-item><p>Recombination of the vector (older generation vectors)</p></list-item><list-item><p>Insertional mutagenesis and carcinogenesis (older generation retroviral vectors)</p></list-item></list><p>Various candidate viral vectors are compared in Table <xref ref-type="table" rid="T5">5</xref>, based on the studies of Doherty et al. (<xref rid="B49" ref-type="bibr">2011</xref>) and Howarth et al. (<xref rid="B82" ref-type="bibr">2010</xref>).</p><p>Transfection-related properties of different vectors are summarized in Table <xref ref-type="table" rid="T6">6</xref>.</p><table-wrap id="T6" position="float"><label>Table 6</label><caption><p>Transfection properties of viral vectors most common in human gene therapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"><bold>Adenovirus (AV)</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Lentivirus</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>AAV</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>HSV</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Payload</td><td valign="top" align="left" rowspan="1" colspan="1">3.0&#x02013;8.0 kbp</td><td valign="top" align="left" rowspan="1" colspan="1">2.5&#x02013;8.0 kbp</td><td valign="top" align="left" rowspan="1" colspan="1">2.5&#x02013;5.0 kbp</td><td valign="top" align="left" rowspan="1" colspan="1">16.5<xref ref-type="table-fn" rid="TN2"><sup>*</sup></xref>&#x02013;125 kbp</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Latency to peak transgene expression</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02013;5 days</td><td valign="top" align="left" rowspan="1" colspan="1">7 days</td><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;4 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02013;5 days</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rate limiting step before expression</td><td valign="top" align="left" rowspan="1" colspan="1">Translocation to nucleus</td><td valign="top" align="left" rowspan="1" colspan="1">Genome integration</td><td valign="top" align="left" rowspan="1" colspan="1">Second strand synthesis</td><td valign="top" align="left" rowspan="1" colspan="1">Translocation to nucleus</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Integrates in host genome</td><td valign="top" align="left" rowspan="1" colspan="1">No, but in nucleus</td><td valign="top" align="left" rowspan="1" colspan="1">Yes, non-specific</td><td valign="top" align="left" rowspan="1" colspan="1">Yes, inefficient</td><td valign="top" align="left" rowspan="1" colspan="1">No</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Expression requires integration?</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">No</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Transduces post-mitotic cells?</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of transgene expression</td><td valign="top" align="left" rowspan="1" colspan="1">Weeks/months</td><td valign="top" align="left" rowspan="1" colspan="1">Years</td><td valign="top" align="left" rowspan="1" colspan="1">Years</td><td valign="top" align="left" rowspan="1" colspan="1">Weeks/months</td></tr></tbody></table><table-wrap-foot><fn id="TN2"><label>*</label><p><italic>Miyagawa et al. (<xref rid="B140" ref-type="bibr">2015</xref>) but up to 120 kbp theoretically (Kantor et al., <xref rid="B89" ref-type="bibr">2014</xref>); bp, base pair</italic>.</p></fn></table-wrap-foot></table-wrap><p>We can identify some desirable properties of the ideal vector, considering the specific application:</p><list list-type="bullet"><list-item><p>very low insertional mutagenesis potential&#x02014;due to necessity of long-term action;</p></list-item><list-item><p>very low immunogenic potential&#x02014;for the same reasons and considering the importance of chronic neuroinflammation in the pathogenesis of neurodegenerative diseases;</p></list-item><list-item><p>neurotropism;</p></list-item><list-item><p>low recombination potential.</p></list-item></list><p>The payload capacity is not a differentiating factor for optogenetics applications as the channelrhodopsins are in the range 1.7 kbp (i.e., hChR2-GFP). Based on these criteria, a preference table can be assembled (Table <xref ref-type="table" rid="T7">7</xref>). From the table it appears that, given the present state of development of the viral vector technology, the best choice for optogenetic application in human is AAV followed by HSV.</p><table-wrap id="T7" position="float"><label>Table 7</label><caption><p>Summary of viral vector comparison.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"><bold>Adenovirus</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Lentivirus</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>AAV</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>HSV</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Insertional mutagenesis potential</td><td valign="top" align="left" rowspan="1" colspan="1">Very low</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">Very low</td><td valign="top" align="left" rowspan="1" colspan="1">Very low</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Immunogenicity</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">Very low</td><td valign="top" align="left" rowspan="1" colspan="1">Very low</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Neuronal transduction</td><td valign="top" align="left" rowspan="1" colspan="1">moderate</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Glial transduction</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">Low</td><td valign="top" align="left" rowspan="1" colspan="1">Low</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Permanent effect</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">No</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of expression</td><td valign="top" align="left" rowspan="1" colspan="1">Long</td><td valign="top" align="left" rowspan="1" colspan="1">Long</td><td valign="top" align="left" rowspan="1" colspan="1">Long</td><td valign="top" align="left" rowspan="1" colspan="1">Short</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombination potential</td><td valign="top" align="left" rowspan="1" colspan="1">Low</td><td valign="top" align="left" rowspan="1" colspan="1">Very Low</td><td valign="top" align="left" rowspan="1" colspan="1">Low</td><td valign="top" align="left" rowspan="1" colspan="1">Low</td></tr><tr style="border-top: thin solid #000000;"><td valign="top" align="left" rowspan="1" colspan="1">Preference</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">2</td></tr></tbody></table></table-wrap></sec><sec><title>6.8. Alternatives for gene delivery</title><p>Non-viral alternatives for gene delivery have been developed in parallel to viral vector technology. These are for example, transfection by electroporation (Nomura et al., <xref rid="B155" ref-type="bibr">2016</xref>) or focused ultrasounds (Wang et al., <xref rid="B220" ref-type="bibr">2017</xref>). Another potential alternative is laser photoporation, currently developed <italic>in vitro</italic> (Antkowiak et al., <xref rid="B5" ref-type="bibr">2013</xref>). For various reasons however, it is the viral vector-based gene delivery that stands out as the most mature transfection technology.</p></sec></sec><sec id="s7"><title>7. Implanted optical brain stimulator</title><p>Research on implantable hybrid optoelectronic probes has progressed rapidly in the last couple of years. Optical stimulation can be applied in several ways. Available techniques include fiber optics, on-probe &#x003bc;LED-s and waveguide-based approaches. A recent overview on the topic can be found in Iseri and Kuzum (<xref rid="B84" ref-type="bibr">2017</xref>). Focal optic stimulation can be achieved with proper optical design, for example using independently controllable GaN light emitting diodes (McAlinden et al., <xref rid="B131" ref-type="bibr">2015</xref>). Optical brain stimulators can work with several wavelengths to activate selectively differently transfected cells within the same region (Emiliani et al., <xref rid="B53" ref-type="bibr">2015</xref>); or they can be designed to provide complex illumination patterns (Segev et al., <xref rid="B183" ref-type="bibr">2017</xref>).</p><sec><title>7.1. Alternative realization</title><p>Micro and perhaps nanotechnologies are at stake here when considering the development of the appropriate stimulation system (Pisanello et al., <xref rid="B165" ref-type="bibr">2016</xref>). Multi-functional devices can combine photo-stimulation and electrical recording (Wang et al., <xref rid="B219" ref-type="bibr">2012</xref>) including micro-electrode arrays placed in the vicinity of the target (Buzsaki et al., <xref rid="B26" ref-type="bibr">2015</xref>; Naughton et al., <xref rid="B149" ref-type="bibr">2016</xref>).</p></sec><sec><title>7.2. Limitations</title><p>Designing probes that can be safely inserted in the brain is a significant challenge. Generic tissue reactions to the implant device have been discussed elsewhere (Prodanov and Delbeke, <xref rid="B166" ref-type="bibr">2016a</xref>). For any implanted device, power dissipation and thus local temperature must be kept at an acceptable level (Arias-Gil et al., <xref rid="B6" ref-type="bibr">2016</xref>; Shin et al., <xref rid="B189" ref-type="bibr">2016</xref>). The strong light power used in photogenetic could transform photochemically some cell molecules into toxic agents. Chronic aspects are important to consider: a good example is the mitochondria-mediated apoptosis induced by prolonged ChR2 activation (Perny et al., <xref rid="B163" ref-type="bibr">2016</xref>). Whether electric, microfluidic or optical, any application must take into account the diffusion and depth of penetration. Although only mentioned in animals, light leaks might influence an implant (Eckmier et al., <xref rid="B52" ref-type="bibr">2016</xref>), considering that near infra-red spectroscopy is a technique based on light transmission through scalp, skull and brain (Benaron et al., <xref rid="B12" ref-type="bibr">2000</xref>). Optic implants are new and require a specific encapsulation still lacking chronic evaluation (Rossi et al., <xref rid="B175" ref-type="bibr">2015</xref>). On the other hand, it is much easier to make optic devices Magnetic Resonance Imaging (MRI) compatible than their electrical counterparts. This is an important factor for the modern clinical practice.</p></sec><sec><title>7.3. Possible applications</title><p>DBS is presently used in Parkinson's disease, epilepsy, pain, dyskinesia, tremor, dystonia, major depression and obsessive compulsive disorder (OCD). The exact mechanism of action is unknown and it is assumed that all neurons within a given volume are being activated. Because the cell type activated can be very different and sometimes non-neuronal (Nam et al., <xref rid="B148" ref-type="bibr">2016</xref>), optical stimulation of the same volume might not perform an equivalent job. Epilepsy is presently the object of many attempts to apply neuro-modulation. This is justified by the large number of therapy resistant cases. However the pathophysiology of this condition remains obscure. The selectivity of optogenic stimulation might help sort out the pathophysiology and arrive at an efficient clinical treatment (Xu et al., <xref rid="B231" ref-type="bibr">2016</xref>; Yekhlef et al., <xref rid="B233" ref-type="bibr">2017</xref>). Also for conditions, such as retinal diseases, light stimulation would probably make the generation of meaningful visual perceptions easier in a retinal prosthesis (Nirenberg and Pandarinath, <xref rid="B154" ref-type="bibr">2012</xref>; Al Atabany et al., <xref rid="B2" ref-type="bibr">2013</xref>). Stimulation and sensing can be implemented exclusively with optical elements (Inagaki et al., <xref rid="B83" ref-type="bibr">2017</xref>). A combination of techniques, such as electrophysiology and optogenetics (Chen et al., <xref rid="B29" ref-type="bibr">2017</xref>) or micro-fluidics (Rubehn et al., <xref rid="B177" ref-type="bibr">2013</xref>; McCall et al., <xref rid="B132" ref-type="bibr">2017</xref>), can offer additional perspectives in feedback controlled systems.</p></sec></sec><sec id="s8"><title>8. Biocompatibility issues</title><sec><title>8.1. Gene delivery</title><p>In a standard optogenetics protocol the channelrhodopsin gene is delivered by viral vector injection. However, as already mentioned, innate immunity and antigen-specific adaptive immune responses against vector-derived antigens could reduce the efficacy and stability of the gene transfer when this technique is translated to the clinic (for an overview, see Bessis et al., <xref rid="B14" ref-type="bibr">2004</xref>; Nayak and Herzog, <xref rid="B150" ref-type="bibr">2009</xref>). In the case of human gene therapy, AAV vectors are frequently put forward as optimal solutions due to their good safety profiles (Carter, <xref rid="B27" ref-type="bibr">2005</xref>). Innate immune response are limited, but have been observed at high doses or with specific serotypes (Lowenstein et al., <xref rid="B120" ref-type="bibr">2007</xref>; Hadaczek et al., <xref rid="B73" ref-type="bibr">2009</xref>). Adaptive immune responses, on the other hand, are more common. Anti-AAV antibodies are predominantly directed at the vector's capsid protein (Mingozzi and High, <xref rid="B137" ref-type="bibr">2013</xref>). Neutralizing antibodies constitute one of the main challenges of successful gene delivery, as they impact transfection efficiency in animal (Arruda et al., <xref rid="B7" ref-type="bibr">2010</xref>; Haurigot et al., <xref rid="B78" ref-type="bibr">2010</xref>; Jiang et al., <xref rid="B86" ref-type="bibr">2013</xref>) and clinical studies (Manno et al., <xref rid="B128" ref-type="bibr">2006</xref>), even at low titers (Scallan et al., <xref rid="B180" ref-type="bibr">2006</xref>). Especially persons with pre-existing anti-AAV antibodies would be at a disadvantage, though there is a difference in neutralizing effect depending on the serotype (Xiao et al., <xref rid="B229" ref-type="bibr">1999</xref>). Other studies in the brain (Lo et al., <xref rid="B117" ref-type="bibr">1999</xref>; Mastakov et al., <xref rid="B130" ref-type="bibr">2002</xref>), muscle (Kay et al., <xref rid="B93" ref-type="bibr">2000</xref>) and retina (Anand et al., <xref rid="B4" ref-type="bibr">2002</xref>) revealed, however, no relation between the presence of the anti-capsid antibodies and the amount of transgene expression.</p><p>At present, it is seems too early to choose between systemic vs. local viral vector application. Systemic application of viral vectors could be favorable in the case mechanisms of DBS turn out to be more delocalized. On the other hand, in this case the volume of illumination can turn out to be the performance limiting factor. Localized application by the device itself may pose conflicting engineering requirements (e.g., microfluidics), which could decrease reliability.</p></sec><sec><title>8.2. Expression of the transgene</title><p>Besides vector-specific antibodies, the body might also mount an immune response against the transgene itself. Transgene-specific immune responses are dependent on the target organ, the administration route and dosage (Toromanoff et al., <xref rid="B208" ref-type="bibr">2010</xref>; Mingozzi and High, <xref rid="B137" ref-type="bibr">2013</xref>). Target tissue such as the liver display a high level of tolerance to the transgene product (LoDuca et al., <xref rid="B118" ref-type="bibr">2009</xref>), while muscle (Ross et al., <xref rid="B174" ref-type="bibr">2006</xref>) is more prone to activation of the immune system. In the case of neural tissue, opsins do not seem toxic to human neurons in the brain or retina (Busskamp et al., <xref rid="B24" ref-type="bibr">2010</xref>; Valtcheva et al., <xref rid="B212" ref-type="bibr">2016</xref>). However, high levels of opsin expression might still induce cell death (Klein et al., <xref rid="B95" ref-type="bibr">2006</xref>), alteration in electrical membrane properties or form aggregates in neurons (Gradinaru et al., <xref rid="B62" ref-type="bibr">2008</xref>; Zimmermann and Dours-Zimmermann, <xref rid="B240" ref-type="bibr">2008</xref>; Diester et al., <xref rid="B48" ref-type="bibr">2011</xref>), while no observable damage has been reported (Han et al., <xref rid="B76" ref-type="bibr">2009</xref>). The diversity in responses points to the difficulty of determining the correct levels of expression (Allen et al., <xref rid="B3" ref-type="bibr">2015</xref>; Jarvis and Schultz, <xref rid="B85" ref-type="bibr">2015</xref>). Therefore, to counter potential toxicity, different modification strategies have been developed, leading to safe expression even at high titers (Gradinaru et al., <xref rid="B62" ref-type="bibr">2008</xref>). Finally, as in any gene therapy case, there is a risk that the opsin might insert randomly into the genome and thereby result in oncogenesis (Hacein-bey abina et al., <xref rid="B72" ref-type="bibr">2008</xref>).</p></sec><sec><title>8.3. Bio-mechanical device compliance</title><p>The light-delivering device can either be implanted into or remain external to the brain. The necessity of opening a pathway in the first case bears the risk of tissue damage due to the insertion or chronic presence in the body as with any implantable device (for a review, see Prodanov and Delbeke, <xref rid="B166" ref-type="bibr">2016a</xref>). Acute vascular damage can be controlled to some extent by the shape of the implant and the surgical trajectory; while the amount of micromotion is a function of the implant inertial properties and the mode of attachment to the skull. Both parameters are difficult to modify, once an application has been chosen. To prevent mechanical damage, the device should be as small as possible, while providing sufficient light to the target deep brain structures. For this purpose, multiple solutions have been proposed: for example, novel probe designs or adaptations of high-density fiber arrays (Zorzos et al., <xref rid="B241" ref-type="bibr">2010</xref>; Han, <xref rid="B75" ref-type="bibr">2012</xref>; Ozden et al., <xref rid="B161" ref-type="bibr">2013</xref>; Hoffman et al., <xref rid="B81" ref-type="bibr">2015</xref>).</p></sec><sec><title>8.4. Optical stimulation</title><p>Light absorbed by brain tissue can produce non-specific effects due to heating or photodamage. Heating may alter the activity of neurons or even behavior (Moser and Mathiesen, <xref rid="B143" ref-type="bibr">1996</xref>; Long and Fee, <xref rid="B119" ref-type="bibr">2008</xref>). The risk of overheating constraints the power that can be used by the device and hence limits the illumination volume. A possible solution is to place the device further from the neurons of interest or even outside the brain and use red light in combination with red-shifted opsins (Lin et al., <xref rid="B112" ref-type="bibr">2013</xref>).</p><p>Whereas most of the optogenetic protocols do not induce excessive tissue damage (Gysbrechts et al., <xref rid="B71" ref-type="bibr">2016</xref>), heating effects were also observed at standard light powers (Christie et al., <xref rid="B35" ref-type="bibr">2013</xref>; Stujenske et al., <xref rid="B202" ref-type="bibr">2015</xref>) and even in non-transduced cells (Han, <xref rid="B75" ref-type="bibr">2012</xref>). On the other hand, heat itself has been used as well to perform optical stimulation of wild-type cells, using infrared pulses (Shapiro et al., <xref rid="B185" ref-type="bibr">2012</xref>; Carvalho-de Souza et al., <xref rid="B28" ref-type="bibr">2015</xref>). The light might also have non-thermal effects on neural tissue. Light-sensitive pathways naturally present in cells could produce unwanted effects to both targeted and surrounding cells (Koyanagi et al., <xref rid="B99" ref-type="bibr">2013</xref>; Cheng et al., <xref rid="B30" ref-type="bibr">2016</xref>).</p></sec><sec><title>8.5. Long-term effects</title><p>Finally, a favorable acute response does not necessarily predict the chronic stimulation effects on neuronal tissue. Changes at single-cell and network level need to be considered when translating optogenetics to the clinic. Long-term exposure to light pulses has been known to plastically modify the behavior of transfected neurons, changing their response to stimulation (Schultheis et al., <xref rid="B182" ref-type="bibr">2011</xref>; Lignani et al., <xref rid="B110" ref-type="bibr">2013</xref>), or induce long-term potentiation (Zhang and Oertner, <xref rid="B239" ref-type="bibr">2007</xref>). Some of these chronic effects may prove to be beneficial in a clinical context, leading for example to a reduction of the stimulation periods. On a single-cell level, changes in neuron morphology have been observed, due to the prolonged expression (Miyashita et al., <xref rid="B141" ref-type="bibr">2013</xref>) or stimulation (Goold and Nicoll, <xref rid="B60" ref-type="bibr">2010</xref>; Grubb and Burrone, <xref rid="B70" ref-type="bibr">2010</xref>).</p><p>Four main aspects contributing to compromised long-term compliance can be outlined:</p><list list-type="bullet"><list-item><p>acute vasuclar damage including hemorrhage;</p></list-item><list-item><p>micromotion of the implant;</p></list-item><list-item><p>localized blood-brain barrier (BBB) breakdown;</p></list-item><list-item><p>formation of reactive oxygen species (ROS, i.e., oxidative stress).</p></list-item></list><p>The disruption of BBB leads to the deposition of plasma proteins foreign to the CNS, such as albumin, globulins, fibrin/fibrinogen, thrombin, plasmin, complement (Kozai et al., <xref rid="B100" ref-type="bibr">2015</xref>). The vascular damage is accompanied by fluid displacement, dragging of the blood vessels and eventual hemorrhage observed after implantation (Bjornsson et al., <xref rid="B16" ref-type="bibr">2006</xref>). Hemorrhages have been shown to be particularly detrimental for long term recording (Stensaas and Stensaas, <xref rid="B200" ref-type="bibr">1976</xref>; Turner et al., <xref rid="B210" ref-type="bibr">1999</xref>; Grand et al., <xref rid="B63" ref-type="bibr">2010</xref>). The cerebral vasculature is particularly susceptible to the action of ROS, which is of great importance since cerebral endothelial cells play a major role in the creation and maintenance of BBB (review in Obermeier et al., <xref rid="B157" ref-type="bibr">2013</xref>). Such BBB dysfunction can result in an imbalance of ions, transmitters and metabolic products in the interstitial fluid, causing abnormal neuronal activity. In the implantation setting ROS can be linked to the catalytic function of <italic>Fe</italic><sup>3+</sup> present in the blood clot, which can lead to formation of stationary diffusion-limited concentration gradients around the implant (Prodanov and Delbeke, <xref rid="B167" ref-type="bibr">2016b</xref>).</p></sec></sec><sec id="s9"><title>9. Neuromodulation</title><p>The clinical application of optogenetic systems (i.e., optical brain stimulators) will require much more attention for the target selection, stimulus characteristics (Shiri et al., <xref rid="B190" ref-type="bibr">2017</xref>; Weible et al., <xref rid="B221" ref-type="bibr">2017</xref>) and therapy regimen than has been the case hitherto. Within the framework of DBS, several different neural targets are still being proposed for electrical neurostimulation. Cortical stimulation is being considered for pain (Liu and Tao, <xref rid="B116" ref-type="bibr">2016</xref>) and epilepsy as well as for totally different applications such as providing sense of touch to prosthetic hands (Nghiem et al., <xref rid="B152" ref-type="bibr">2015</xref>).</p><sec><title>9.1. Critera for clinical acceptance</title><p>Refractory epilepsy and Parkinson's disease present different cases for an eventual application of optogenetics. While the Parkinson's disease is an established target for DBS since 1997, long-term efficacy of electrical stimulation for refractory epilepsy is still an ongoing investigation. Despite maximal antiepileptic drug therapy, more than 30% of patients with epilepsy suffer from persistent seizures, while up to 40% of patients are not candidates for surgical resection (Halpern et al., <xref rid="B74" ref-type="bibr">2008</xref>). The SANTE trial<xref ref-type="fn" rid="fn0003"><sup>3</sup></xref> fond out that the median percent seizure reduction from baseline at 1 year was 41%, and 69% at 5 years. The long-term follow-up of anterior thalamic nucelus (ANT) DBS showed sustained efficacy and safety in a treatment-resistant population (Salanova et al., <xref rid="B178" ref-type="bibr">2015</xref>). The readers are directed to the recent review of Laxpati et al. (<xref rid="B104" ref-type="bibr">2014</xref>) for a summary of the clinical trials in epilepsy.</p><p>While for Parkinson's disease an optogenetic stimulator must demonstrate superiority to eventually become an accepted therapy, in epilepsy the target can be somehow lowered to non-inferiority. This indicates that optogenetic modulation of refractory epilepsy could in fact be achieved first.</p></sec><sec><title>9.2. Alternative realization</title><p>Optogenetics also offers the possibility to work with cells other than neurons (Cho et al., <xref rid="B33" ref-type="bibr">2016</xref>). Systems combining optic simulation and electrical recording have been developed (Wang et al., <xref rid="B219" ref-type="bibr">2012</xref>; Rubehn et al., <xref rid="B177" ref-type="bibr">2013</xref>; Hoffman et al., <xref rid="B81" ref-type="bibr">2015</xref>, <xref rid="B80" ref-type="bibr">2016</xref>; Naughton et al., <xref rid="B149" ref-type="bibr">2016</xref>; Segev et al., <xref rid="B183" ref-type="bibr">2017</xref>). Targets have not been limited to the brain and include the spinal cord and peripheral nerves (VNS for epilepsy and depression, motor nerves for various palsies, hypoglossal nerve for sleep apnoea and many more). For some peripheral nerves, optic stimulation could be realized without implant or transfection (Maimon et al., <xref rid="B124" ref-type="bibr">2017</xref>). Alternatively, non invasive techniques are being developed with Transcranial Direct Current Stimulation (tDCS), transcutaneous VNS (tVNS), Repetitive Transcranial Magnetic Stimulation (rTMS) and others.</p></sec><sec><title>9.3. Limitations</title><p>Despite its acceptance, there is still much room for progress in the practice of DBS&#x02014;for example, by providing bi-directional (i.e., including sensing) interfaces, which would open the path for closed-loop approaches and titration of stimulation. Neural tissue does not necessarily provide a stable response to chronic stimuli (McCreery et al., <xref rid="B134" ref-type="bibr">1997</xref>). Poorly controllable brain plasticity can turn out to be an ally or an enemy in chronic applications. Along the same line, cellular biology homeostasis (Sinnen et al., <xref rid="B192" ref-type="bibr">2017</xref>) should be considered. It is known that long term potentiation or depression (LTP, LTD) (Nabavi et al., <xref rid="B145" ref-type="bibr">2014</xref>; Correia et al., <xref rid="B40" ref-type="bibr">2017</xref>) can be induced by some stimulation conditions. Specific strategies might be essential in the control of epileptic activity (Ching and Ritt, <xref rid="B32" ref-type="bibr">2013</xref>). Cell-type and even sub-cellular specificity hold the promise for real progress (Dvorzhak et al., <xref rid="B51" ref-type="bibr">in press</xref>) but we lack the knowledge to benefit from such developments. Also stimulus phase timing (Witt et al., <xref rid="B225" ref-type="bibr">2013</xref>) can be important. Appropriate stimulation can shift the excitability of the cortex (Heitmann et al., <xref rid="B79" ref-type="bibr">2017</xref>). Stimulation regimens are important (Shiri et al., <xref rid="B190" ref-type="bibr">2017</xref>) but mostly established on empirical basis because of a lack of neurophysiological and pathophysiological understanding (Gradinaru et al., <xref rid="B61" ref-type="bibr">2009</xref>; Dvorzhak et al., <xref rid="B51" ref-type="bibr">in press</xref>). Safe limits for the various stimulation parameters have not been firmly established. Despite the brain being essentially a control system, most rational explanations are still in terms of a simple balance between excitatory and inhibitory influences. Closed loop system are being presented (Grosenick et al., <xref rid="B68" ref-type="bibr">2015</xref>) but they still represent &#x0201c;event-triggered&#x0201d; stimulation rather than network integrated devices.</p></sec><sec><title>9.4. Possible applications</title><p>DBS is a recognized therapy in Parkinson's disease and it has also benefited some cases of major depression. An optogenetics equivalent could do equally well or perhaps even better but there is no clinical evidence yet. Present findings point to a number of pathways along which optogenetics is likely to play a role in the near future, namely in the treatment of epilepsy (Mantoan Ritter et al., <xref rid="B129" ref-type="bibr">2014</xref>). With the assumption that various issues related to genetic manipulations of adult patients can be resolved, optogenetics could soon become an alternative to DBS (Karas et al., <xref rid="B91" ref-type="bibr">2013</xref>) in the treatment of <italic>Parkinson's disease</italic> (Beitz, <xref rid="B9" ref-type="bibr">2014</xref>) and <italic>epilepsy</italic> (see for example Boon et al., <xref rid="B18" ref-type="bibr">2007</xref>; Cox et al., <xref rid="B41" ref-type="bibr">2014</xref>). Many more conditions might soon enter the therapeutic perspective including Alzheimer's disease (Kastanenka et al., <xref rid="B92" ref-type="bibr">2017</xref>), the cochlear prosthesis (Richardson et al., <xref rid="B172" ref-type="bibr">2017</xref>), visual pathologies (Scholl et al., <xref rid="B181" ref-type="bibr">2016</xref>; Sengupta et al., <xref rid="B184" ref-type="bibr">2016</xref>) and perhaps cardiac (Entcheva and Bub, <xref rid="B54" ref-type="bibr">2016</xref>) or other non-neural conditions.</p></sec></sec><sec id="s10"><title>10. Conclusions and outlook</title><p>Presented brief overview of the perspectives of optogenetics for DBS and neuromodulation leads to the following conclusions:</p><p>On the first place, the term &#x0201c;optogenetics&#x0201d; cannot be reduced to a single method or technique but can be broken down into a number of components that could be used independently of assembled in various combinations leading to a very broad spectrum of exciting therapeutic perspectives. A bright future for such applications can be foreseen. Optogenetics thus appears as a challenge well worth the substantial research effort that it still requires.</p><p>Secondly, safety of viral vectors is not a roadblock toward human application of optogenetics. There is already sufficient experience with clinical trials and level of maturity of viral vector technology. Despite the major input of technology in the field, it also appears that a lack in fundamental knowledge remains a major obstacle to progress (Jarvis and Schultz, <xref rid="B85" ref-type="bibr">2015</xref>). Investing massively in applied trials while neglecting basic science might not be the most cost-effective way on the long run. Safety, optimization and chronic applicability would surely benefit from such a basic knowledge-first based approach.</p><p>Thirdly, attempts to apply optogenetics immediately confront researchers with the large gaps in our knowledge of the brain. Clearly, trials based only on partial understanding will lead to inefficiency and increasing risks as already shown by the early failures in gene therapy. The shortest path toward successful optogenetics applications appears to be to focus on fundamental research on mechanisms of DBS.</p><p>Optogenetics itself seems to offer the necessary tools to perform the experimental brain studies that are so badly needed. Progress in the field precisely identifies the function of specific populations of neurons in a complex anatomical substrate. Chronic clinical evaluation is necessary before it can be stated that initial results will be maintained in time. Long term evolution of the therapeutic effects, however can turn out either way. It may be either favorable or leading to inefficiency and side effects.</p><p>Optogenetics can be considered as a case demonstrating the value of exploratory research. This is clearly recognized by Deisseroth (<xref rid="B43" ref-type="bibr">2015</xref>), who further admits that pioneering optogenetic experiments were not suitable to typical grant programs focusing on a disease state, on a translational question, or even on solidly justified basic science.</p><p>Finally, optogenetics provides a large variety of tools, which enable further fundamental research. On the other hand it also raises challenges because of its transdisciplinary character. The extraordinary therapeutic breakthroughs that can be foreseen, the sheer number of conditions for which an application seems ultimately possible and the accumulating evidence balances the hurdles described in the preceding sections.</p></sec><sec id="s11"><title>Author contributions</title><p>All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer WW declared a past co-authorship with one of the authors JD to the handling Editor.</p></sec></sec></body><back><ack><p>The work has been supported in part by a project grant from Research Fund&#x02014;Flanders (FWO), Belgium, contract number G.0C75.13N and an individual PhD FWO fellowship to KM.</p></ack><fn-group><fn id="fn0001"><p><sup>1</sup>Conditioned on prior gene transfection by viral vectors or other means.</p></fn><fn id="fn0002"><p><sup>2</sup>International Neuromodulation Society: <ext-link ext-link-type="uri" xlink:href="http://www.neuromodulation.com/about-neuromodulation">http://www.neuromodulation.com/about-neuromodulation</ext-link>.</p></fn><fn id="fn0003"><p><sup>3</sup>Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy trial (SANTE; NCT00101933, Medtronic, Minneapolis, MN, USA).</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akache</surname><given-names>B.</given-names></name><name><surname>Grimm</surname><given-names>D.</given-names></name><name><surname>Pandey</surname><given-names>K.</given-names></name><name><surname>Yant</surname><given-names>S. R.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Kay</surname><given-names>M. A.</given-names></name></person-group> (<year>2006</year>). <article-title>The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9</article-title>. <source>J. Virol.</source>
<volume>80</volume>, <fpage>9831</fpage>&#x02013;<lpage>9836</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00878-06</pub-id><?supplied-pmid 16973587?><pub-id pub-id-type="pmid">16973587</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Atabany</surname><given-names>W.</given-names></name><name><surname>McGovern</surname><given-names>B.</given-names></name><name><surname>Mehran</surname><given-names>K.</given-names></name><name><surname>Berlinguer-Palmini</surname><given-names>R.</given-names></name><name><surname>Degenaar</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>). <article-title>A processing platform for optoelectronic/optogenetic retinal prosthesis</article-title>. <source>IEEE Trans. Biomed. Eng.</source>
<volume>60</volume>, <fpage>781</fpage>&#x02013;<lpage>791</lpage>. <pub-id pub-id-type="doi">10.1109/TBME.2011.2177498</pub-id><?supplied-pmid 22127992?><pub-id pub-id-type="pmid">22127992</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>B. D.</given-names></name><name><surname>Singer</surname><given-names>A. C.</given-names></name><name><surname>Boyden</surname><given-names>E. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Principles of designing interpretable optogenetic behavior experiments</article-title>. <source>Learn. Mem.</source>
<volume>22</volume>, <fpage>232</fpage>&#x02013;<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1101/lm.038026.114</pub-id><?supplied-pmid 25787711?><pub-id pub-id-type="pmid">25787711</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>V.</given-names></name><name><surname>Duffy</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Dejneka</surname><given-names>N. S.</given-names></name><name><surname>Maguire</surname><given-names>A. M.</given-names></name><name><surname>Bennett</surname><given-names>J.</given-names></name></person-group> (<year>2002</year>). <article-title>A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus</article-title>. <source>Mol. Ther.</source>
<volume>5</volume>, <fpage>125</fpage>&#x02013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1006/mthe.2002.0525</pub-id><?supplied-pmid 11829519?><pub-id pub-id-type="pmid">11829519</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antkowiak</surname><given-names>M.</given-names></name><name><surname>Torres-Mapa</surname><given-names>M. L.</given-names></name><name><surname>Witts</surname><given-names>E. C.</given-names></name><name><surname>Miles</surname><given-names>G. B.</given-names></name><name><surname>Dholakia</surname><given-names>K.</given-names></name><name><surname>Gunn-Moore</surname><given-names>F. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Fast targeted gene transfection and optogenetic modification of single neurons using femtosecond laser irradiation</article-title>. <source>Sci. Rep.</source>
<volume>3</volume>:<fpage>3281</fpage>. <pub-id pub-id-type="doi">10.1038/srep03281</pub-id><?supplied-pmid 24257461?><pub-id pub-id-type="pmid">24257461</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arias-Gil</surname><given-names>G.</given-names></name><name><surname>Ohl</surname><given-names>F. W.</given-names></name><name><surname>Takagaki</surname><given-names>K.</given-names></name><name><surname>Lippert</surname><given-names>M. T.</given-names></name></person-group> (<year>2016</year>). <article-title>Measurement, modeling, and prediction of temperature rise due to optogenetic brain stimulation</article-title>. <source>Neurophotonics</source>
<volume>3</volume>:<fpage>045007</fpage>. <pub-id pub-id-type="doi">10.1117/1.NPh.3.4.045007</pub-id><?supplied-pmid 27981063?><pub-id pub-id-type="pmid">27981063</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arruda</surname><given-names>V. R.</given-names></name><name><surname>Stedman</surname><given-names>H. H.</given-names></name><name><surname>Haurigot</surname><given-names>V.</given-names></name><name><surname>Buchlis</surname><given-names>G.</given-names></name><name><surname>Baila</surname><given-names>S.</given-names></name><name><surname>Favaro</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B</article-title>. <source>Blood</source>
<volume>115</volume>, <fpage>4678</fpage>&#x02013;<lpage>4688</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2009-12-261156</pub-id><?supplied-pmid 20335222?><pub-id pub-id-type="pmid">20335222</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldo</surname><given-names>A.</given-names></name><name><surname>van den Akker</surname><given-names>E.</given-names></name><name><surname>Bergmans</surname><given-names>H. E.</given-names></name><name><surname>Lim</surname><given-names>F.</given-names></name><name><surname>Pauwels</surname><given-names>K.</given-names></name></person-group> (<year>2013</year>). <article-title>General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination</article-title>. <source>Curr. Gene Ther.</source>
<volume>13</volume>, <fpage>385</fpage>&#x02013;<lpage>394</lpage>. <pub-id pub-id-type="doi">10.2174/15665232113136660005</pub-id><?supplied-pmid 24195604?><pub-id pub-id-type="pmid">24195604</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beitz</surname><given-names>J. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Parkinson's disease: a review</article-title>. <source>Front. Biosci. (Schol Ed.)</source>
<volume>6</volume>, <fpage>65</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.2741/S415</pub-id><?supplied-pmid 24389262?><pub-id pub-id-type="pmid">24389262</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Menachem</surname><given-names>E.</given-names></name><name><surname>French</surname><given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>VNS Therapy versus the latest antiepileptic drug</article-title>. <source>Epileptic Disord.</source>
<volume>7</volume>, <fpage>S22</fpage>&#x02013;<lpage>S26</lpage>. <?supplied-pmid 16120490?><pub-id pub-id-type="pmid">16120490</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benabid</surname><given-names>A. L.</given-names></name><name><surname>Pollak</surname><given-names>P.</given-names></name><name><surname>Gao</surname><given-names>D.</given-names></name><name><surname>Hoffmann</surname><given-names>D.</given-names></name><name><surname>Limousin</surname><given-names>P.</given-names></name><name><surname>Gay</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>1996</year>). <article-title>Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders</article-title>. <source>J. Neurosurg.</source>
<volume>84</volume>, <fpage>203</fpage>&#x02013;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.3171/jns.1996.84.2.0203</pub-id><?supplied-pmid 8592222?><pub-id pub-id-type="pmid">8592222</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benaron</surname><given-names>D. A.</given-names></name><name><surname>Hintz</surname><given-names>S. R.</given-names></name><name><surname>Villringer</surname><given-names>A.</given-names></name><name><surname>Boas</surname><given-names>D.</given-names></name><name><surname>Kleinschmidt</surname><given-names>A.</given-names></name><name><surname>Frahm</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2000</year>). <article-title>Noninvasive functional imaging of human brain using light</article-title>. <source>J. Cereb. Blood Flow Metab.</source>
<volume>20</volume>, <fpage>469</fpage>&#x02013;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1097/00004647-200003000-00005</pub-id><?supplied-pmid 10724111?><pub-id pub-id-type="pmid">10724111</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>J. G.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Henninger</surname><given-names>M. A.</given-names></name><name><surname>Ko</surname><given-names>E. Y.</given-names></name><name><surname>Qian</surname><given-names>X.</given-names></name><name><surname>Franzesi</surname><given-names>G. T.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Prosthetic systems for therapeutic optical activation and silencing of genetically-targeted neurons</article-title>. <source>Proc. SPIE Int. Soc. Opt. Eng.</source>
<volume>6854</volume>:<fpage>68540H</fpage>. <pub-id pub-id-type="doi">10.1117/12.768798</pub-id><?supplied-pmid 18458792?><pub-id pub-id-type="pmid">18458792</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bessis</surname><given-names>N.</given-names></name><name><surname>GarciaCozar</surname><given-names>F. J.</given-names></name><name><surname>Boissier</surname><given-names>M. C.</given-names></name></person-group> (<year>2004</year>). <article-title>Immune responses to gene therapy vectors: influence on vector function and effector mechanisms</article-title>. <source>Gene Ther.</source>
<volume>11</volume>(<issue>Suppl. 1</issue>):<fpage>S10</fpage>&#x02013;<lpage>S17</lpage>. <pub-id pub-id-type="doi">10.1038/sj.gt.3302364</pub-id><?supplied-pmid 15454952?><pub-id pub-id-type="pmid">15454952</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhadra</surname><given-names>N.</given-names></name><name><surname>Peckham</surname><given-names>P.</given-names></name></person-group> (<year>1997</year>). <article-title>Peripheral nerve stimulation for restoration of motor function</article-title>. <source>J. Clin. Neurophysiol.</source>
<volume>14</volume>, <fpage>378</fpage>&#x02013;<lpage>393</lpage>. <pub-id pub-id-type="doi">10.1097/00004691-199709000-00004</pub-id><?supplied-pmid 9415385?><pub-id pub-id-type="pmid">9415385</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjornsson</surname><given-names>C. S.</given-names></name><name><surname>Oh</surname><given-names>S. J.</given-names></name><name><surname>Al-Kofahi</surname><given-names>Y. A.</given-names></name><name><surname>Lim</surname><given-names>Y. J.</given-names></name><name><surname>Smith</surname><given-names>K. L.</given-names></name><name><surname>Turner</surname><given-names>J. N.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Effects of insertion conditions on tissue strain and vascular damage during neuroprosthetic device insertion</article-title>. <source>J. Neural Eng.</source>
<volume>3</volume>, <fpage>196</fpage>&#x02013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1088/1741-2560/3/3/002</pub-id><?supplied-pmid 16921203?><pub-id pub-id-type="pmid">16921203</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackburn</surname><given-names>S. D.</given-names></name><name><surname>Steadman</surname><given-names>R. A.</given-names></name><name><surname>Johnson</surname><given-names>F. B.</given-names></name></person-group> (<year>2006</year>). <article-title>Attachment of adeno-associated virus type 3h to fibroblast growth factor receptor 1</article-title>. <source>Arch. Virol.</source>
<volume>151</volume>, <fpage>617</fpage>&#x02013;<lpage>623</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-005-0650-6</pub-id><?supplied-pmid 16195782?><pub-id pub-id-type="pmid">16195782</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boon</surname><given-names>P.</given-names></name><name><surname>De Herdt</surname><given-names>V.</given-names></name><name><surname>Vonck</surname><given-names>K.</given-names></name><name><surname>Van Roost</surname><given-names>D.</given-names></name></person-group> (<year>2007</year>). <article-title>Clinical experience with vagus nerve stimulation and deep brain stimulation in epilepsy</article-title>. <source>Acta Neurochirurgica. Suppl.</source>
<volume>97</volume>, <fpage>273</fpage>&#x02013;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-211-33081-4_30</pub-id><?supplied-pmid 17691313?><pub-id pub-id-type="pmid">17691313</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bostock</surname><given-names>H.</given-names></name></person-group> (<year>1983</year>). <article-title>The strength-duration relationship for excitation of myelinated nerve: computed dependence on membrane parameters</article-title>. <source>J. Physiol.</source>
<volume>341</volume>, <fpage>59</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.1983.sp014792</pub-id><?supplied-pmid 6312032?><pub-id pub-id-type="pmid">6312032</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Boyden</surname><given-names>E.</given-names></name><name><surname>Eisenach</surname><given-names>J.</given-names></name><name><surname>Greenberg</surname><given-names>K.</given-names></name><name><surname>Horsager</surname><given-names>A.</given-names></name><name><surname>Matteo</surname><given-names>B.</given-names></name><name><surname>Ririe</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2012</year>). <source>Methods and Compositions for Decreasing Chronic Pain.</source> WO Patent App. No. PCT/US2011/031297.</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyden</surname><given-names>E. S.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Bamberg</surname><given-names>E.</given-names></name><name><surname>Nagel</surname><given-names>G.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group> (<year>2005</year>). <article-title>Millisecond-timescale, genetically targeted optical control of neural activity</article-title>. <source>Nat. Neurosci.</source>
<volume>8</volume>, <fpage>1263</fpage>&#x02013;<lpage>1268</lpage>. <pub-id pub-id-type="doi">10.1038/nn1525</pub-id><?supplied-pmid 16116447?><pub-id pub-id-type="pmid">16116447</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brechun</surname><given-names>K. E.</given-names></name><name><surname>Arndt</surname><given-names>K. M.</given-names></name><name><surname>Woolley</surname><given-names>G. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Strategies for the photo-control of endogenous protein activity</article-title>. <source>Curr. Opin. Struct. Biol.</source>
<volume>45</volume>, <fpage>53</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.sbi.2016.11.014</pub-id><?supplied-pmid 27907886?><pub-id pub-id-type="pmid">27907886</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f8;rretzen</surname><given-names>M. N.</given-names></name><name><surname>Bjerknes</surname><given-names>S.</given-names></name><name><surname>S&#x000e6;hle</surname><given-names>T.</given-names></name><name><surname>Skjelland</surname><given-names>M.</given-names></name><name><surname>Skogseid</surname><given-names>I. M.</given-names></name><name><surname>Toft</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Long-term follow-up of thalamic deep brain stimulation for essential tremor - patient satisfaction and mortality</article-title>. <source>BMC Neurol.</source>
<volume>14</volume>:<fpage>120</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2377-14-120</pub-id><?supplied-pmid 24903550?><pub-id pub-id-type="pmid">24903550</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busskamp</surname><given-names>V.</given-names></name><name><surname>Duebel</surname><given-names>J.</given-names></name><name><surname>Balya</surname><given-names>D.</given-names></name><name><surname>Fradot</surname><given-names>M.</given-names></name><name><surname>Viney</surname><given-names>T. J.</given-names></name><name><surname>Siegert</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa</article-title>. <source>Science</source>
<volume>329</volume>, <fpage>413</fpage>&#x02013;<lpage>417</lpage>. <pub-id pub-id-type="doi">10.1126/science.1190897</pub-id><?supplied-pmid 20576849?><pub-id pub-id-type="pmid">20576849</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butson</surname><given-names>C. R.</given-names></name><name><surname>Cooper</surname><given-names>S. E.</given-names></name><name><surname>Henderson</surname><given-names>J. M.</given-names></name><name><surname>McIntyre</surname><given-names>C. C.</given-names></name></person-group> (<year>2007</year>). <article-title>Patient-specific analysis of the volume of tissue activated during deep brain stimulation</article-title>. <source>Neuroimage</source>
<volume>34</volume>, <fpage>661</fpage>&#x02013;<lpage>670</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.09.034</pub-id><?supplied-pmid 17113789?><pub-id pub-id-type="pmid">17113789</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buzs&#x000e1;ki</surname><given-names>G.</given-names></name><name><surname>Stark</surname><given-names>E.</given-names></name><name><surname>Ber&#x000e9;nyi</surname><given-names>A.</given-names></name><name><surname>Khodagholy</surname><given-names>D.</given-names></name><name><surname>Kipke</surname><given-names>D.</given-names></name><name><surname>Yoon</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Tools for probing local circuits: high-density silicon probes combined with optogenetics</article-title>. <source>Neuron</source>
<volume>86</volume>, <fpage>92</fpage>&#x02013;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.01.028</pub-id><?supplied-pmid 25856489?><pub-id pub-id-type="pmid">25856489</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>B. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Adeno-associated virus vectors in clinical trials</article-title>. <source>Hum. Gene Ther.</source>
<volume>16</volume>, <fpage>541</fpage>&#x02013;<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1089/hum.2005.16.541</pub-id><?supplied-pmid 15916479?><pub-id pub-id-type="pmid">15916479</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho-de Souza</surname><given-names>J. L.</given-names></name><name><surname>Treger</surname><given-names>J. S.</given-names></name><name><surname>Dang</surname><given-names>B.</given-names></name><name><surname>Kent</surname><given-names>S. B.</given-names></name><name><surname>Pepperberg</surname><given-names>D. R.</given-names></name><name><surname>Bezanilla</surname><given-names>F.</given-names></name></person-group> (<year>2015</year>). <article-title>Photosensitivity of neurons enabled by cell-targeted gold nanoparticles</article-title>. <source>Neuron</source>
<volume>86</volume>, <fpage>207</fpage>&#x02013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.02.033</pub-id><?supplied-pmid 25772189?><pub-id pub-id-type="pmid">25772189</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C. H.</given-names></name><name><surname>McCullagh</surname><given-names>E. A.</given-names></name><name><surname>Pun</surname><given-names>S. H.</given-names></name><name><surname>Mak</surname><given-names>P. U.</given-names></name><name><surname>Vai</surname><given-names>M. I.</given-names></name><name><surname>Mak</surname><given-names>P. I.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>An integrated circuit for simultaneous extracellular electrophysiology recording and optogenetic neural manipulation</article-title>. <source>IEEE Trans. Biomed. Eng.</source>
<volume>64</volume>, <fpage>557</fpage>&#x02013;<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1109/TBME.2016.2609412</pub-id><?supplied-pmid 28221990?><pub-id pub-id-type="pmid">28221990</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>K. P.</given-names></name><name><surname>Kiernan</surname><given-names>E. A.</given-names></name><name><surname>Eliceiri</surname><given-names>K. W.</given-names></name><name><surname>Williams</surname><given-names>J. C.</given-names></name><name><surname>Watters</surname><given-names>J. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Blue light modulates murine microglial gene expression in the absence of optogenetic protein expression</article-title>. <source>Sci. Rep.</source>
<volume>6</volume>:<fpage>21172</fpage>. <pub-id pub-id-type="doi">10.1038/srep21172</pub-id><?supplied-pmid 26883795?><pub-id pub-id-type="pmid">26883795</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiken</surname><given-names>S.</given-names></name><name><surname>Nambu</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Mechanism of deep brain stimulation: inhibition, excitation, or disruption?</article-title>
<source>Neuroscientist</source>
<volume>22</volume>, <fpage>313</fpage>&#x02013;<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1177/1073858415581986</pub-id><pub-id pub-id-type="pmid">25888630</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ching</surname><given-names>S.</given-names></name><name><surname>Ritt</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>Control strategies for underactuated neural ensembles driven by optogenetic stimulation</article-title>. <source>Front. Neural Circuits</source>
<volume>7</volume>:<fpage>54</fpage>. <pub-id pub-id-type="doi">10.3389/fncir.2013.00054</pub-id><?supplied-pmid 23576956?><pub-id pub-id-type="pmid">23576956</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>W. H.</given-names></name><name><surname>Barcelon</surname><given-names>E.</given-names></name><name><surname>Lee</surname><given-names>S. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Optogenetic glia manipulation: possibilities and future prospects</article-title>. <source>Exp. Neurobiol.</source>
<volume>25</volume>, <fpage>197</fpage>&#x02013;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.5607/en.2016.25.5.197</pub-id><?supplied-pmid 27790054?><pub-id pub-id-type="pmid">27790054</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>B. Y.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Dobry</surname><given-names>A. S.</given-names></name><name><surname>Qian</surname><given-names>X.</given-names></name><name><surname>Chuong</surname><given-names>A. S.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>High-performance genetically targetable optical neural silencing by light-driven proton pumps</article-title>. <source>Nature</source>
<volume>463</volume>, <fpage>98</fpage>&#x02013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1038/nature08652</pub-id><?supplied-pmid 20054397?><pub-id pub-id-type="pmid">20054397</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christie</surname><given-names>I. N.</given-names></name><name><surname>Wells</surname><given-names>J. A.</given-names></name><name><surname>Southern</surname><given-names>P.</given-names></name><name><surname>Marina</surname><given-names>N.</given-names></name><name><surname>Kasparov</surname><given-names>S.</given-names></name><name><surname>Gourine</surname><given-names>A. V.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>FMRI response to blue light delivery in the na&#x000ef;ve brain: implications for combined optogenetic fMRI studies</article-title>. <source>NeuroImage</source>
<volume>66</volume>, <fpage>634</fpage>&#x02013;<lpage>641</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.10.074</pub-id><?supplied-pmid 23128081?><pub-id pub-id-type="pmid">23128081</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christine</surname><given-names>C. W.</given-names></name><name><surname>Starr</surname><given-names>P. A.</given-names></name><name><surname>Larson</surname><given-names>P. S.</given-names></name><name><surname>Eberling</surname><given-names>J. L.</given-names></name><name><surname>Jagust</surname><given-names>W. J.</given-names></name><name><surname>Hawkins</surname><given-names>R. A.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Safety and tolerability of putaminal aadc gene therapy for parkinson disease</article-title>. <source>Neurology</source>
<volume>73</volume>, <fpage>1662</fpage>&#x02013;<lpage>1669</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181c29356</pub-id><?supplied-pmid 19828868?><pub-id pub-id-type="pmid">19828868</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>M.</given-names></name><name><surname>Thrasher</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Gene therapy: progress and predictions</article-title>. <source>Proc. Biol. Sci.</source>
<volume>282</volume>:<fpage>20143003</fpage>. <pub-id pub-id-type="doi">10.1098/rspb.2014.3003</pub-id><?supplied-pmid 26702034?><pub-id pub-id-type="pmid">26702034</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>R.</given-names></name><name><surname>Assayag</surname><given-names>O.</given-names></name><name><surname>de</surname><given-names>V. S.</given-names></name><name><surname>Guillon</surname><given-names>M.</given-names></name><name><surname>Emiliani</surname><given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Computer generated holography with intensity-graded patterns</article-title>. <source>Front. Cell. Neurosci.</source>
<volume>10</volume>:<fpage>236</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2016.00236</pub-id><?supplied-pmid 27799896?><pub-id pub-id-type="pmid">27799896</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Corlan</surname><given-names>A. D.</given-names></name></person-group> (<year>2004</year>). <source>Medline Trend: Automated Yearly Statistics of PubMed Results for Any Query</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="http://dan.corlan.net/medline-trend.html">http://dan.corlan.net/medline-trend.html</ext-link></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correia</surname><given-names>P. A.</given-names></name><name><surname>Lottem</surname><given-names>E.</given-names></name><name><surname>Banerjee</surname><given-names>D.</given-names></name><name><surname>Machado</surname><given-names>A. S.</given-names></name><name><surname>Carey</surname><given-names>M. R.</given-names></name><name><surname>Mainen</surname><given-names>Z. F.</given-names></name></person-group> (<year>2017</year>). <article-title>Transient inhibition and long-term facilitation of locomotion by phasic optogenetic activation of serotonin neurons</article-title>. <source>eLife</source>
<volume>6</volume>:<fpage>e20975</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.20975</pub-id><?supplied-pmid 28193320?><pub-id pub-id-type="pmid">28193320</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J. H.</given-names></name><name><surname>Seri</surname><given-names>S.</given-names></name><name><surname>Cavanna</surname><given-names>A. E.</given-names></name></person-group> (<year>2014</year>). <article-title>Clinical utility of implantable neurostimulation devices as adjunctive treatment of uncontrolled seizures</article-title>. <source>Neuropsychiatr. Dis. Treatment</source>
<volume>10</volume>, <fpage>2191</fpage>&#x02013;<lpage>2200</lpage>. <pub-id pub-id-type="doi">10.2147/NDT.S60854</pub-id><?supplied-pmid 25484587?><pub-id pub-id-type="pmid">25484587</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawydow</surname><given-names>A.</given-names></name><name><surname>Gueta</surname><given-names>R.</given-names></name><name><surname>Ljaschenko</surname><given-names>D.</given-names></name><name><surname>Ullrich</surname><given-names>S.</given-names></name><name><surname>Hermann</surname><given-names>M.</given-names></name><name><surname>Ehmann</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Channelrhodopsin-2-XXL, a powerful optogenetic tool for low-light applications</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>111</volume>, <fpage>13972</fpage>&#x02013;<lpage>13977</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1408269111</pub-id><?supplied-pmid 25201989?><pub-id pub-id-type="pmid">25201989</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group> (<year>2015</year>). <article-title>Optogenetics: 10 years of microbial opsins in neuroscience</article-title>. <source>Nat. Neurosci.</source>
<volume>18</volume>, <fpage>1213</fpage>&#x02013;<lpage>1225</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4091</pub-id><?supplied-pmid 26308982?><pub-id pub-id-type="pmid">26308982</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Deisseroth</surname><given-names>K.</given-names></name><name><surname>Delp</surname><given-names>S.</given-names></name><name><surname>Llewellyn</surname><given-names>M.</given-names></name><name><surname>Payne</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>). <source>Materials and Approaches for Optical Stimulation of the Peripheral Nervous System.</source> US Patent 9,308,392.</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Deisseroth</surname><given-names>K.</given-names></name><name><surname>Schneider</surname><given-names>M.</given-names></name><name><surname>Mishelevich</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). <source>System for Optical Stimulation of Target Cells</source>. US Patent 8,926,959.</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Deisseroth</surname><given-names>K.</given-names></name><name><surname>Yizhar</surname><given-names>O.</given-names></name><name><surname>Gunaydin</surname><given-names>L.</given-names></name><name><surname>Hegemann</surname><given-names>P.</given-names></name><name><surname>Berndt</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <source>Optically-Based Stimulation of Target Cells and Modifications Thereto</source>. US Patent 8,716,447.</mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Pasquale</surname><given-names>G.</given-names></name><name><surname>Davidson</surname><given-names>B. L.</given-names></name><name><surname>Stein</surname><given-names>C. S.</given-names></name><name><surname>Martins</surname><given-names>I.</given-names></name><name><surname>Scudiero</surname><given-names>D.</given-names></name><name><surname>Monks</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Identification of pdgfr as a receptor for aav-5 transduction</article-title>. <source>Nat. Med.</source>
<volume>9</volume>, <fpage>1306</fpage>&#x02013;<lpage>1312</lpage>. <pub-id pub-id-type="doi">10.1038/nm929</pub-id><?supplied-pmid 14502277?><pub-id pub-id-type="pmid">14502277</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diester</surname><given-names>I.</given-names></name><name><surname>Kaufman</surname><given-names>M. T.</given-names></name><name><surname>Mogri</surname><given-names>M.</given-names></name><name><surname>Pashaie</surname><given-names>R.</given-names></name><name><surname>Goo</surname><given-names>W.</given-names></name><name><surname>Yizhar</surname><given-names>O.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>An optogenetic toolbox designed for primates</article-title>. <source>Nat. Neurosci.</source>
<volume>14</volume>, <fpage>387</fpage>&#x02013;<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2749</pub-id><?supplied-pmid 21278729?><pub-id pub-id-type="pmid">21278729</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doherty</surname><given-names>F. C.</given-names></name><name><surname>Schaack</surname><given-names>J. B.</given-names></name><name><surname>Sladek</surname><given-names>C. D.</given-names></name></person-group> (<year>2011</year>). <article-title>Comparison of the efficacy of four viral vectors for transducing hypothalamic magnocellular neurosecretory neurons in the rat supraoptic nucleus</article-title>. <source>J. Neurosci. Methods</source>
<volume>197</volume>, <fpage>238</fpage>&#x02013;<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2011.02.026</pub-id><?supplied-pmid 21392530?><pub-id pub-id-type="pmid">21392530</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>B.</given-names></name><name><surname>Pillon</surname><given-names>B.</given-names></name><name><surname>De Saxce</surname><given-names>H.</given-names></name><name><surname>Lhermitte</surname><given-names>F.</given-names></name><name><surname>Agid</surname><given-names>Y.</given-names></name></person-group> (<year>1986</year>). <article-title>Disappearance of parkinsonian signs after spontaneous vascular &#x02018;thalamotomy&#x02019;</article-title>. <source>Arch. Neurol.</source>
<volume>43</volume>, <fpage>815</fpage>&#x02013;<lpage>817</lpage>. <pub-id pub-id-type="doi">10.1001/archneur.1986.00520080057021</pub-id><?supplied-pmid 3729763?><pub-id pub-id-type="pmid">3729763</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dvorzhak</surname><given-names>A.</given-names></name><name><surname>Melnick</surname><given-names>I.</given-names></name><name><surname>Grantyn</surname><given-names>R.</given-names></name></person-group> (<year>in press</year>). <article-title>Astrocytes and presynaptic plasticity in the striatum: evidence and unanswered questions</article-title>. <source>Brain Res. Bull</source>. <pub-id pub-id-type="doi">10.1016/j.brainresbull.2017.01.001</pub-id><?supplied-pmid 28069435?><pub-id pub-id-type="pmid">28069435</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckmier</surname><given-names>A.</given-names></name><name><surname>Daney de Marcillac</surname><given-names>W.</given-names></name><name><surname>M&#x000ee;tre</surname><given-names>A.</given-names></name><name><surname>Jay</surname><given-names>T. M.</given-names></name><name><surname>Sanders</surname><given-names>M. J.</given-names></name><name><surname>Godsil</surname><given-names>B. P.</given-names></name></person-group> (<year>2016</year>). <article-title>Rats can acquire conditional fear of faint light leaking through the acrylic resin used to mount fiber optic cannulas</article-title>. <source>Learn. Mem.</source>
<volume>23</volume>, <fpage>684</fpage>&#x02013;<lpage>688</lpage>. <pub-id pub-id-type="doi">10.1101/lm.042465.116</pub-id><?supplied-pmid 27918272?><pub-id pub-id-type="pmid">27918272</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emiliani</surname><given-names>V.</given-names></name><name><surname>Cohen</surname><given-names>A. E.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name><name><surname>H&#x000e4;usser</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>All-optical interrogation of neural circuits</article-title>. <source>J. Neurosci.</source>
<volume>35</volume>, <fpage>13917</fpage>&#x02013;<lpage>13926</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2916-15.2015</pub-id><?supplied-pmid 26468193?><pub-id pub-id-type="pmid">26468193</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Entcheva</surname><given-names>E.</given-names></name><name><surname>Bub</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>All-optical control of cardiac excitation: combined high-resolution optogenetic actuation and optical mapping</article-title>. <source>J. Physiol.</source>
<volume>594</volume>, <fpage>2503</fpage>&#x02013;<lpage>2510</lpage>. <pub-id pub-id-type="doi">10.1113/JP271559</pub-id><?supplied-pmid 26857427?><pub-id pub-id-type="pmid">26857427</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enterina</surname><given-names>J. R.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Campbell</surname><given-names>R. E.</given-names></name></person-group> (<year>2015</year>). <article-title>Emerging fluorescent protein technologies</article-title>. <source>Curr. Opin. Chem. Biol.</source>
<volume>27</volume>, <fpage>10</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbpa.2015.05.001</pub-id><?supplied-pmid 26043278?><pub-id pub-id-type="pmid">26043278</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>F. Hern&#x000e1;ndez</surname><given-names>L.</given-names></name><name><surname>Castela</surname><given-names>I.</given-names></name><name><surname>Ruiz-DeDiego</surname><given-names>I.</given-names></name><name><surname>Obeso</surname><given-names>J. A.</given-names></name><name><surname>Moratalla</surname><given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of parkinson disease</article-title>. <source>Mov. Disord.</source>
<volume>32</volume>, <fpage>530</fpage>&#x02013;<lpage>537</lpage>. <pub-id pub-id-type="doi">10.1002/mds.26947</pub-id><?supplied-pmid 28256089?><pub-id pub-id-type="pmid">28256089</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feigin</surname><given-names>A.</given-names></name><name><surname>Kaplitt</surname><given-names>M. G.</given-names></name><name><surname>Tang</surname><given-names>C.</given-names></name><name><surname>Lin</surname><given-names>T.</given-names></name><name><surname>Mattis</surname><given-names>P.</given-names></name><name><surname>Dhawan</surname><given-names>V.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Modulation of metabolic brain networks after subthalamic gene therapy for parkinson's disease</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>104</volume>, <fpage>19559</fpage>&#x02013;<lpage>19564</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0706006104</pub-id><?supplied-pmid 18042721?><pub-id pub-id-type="pmid">18042721</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fran&#x000e7;ois</surname><given-names>A.</given-names></name><name><surname>Low</surname><given-names>S. A.</given-names></name><name><surname>Sypek</surname><given-names>E. I.</given-names></name><name><surname>Christensen</surname><given-names>A. J.</given-names></name><name><surname>Sotoudeh</surname><given-names>C.</given-names></name><name><surname>Beier</surname><given-names>K. T.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>A brainstem-spinal cord inhibitory circuit for mechanical pain modulation by GABA and enkephalins</article-title>. <source>Neuron</source>
<volume>93</volume>, <fpage>822</fpage>&#x02013;<lpage>839</lpage>.e6. <pub-id pub-id-type="doi">10.1016/j.neuron.2017.01.008</pub-id><?supplied-pmid 28162807?><pub-id pub-id-type="pmid">28162807</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>J. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Refractory epilepsy: one size does not fit all</article-title>. <source>Epilepsy Curr.</source>
<volume>6</volume>, <fpage>177</fpage>&#x02013;<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1111/j.1535-7511.2006.00137.x</pub-id><pub-id pub-id-type="pmid">17260051</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goold</surname><given-names>C. P.</given-names></name><name><surname>Nicoll</surname><given-names>R. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Single-cell optogenetic excitation drives homeostatic synaptic depression</article-title>. <source>Neuron</source>
<volume>68</volume>, <fpage>512</fpage>&#x02013;<lpage>528</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.020</pub-id><?supplied-pmid 21040851?><pub-id pub-id-type="pmid">21040851</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gradinaru</surname><given-names>V.</given-names></name><name><surname>Mogri</surname><given-names>M.</given-names></name><name><surname>Thompson</surname><given-names>K. R.</given-names></name><name><surname>Henderson</surname><given-names>J. M.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group> (<year>2009</year>). <article-title>Optical deconstruction of parkinsonian neural circuitry</article-title>. <source>Science</source>
<volume>324</volume>, <fpage>354</fpage>&#x02013;<lpage>359</lpage>. <pub-id pub-id-type="doi">10.1126/science.1167093</pub-id><?supplied-pmid 19299587?><pub-id pub-id-type="pmid">19299587</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gradinaru</surname><given-names>V.</given-names></name><name><surname>Thompson</surname><given-names>K. R.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group> (<year>2008</year>). <article-title>eNpHR: a natronomonas halorhodopsin enhanced for optogenetic applications</article-title>. <source>Brain Cell Biol.</source>
<volume>36</volume>, <fpage>129</fpage>&#x02013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1007/s11068-008-9027-6</pub-id><?supplied-pmid 18677566?><pub-id pub-id-type="pmid">18677566</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grand</surname><given-names>L.</given-names></name><name><surname>Wittner</surname><given-names>L.</given-names></name><name><surname>Herwik</surname><given-names>S.</given-names></name><name><surname>G&#x000f6;thelid</surname><given-names>E.</given-names></name><name><surname>Ruther</surname><given-names>P.</given-names></name><name><surname>Oscarsson</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Short and long term biocompatibility of neuroprobes silicon probes</article-title>. <source>J. Neurosci. Methods</source>
<volume>189</volume>, <fpage>216</fpage>&#x02013;<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2010.04.009</pub-id><?supplied-pmid 20399227?><pub-id pub-id-type="pmid">20399227</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>S. J.</given-names></name><name><surname>Blake</surname><given-names>B. L.</given-names></name><name><surname>Criswell</surname><given-names>H. E.</given-names></name><name><surname>Nicolson</surname><given-names>S. C.</given-names></name><name><surname>Samulski</surname><given-names>R. J.</given-names></name><name><surname>McCown</surname><given-names>T. J.</given-names></name><etal/></person-group>. (<year>2010a</year>). <article-title>Directed evolution of a novel adeno-associated virus (aav) vector that crosses the seizure-compromised blood-brain barrier (bbb)</article-title>. <source>Mol. Ther.</source>
<volume>18</volume>, <fpage>570</fpage>&#x02013;<lpage>578</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2009.292</pub-id><?supplied-pmid 20040913?><pub-id pub-id-type="pmid">20040913</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>S. J.</given-names></name><name><surname>Woodard</surname><given-names>K. T.</given-names></name><name><surname>Samulski</surname><given-names>R. J.</given-names></name></person-group> (<year>2010b</year>). <article-title>Viral vectors and delivery strategies for cns gene therapy</article-title>. <source>Ther. Deliv.</source>
<volume>1</volume>, <fpage>517</fpage>&#x02013;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.4155/tde.10.50</pub-id><?supplied-pmid 22833965?><pub-id pub-id-type="pmid">22833965</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>B. D.</given-names></name><name><surname>Gabriels</surname><given-names>L. A.</given-names></name><name><surname>Malone</surname><given-names>D.</given-names><suffix>Jr.</suffix></name><name><surname>Rezai</surname><given-names>A. R.</given-names></name><name><surname>Friehs</surname><given-names>G. M.</given-names></name><name><surname>Okun</surname><given-names>M. S.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience</article-title>. <source>Mol. Psychiatry</source>
<volume>15</volume>, <fpage>64</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2008.55</pub-id><?supplied-pmid 18490925?><pub-id pub-id-type="pmid">18490925</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grill</surname><given-names>W. M.</given-names></name><name><surname>Norman</surname><given-names>S. E.</given-names></name><name><surname>Bellamkonda</surname><given-names>R. V.</given-names></name></person-group> (<year>2009</year>). <article-title>Implanted neural interfaces: biochallenges and engineered solutions</article-title>. <source>Ann. Rev. Biomed. Eng.</source>
<volume>11</volume>, <fpage>1</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-bioeng-061008-124927</pub-id><?supplied-pmid 19400710?><pub-id pub-id-type="pmid">19400710</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosenick</surname><given-names>L.</given-names></name><name><surname>Marshel</surname><given-names>J. H.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group> (<year>2015</year>). <article-title>Closed-loop and activity-guided optogenetic control</article-title>. <source>Neuron</source>
<volume>86</volume>, <fpage>106</fpage>&#x02013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.03.034</pub-id><?supplied-pmid 25856490?><pub-id pub-id-type="pmid">25856490</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>N.</given-names></name><name><surname>Nikolic</surname><given-names>K.</given-names></name><name><surname>Toumazou</surname><given-names>C.</given-names></name><name><surname>Degenaar</surname><given-names>P.</given-names></name></person-group> (<year>2011</year>). <article-title>Modeling study of the light stimulation of a neuron cell with channelrhodopsin-2 mutants</article-title>. <source>IEEE Trans. Biomed. Eng.</source>
<volume>58</volume>, <fpage>1742</fpage>&#x02013;<lpage>1751</lpage>. <pub-id pub-id-type="doi">10.1109/TBME.2011.2114883</pub-id><?supplied-pmid 21324771?><pub-id pub-id-type="pmid">21324771</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grubb</surname><given-names>M. S.</given-names></name><name><surname>Burrone</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>Activity-dependent relocation of the axon initial segment fine-tunes neuronal excitability</article-title>. <source>Nature</source>
<volume>465</volume>, <fpage>1070</fpage>&#x02013;<lpage>1074</lpage>. <pub-id pub-id-type="doi">10.1038/nature09160</pub-id><?supplied-pmid 20543823?><pub-id pub-id-type="pmid">20543823</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gysbrechts</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Trong</surname><given-names>N. N. D.</given-names></name><name><surname>Cabral</surname><given-names>H.</given-names></name><name><surname>Navratilova</surname><given-names>Z.</given-names></name><name><surname>Battaglia</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Light distribution and thermal effects in the rat brain under optogenetic stimulation</article-title>. <source>J. Biophoton.</source>
<volume>9</volume>, <fpage>576</fpage>&#x02013;<lpage>585</lpage>. <pub-id pub-id-type="doi">10.1002/jbio.201500106</pub-id><?supplied-pmid 26192551?><pub-id pub-id-type="pmid">26192551</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hacein-bey abina</surname><given-names>S.</given-names></name><name><surname>Garrigue</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>G. P.</given-names></name><name><surname>Soulier</surname><given-names>J.</given-names></name><name><surname>Lim</surname><given-names>A.</given-names></name><name><surname>Morillon</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1</article-title>. <source>J. Clin. Invest.</source>
<volume>118</volume>, <fpage>3132</fpage>&#x02013;<lpage>3142</lpage>. <pub-id pub-id-type="doi">10.1172/JCI35700</pub-id><?supplied-pmid 18688285?><pub-id pub-id-type="pmid">18688285</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadaczek</surname><given-names>P.</given-names></name><name><surname>Forsayeth</surname><given-names>J.</given-names></name><name><surname>Mirek</surname><given-names>H.</given-names></name><name><surname>Munson</surname><given-names>K.</given-names></name><name><surname>Bringas</surname><given-names>J.</given-names></name><name><surname>Pivirotto</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response</article-title>. <source>Hum. Gene Ther.</source>
<volume>20</volume>, <fpage>225</fpage>&#x02013;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1089/hum.2008.151</pub-id><?supplied-pmid 19292604?><pub-id pub-id-type="pmid">19292604</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halpern</surname><given-names>C. H.</given-names></name><name><surname>Samadani</surname><given-names>U.</given-names></name><name><surname>Litt</surname><given-names>B.</given-names></name><name><surname>Jaggi</surname><given-names>J. L.</given-names></name><name><surname>Baltuch</surname><given-names>G. H.</given-names></name></person-group> (<year>2008</year>). <article-title>Deep brain stimulation for epilepsy</article-title>. <source>Neurotherapeutics</source>
<volume>5</volume>, <fpage>59</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.nurt.2007.10.065</pub-id><?supplied-pmid 18164484?><pub-id pub-id-type="pmid">18164484</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X.</given-names></name></person-group> (<year>2012</year>). <article-title><italic>In vivo</italic> application of optogenetics for neural circuit analysis</article-title>. <source>ACS Chem. Neurosci.</source>
<volume>3</volume>, <fpage>577</fpage>&#x02013;<lpage>584</lpage>. <pub-id pub-id-type="doi">10.1021/cn300065j</pub-id><?supplied-pmid 22896801?><pub-id pub-id-type="pmid">22896801</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Qian</surname><given-names>X.</given-names></name><name><surname>Bernstein</surname><given-names>J. G.</given-names></name><name><surname>Zhou</surname><given-names>H. H.</given-names></name><name><surname>Franzesi</surname><given-names>G. T.</given-names></name><name><surname>Stern</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Millisecond-timescale optical control of neural dynamics in the nonhuman primate brain</article-title>. <source>Ne</source>
<volume>62</volume>, <fpage>191</fpage>&#x02013;<lpage>198</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2009.03.011</pub-id><?supplied-pmid 19409264?><pub-id pub-id-type="pmid">19409264</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harui</surname><given-names>A.</given-names></name><name><surname>Suzuki</surname><given-names>S.</given-names></name><name><surname>Kochanek</surname><given-names>S.</given-names></name><name><surname>Mitani</surname><given-names>K.</given-names></name></person-group> (<year>1999</year>). <article-title>Frequency and stability of chromosomal integration of adenovirus vectors</article-title>. <source>J. Virol.</source>
<volume>73</volume>, <fpage>6141</fpage>&#x02013;<lpage>6146</lpage>. <?supplied-pmid 10364373?><pub-id pub-id-type="pmid">10364373</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haurigot</surname><given-names>V.</given-names></name><name><surname>Mingozzi</surname><given-names>F.</given-names></name><name><surname>Buchlis</surname><given-names>G.</given-names></name><name><surname>Hui</surname><given-names>D. J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Basner-Tschakarjan</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs</article-title>. <source>Mol. Ther.</source>
<volume>18</volume>, <fpage>1318</fpage>&#x02013;<lpage>1329</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2010.73</pub-id><?supplied-pmid 20424599?><pub-id pub-id-type="pmid">20424599</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heitmann</surname><given-names>S.</given-names></name><name><surname>Rule</surname><given-names>M.</given-names></name><name><surname>Truccolo</surname><given-names>W.</given-names></name><name><surname>Ermentrout</surname><given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>Optogenetic stimulation shifts the excitability of cerebral cortex from type I to type II: oscillation onset and wave propagation</article-title>. <source>PLoS Comput. Biol.</source>
<volume>13</volume>:<fpage>e1005349</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pcbi.1005349</pub-id><?supplied-pmid 28118355?><pub-id pub-id-type="pmid">28118355</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>L.</given-names></name><name><surname>Subramanian</surname><given-names>A.</given-names></name><name><surname>Helin</surname><given-names>P.</given-names></name><name><surname>Bois</surname><given-names>B. D.</given-names></name><name><surname>Baets</surname><given-names>R.</given-names></name><name><surname>Dorpe</surname><given-names>P. V.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Low loss CMOS-compatible PECVD silicon nitride waveguides and grating couplers for blue light optogenetic applications</article-title>. <source>IEEE Photon. J.</source>
<volume>8</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1109/JPHOT.2016.2601782</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>L.</given-names></name><name><surname>Welkenhuysen</surname><given-names>M.</given-names></name><name><surname>Andrei</surname><given-names>A.</given-names></name><name><surname>Musa</surname><given-names>S.</given-names></name><name><surname>Luo</surname><given-names>Z.</given-names></name><name><surname>Libbrecht</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>High-density optrode-electrode neural probe using SixNy photonics for <italic>in vivo</italic> optogenetics</article-title>, in <source>2015 IEEE International Electron Devices Meeting (IEDM)</source> (<publisher-loc>Washington, DC</publisher-loc>: <publisher-name>Institute of Electrical and Electronics Engineers (IEEE))</publisher-name>
<pub-id pub-id-type="doi">10.1109/IEDM.2015.7409795</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howarth</surname><given-names>J. L.</given-names></name><name><surname>Lee</surname><given-names>Y. B.</given-names></name><name><surname>Uney</surname><given-names>J. B.</given-names></name></person-group> (<year>2010</year>). <article-title>Using viral vectors as gene transfer tools (cell biology and toxicology special issue: Etcs-uk 1 day meeting on genetic manipulation of cells)</article-title>. <source>Cell Biol. Toxicol.</source>
<volume>26</volume>, <fpage>1</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1007/s10565-009-9139-5</pub-id><?supplied-pmid 19830583?><pub-id pub-id-type="pmid">19830583</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>S.</given-names></name><name><surname>Tsutsui</surname><given-names>H.</given-names></name><name><surname>Suzuki</surname><given-names>K.</given-names></name><name><surname>Agetsuma</surname><given-names>M.</given-names></name><name><surname>Arai</surname><given-names>Y.</given-names></name><name><surname>Jinno</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Genetically encoded bioluminescent voltage indicator for multi-purpose use in wide range of bioimaging</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>:<fpage>42398</fpage>. <pub-id pub-id-type="doi">10.1038/srep42398</pub-id><?supplied-pmid 28205521?><pub-id pub-id-type="pmid">28205521</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iseri</surname><given-names>E.</given-names></name><name><surname>Kuzum</surname><given-names>D.</given-names></name></person-group> (<year>2017</year>). <article-title>Implantable optoelectronic probes for <italic>in vivo</italic> optogenetics</article-title>. <source>J. Neural Eng</source>. <volume>14</volume>:<fpage>031001</fpage>. <pub-id pub-id-type="doi">10.1088/1741-2552/aa60b3</pub-id><?supplied-pmid 28198703?><pub-id pub-id-type="pmid">28198703</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarvis</surname><given-names>S.</given-names></name><name><surname>Schultz</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Prospects for optogenetic augmentation of brain function</article-title>. <source>Front. Syst. Neurosci.</source>
<volume>9</volume>:<fpage>157</fpage>. <pub-id pub-id-type="doi">10.3389/fnsys.2015.00157</pub-id><?supplied-pmid 26635547?><pub-id pub-id-type="pmid">26635547</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Couto</surname><given-names>L. B.</given-names></name><name><surname>Patarroyo-white</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Nagy</surname><given-names>D.</given-names></name><name><surname>Vargas J</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Effects of transient immunosuppression on adenoassociated, Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy</article-title>. <source>Blood</source>
<volume>108</volume>, <fpage>3321</fpage>&#x02013;<lpage>3328</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2006-04-017913</pub-id><?supplied-pmid 16868252?><pub-id pub-id-type="pmid">16868252</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>M. D.</given-names></name><name><surname>Miocinovic</surname><given-names>S.</given-names></name><name><surname>McIntyre</surname><given-names>C. C.</given-names></name><name><surname>Vitek</surname><given-names>J. L.</given-names></name></person-group> (<year>2008</year>). <article-title>Mechanisms and targets of deep brain stimulation in movement disorders</article-title>. <source>Neurotherapeutics</source>
<volume>5</volume>, <fpage>294</fpage>&#x02013;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1016/j.nurt.2008.01.010</pub-id><?supplied-pmid 18394571?><pub-id pub-id-type="pmid">18394571</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaludov</surname><given-names>N.</given-names></name><name><surname>Brown</surname><given-names>K. E.</given-names></name><name><surname>Walters</surname><given-names>R. W.</given-names></name><name><surname>Zabner</surname><given-names>J.</given-names></name><name><surname>Chiorini</surname><given-names>J. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Adeno-associated virus serotype 4 (aav4) and aav5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity</article-title>. <source>J. Virol.</source>
<volume>75</volume>, <fpage>6884</fpage>&#x02013;<lpage>6893</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.75.15.6884-6893.2001</pub-id><?supplied-pmid 11435568?><pub-id pub-id-type="pmid">11435568</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kantor</surname><given-names>B.</given-names></name><name><surname>Bailey</surname><given-names>R. M.</given-names></name><name><surname>Wimberly</surname><given-names>K.</given-names></name><name><surname>Kalburgi</surname><given-names>S. N.</given-names></name><name><surname>Gray</surname><given-names>S. J.</given-names></name></person-group> (<year>2014</year>). <article-title>Methods for gene transfer to the central nervous system</article-title>. <source>Adv. Genet.</source>
<volume>87</volume>, <fpage>125</fpage>&#x02013;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-800149-3.00003-2</pub-id><?supplied-pmid 25311922?><pub-id pub-id-type="pmid">25311922</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplitt</surname><given-names>M. G.</given-names></name><name><surname>Feigin</surname><given-names>A.</given-names></name><name><surname>Tang</surname><given-names>C.</given-names></name><name><surname>Fitzsimons</surname><given-names>H. L.</given-names></name><name><surname>Mattis</surname><given-names>P.</given-names></name><name><surname>Lawlor</surname><given-names>P. A.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Safety and tolerability of gene therapy with an adeno-associated virus (aav) borne gad gene for parkinson's disease: an open label, phase i trial</article-title>. <source>Lancet</source>
<volume>369</volume>, <fpage>2097</fpage>&#x02013;<lpage>2105</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60982-9</pub-id><?supplied-pmid 17586305?><pub-id pub-id-type="pmid">17586305</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karas</surname><given-names>P. J.</given-names></name><name><surname>Mikell</surname><given-names>C. B.</given-names></name><name><surname>Christian</surname><given-names>E.</given-names></name><name><surname>Liker</surname><given-names>M. A.</given-names></name><name><surname>Sheth</surname><given-names>S. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Deep brain stimulation: a mechanistic and clinical update</article-title>. <source>Neurosurg. Focus</source>
<volume>35</volume>:<fpage>E1</fpage>. <pub-id pub-id-type="doi">10.3171/2013.9.FOCUS13383</pub-id><?supplied-pmid 24175861?><pub-id pub-id-type="pmid">24175861</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastanenka</surname><given-names>K. V.</given-names></name><name><surname>Hou</surname><given-names>S. S.</given-names></name><name><surname>Shakerdge</surname><given-names>N.</given-names></name><name><surname>Logan</surname><given-names>R.</given-names></name><name><surname>Feng</surname><given-names>D.</given-names></name><name><surname>Wegmann</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Optogenetic restoration of disrupted slow oscillations halts amyloid deposition and restores calcium homeostasis in an animal model of Alzheimer's disease</article-title>. <source>PLoS ONE</source>
<volume>12</volume>:<fpage>e0170275</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0170275</pub-id><?supplied-pmid 28114405?><pub-id pub-id-type="pmid">28114405</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>M. A.</given-names></name><name><surname>Manno</surname><given-names>C. S.</given-names></name><name><surname>Ragni</surname><given-names>M. V.</given-names></name><name><surname>Larson</surname><given-names>P. J.</given-names></name><name><surname>Couto</surname><given-names>L. B.</given-names></name><name><surname>McClelland</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2000</year>). <article-title>Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector</article-title>. <source>Nat. Genet.</source>
<volume>24</volume>, <fpage>257</fpage>&#x02013;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1038/73464</pub-id><?supplied-pmid 10700178?><pub-id pub-id-type="pmid">10700178</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klapper</surname><given-names>S. D.</given-names></name><name><surname>Swiersy</surname><given-names>A.</given-names></name><name><surname>Bamberg</surname><given-names>E.</given-names></name><name><surname>Busskamp</surname><given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Biophysical properties of optogenetic tools and their application for vision restoration approaches</article-title>. <source>Front. Syst. Neurosci.</source>
<volume>10</volume>:<fpage>74</fpage>. <pub-id pub-id-type="doi">10.3389/fnsys.2016.00074</pub-id><?supplied-pmid 27642278?><pub-id pub-id-type="pmid">27642278</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R. L.</given-names></name><name><surname>Dayton</surname><given-names>R. D.</given-names></name><name><surname>Leidenheimer</surname><given-names>N. J.</given-names></name><name><surname>Jansen</surname><given-names>K.</given-names></name><name><surname>Golde</surname><given-names>T. E.</given-names></name><name><surname>Zweig</surname><given-names>R. M.</given-names></name></person-group> (<year>2006</year>). <article-title>Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins</article-title>. <source>Mol. Ther.</source>
<volume>13</volume>, <fpage>517</fpage>&#x02013;<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2005.10.008</pub-id><pub-id pub-id-type="pmid">16325474</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinlogel</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Optogenetic user's guide to Opto-GPCRs</article-title>. <source>Front. Biosci. (Landmark Edn.)</source>
<volume>21</volume>, <fpage>794</fpage>&#x02013;<lpage>805</lpage>. <pub-id pub-id-type="doi">10.2741/4421</pub-id><?supplied-pmid 26709806?><pub-id pub-id-type="pmid">26709806</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochanek</surname><given-names>S.</given-names></name><name><surname>Schiedner</surname><given-names>G.</given-names></name><name><surname>Volpers</surname><given-names>C.</given-names></name></person-group> (<year>2001</year>). <article-title>High-capacity &#x02018;gutless&#x02019; adenoviral vectors</article-title>. <source>Curr. Opin. Mol. Ther.</source>
<volume>3</volume>, <fpage>454</fpage>&#x02013;<lpage>463</lpage>. <?supplied-pmid 11699889?><pub-id pub-id-type="pmid">11699889</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kov&#x000e1;cs</surname><given-names>A.</given-names></name><name><surname>P&#x000e1;l</surname><given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>Astrocyte-dependent slow inward currents (SICs) participate in neuromodulatory mechanisms in the pedunculopontine nucleus (PPN)</article-title>. <source>Front. Cell. Neurosci.</source>
<volume>11</volume>:<fpage>16</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2017.00016</pub-id><?supplied-pmid 28203147?><pub-id pub-id-type="pmid">28203147</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyanagi</surname><given-names>M.</given-names></name><name><surname>Takada</surname><given-names>E.</given-names></name><name><surname>Nagata</surname><given-names>T.</given-names></name><name><surname>Tsukamoto</surname><given-names>H.</given-names></name><name><surname>Terakita</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Homologs of vertebrate Opn3 potentially serve as a light sensor in nonphotoreceptive tissue</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>110</volume>, <fpage>4998</fpage>&#x02013;<lpage>5003</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1219416110</pub-id><?supplied-pmid 23479626?><pub-id pub-id-type="pmid">23479626</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozai</surname><given-names>T. D.</given-names></name><name><surname>Jaquins-Gerstl</surname><given-names>A. S.</given-names></name><name><surname>Vazquez</surname><given-names>A. L.</given-names></name><name><surname>Michael</surname><given-names>A. C.</given-names></name><name><surname>Cui</surname><given-names>X. T.</given-names></name></person-group> (<year>2015</year>). <article-title>Brain tissue responses to neural implants impact signal sensitivity and intervention strategies</article-title>. <source>ACS Chem. Neurosci.</source>
<volume>6</volume>, <fpage>48</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1021/cn500256e</pub-id><?supplied-pmid 25546652?><pub-id pub-id-type="pmid">25546652</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krisky</surname><given-names>D. M.</given-names></name><name><surname>Wolfe</surname><given-names>D.</given-names></name><name><surname>Goins</surname><given-names>W. F.</given-names></name><name><surname>Marconi</surname><given-names>P. C.</given-names></name><name><surname>Ramakrishnan</surname><given-names>R.</given-names></name><name><surname>Mata</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>1998</year>). <article-title>Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons</article-title>. <source>Gene Ther.</source>
<volume>5</volume>, <fpage>1593</fpage>&#x02013;<lpage>1603</lpage>. <pub-id pub-id-type="doi">10.1038/sj.gt.3300766</pub-id><?supplied-pmid 10023438?><pub-id pub-id-type="pmid">10023438</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krook-Magnuson</surname><given-names>E.</given-names></name><name><surname>Armstrong</surname><given-names>C.</given-names></name><name><surname>Oijala</surname><given-names>M.</given-names></name><name><surname>Soltesz</surname><given-names>I.</given-names></name></person-group> (<year>2013</year>). <article-title>On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy</article-title>. <source>Nat. Commun.</source>
<volume>4</volume>:<fpage>1376</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms2376</pub-id><?supplied-pmid 23340416?><pub-id pub-id-type="pmid">23340416</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuncel</surname><given-names>A. M.</given-names></name><name><surname>Cooper</surname><given-names>S. E.</given-names></name><name><surname>Wolgamuth</surname><given-names>B. R.</given-names></name><name><surname>Clyde</surname><given-names>M. A.</given-names></name><name><surname>Snyder</surname><given-names>S. A.</given-names></name><name><surname>Montgomery</surname><given-names>E. B.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Clinical response to varying the stimulus parameters in deep brain stimulation for essential tremor</article-title>. <source>Mov. Disord.</source>
<volume>21</volume>, <fpage>1920</fpage>&#x02013;<lpage>1928</lpage>. <pub-id pub-id-type="doi">10.1002/mds.21087</pub-id><?supplied-pmid 16972236?><pub-id pub-id-type="pmid">16972236</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laxpati</surname><given-names>N. G.</given-names></name><name><surname>Kasoff</surname><given-names>W. S.</given-names></name><name><surname>Gross</surname><given-names>R. E.</given-names></name></person-group> (<year>2014</year>). <article-title>Deep brain stimulation for the treatment of epilepsy: circuits, targets, and trials</article-title>. <source>Neurotherapeutics</source>
<volume>11</volume>, <fpage>508</fpage>&#x02013;<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-014-0279-9</pub-id><?supplied-pmid 24957200?><pub-id pub-id-type="pmid">24957200</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H. U.</given-names></name><name><surname>Nag</surname><given-names>S.</given-names></name><name><surname>Blasiak</surname><given-names>A.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Thakor</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>I. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Subcellular optogenetic stimulation for activity-dependent myelination of axons in a novel microfluidic compartmentalized platform</article-title>. <source>ACS Chem. Neurosci.</source>
<volume>7</volume>, <fpage>1317</fpage>&#x02013;<lpage>1324</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.6b00157</pub-id><?supplied-pmid 27570883?><pub-id pub-id-type="pmid">27570883</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehman</surname><given-names>R. M.</given-names></name><name><surname>Augustine</surname><given-names>J. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Evolution and rebirth of functional stereotaxy in the subthalamus</article-title>. <source>World Neurosurgery</source>
<volume>80</volume>, <fpage>521</fpage>&#x02013;<lpage>533</lpage>. <pub-id pub-id-type="doi">10.1016/j.wneu.2012.03.006</pub-id><?supplied-pmid 22465370?><pub-id pub-id-type="pmid">22465370</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lentz</surname><given-names>T. B.</given-names></name><name><surname>Gray</surname><given-names>S. J.</given-names></name><name><surname>Samulski</surname><given-names>R. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Viral vectors for gene delivery to the central nervous system</article-title>. <source>Neurobiol. Dis.</source>
<volume>48</volume>, <fpage>179</fpage>&#x02013;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2011.09.014</pub-id><?supplied-pmid 22001604?><pub-id pub-id-type="pmid">22001604</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leone</surname><given-names>P.</given-names></name><name><surname>Shera</surname><given-names>D.</given-names></name><name><surname>McPhee</surname><given-names>S. W. J.</given-names></name><name><surname>Francis</surname><given-names>J. S.</given-names></name><name><surname>Kolodny</surname><given-names>E. H.</given-names></name><name><surname>Bilaniuk</surname><given-names>L. T.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Long-term follow-up after gene therapy for canavan disease</article-title>. <source>Sci. Trans. Med.</source>
<volume>4</volume>:<fpage>165r</fpage>a163. <pub-id pub-id-type="doi">10.1126/scitranslmed.3003454</pub-id><?supplied-pmid 23253610?><pub-id pub-id-type="pmid">23253610</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeWitt</surname><given-names>P. A.</given-names></name><name><surname>Rezai</surname><given-names>A. R.</given-names></name><name><surname>Leehey</surname><given-names>M. A.</given-names></name><name><surname>Ojemann</surname><given-names>S. G.</given-names></name><name><surname>Flaherty</surname><given-names>A. W.</given-names></name><name><surname>Eskandar</surname><given-names>E. N.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Aav2-gad gene therapy for advanced parkinson's disease: a double-blind, sham-surgery controlled, randomised trial</article-title>. <source>Lancet. Neurol.</source>
<volume>10</volume>, <fpage>309</fpage>&#x02013;<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(11)70039-4</pub-id><?supplied-pmid 21419704?><pub-id pub-id-type="pmid">21419704</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lignani</surname><given-names>G.</given-names></name><name><surname>Ferrea</surname><given-names>E.</given-names></name><name><surname>Difato</surname><given-names>F.</given-names></name><name><surname>Amar&#x000f9;</surname><given-names>J.</given-names></name><name><surname>Ferroni</surname><given-names>E.</given-names></name><name><surname>Lugar&#x000e0;</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Long-term optical stimulation of channelrhodopsin-expressing neurons to study network plasticity</article-title>. <source>Front. Mol. Neurosci.</source>
<volume>6</volume>:<fpage>22</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2013.00022</pub-id><?supplied-pmid 23970852?><pub-id pub-id-type="pmid">23970852</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>S. Q.</given-names></name><name><surname>Miesenb&#x000f6;ck</surname><given-names>G.</given-names></name></person-group> (<year>2005</year>). <article-title>Remote control of behavior through genetically targeted photostimulation of neurons</article-title>. <source>Cell</source>
<volume>121</volume>, <fpage>141</fpage>&#x02013;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2005.02.004</pub-id><?supplied-pmid 15820685?><pub-id pub-id-type="pmid">15820685</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J. Y.</given-names></name><name><surname>Knutsen</surname><given-names>P. M.</given-names></name><name><surname>Muller</surname><given-names>A.</given-names></name><name><surname>Kleinfeld</surname><given-names>D.</given-names></name><name><surname>Tsien</surname><given-names>R. Y.</given-names></name></person-group> (<year>2013</year>). <article-title>ReaChR: a red-shifted variant of channelrhodopsin enables deep transcranial optogenetic excitation</article-title>. <source>Nat. Neurosci.</source>
<volume>16</volume>, <fpage>1499</fpage>&#x02013;<lpage>1508</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3502</pub-id><?supplied-pmid 23995068?><pub-id pub-id-type="pmid">23995068</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J. Y.</given-names></name><name><surname>Lin</surname><given-names>M. Z.</given-names></name><name><surname>Steinbach</surname><given-names>P.</given-names></name><name><surname>Tsien</surname><given-names>R. Y.</given-names></name></person-group> (<year>2009</year>). <article-title>Characterization of engineered channelrhodopsin variants with improved properties and kinetics</article-title>. <source>Biophys. J.</source>
<volume>96</volume>, <fpage>1803</fpage>&#x02013;<lpage>1814</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpj.2008.11.034</pub-id><?supplied-pmid 19254539?><pub-id pub-id-type="pmid">19254539</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J.-Y.</given-names></name><name><surname>Xie</surname><given-names>C.-L.</given-names></name><name><surname>Zhang</surname><given-names>S.-F.</given-names></name><name><surname>Yuan</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>Z.-G.</given-names></name></person-group> (<year>2017</year>). <article-title>Current experimental studies of gene therapy in Parkinson's disease</article-title>. <source>Front. Aging Neurosci.</source>
<volume>9</volume>:<fpage>126</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2017.00126</pub-id><?supplied-pmid 28515689?><pub-id pub-id-type="pmid">28515689</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Kalsi</surname><given-names>J. K.</given-names></name><name><surname>Jayandharan</surname><given-names>G. R.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3</article-title>. <source>Hum. Gene Ther.</source>
<volume>21</volume>, <fpage>1741</fpage>&#x02013;<lpage>1747</lpage>. <pub-id pub-id-type="doi">10.1089/hum.2010.075</pub-id><?supplied-pmid 20545554?><pub-id pub-id-type="pmid">20545554</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Tao</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Application of optogenetics-mediated motor cortex stimulation in the treatment of chronic neuropathic pain</article-title>. <source>J. Transl. Sci.</source>
<volume>2</volume>, <fpage>286</fpage>&#x02013;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.15761/JTS.1000153</pub-id><?supplied-pmid 28217367?><pub-id pub-id-type="pmid">28217367</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>W. D.</given-names></name><name><surname>Qu</surname><given-names>G.</given-names></name><name><surname>Sferra</surname><given-names>T. J.</given-names></name><name><surname>Clark</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Johnson</surname><given-names>P. R.</given-names></name></person-group> (<year>1999</year>). <article-title>Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression</article-title>. <source>Hum. Gene Ther.</source>
<volume>10</volume>, <fpage>201</fpage>&#x02013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1089/10430349950018995</pub-id><?supplied-pmid 10022545?><pub-id pub-id-type="pmid">10022545</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LoDuca</surname><given-names>P. A.</given-names></name><name><surname>Hoffman</surname><given-names>B. E.</given-names></name><name><surname>Herzog</surname><given-names>R. W.</given-names></name></person-group> (<year>2009</year>). <article-title>Hepatic gene transfer as a means of tolerance induction to transgene products</article-title>. <source>Curr. Gene Ther.</source>
<volume>9</volume>, <fpage>104</fpage>&#x02013;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.2174/156652309787909490</pub-id><?supplied-pmid 19355868?><pub-id pub-id-type="pmid">19355868</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>M. A.</given-names></name><name><surname>Fee</surname><given-names>M. S.</given-names></name></person-group> (<year>2008</year>). <article-title>Using temperature to analyse temporal dynamics in the songbird motor pathway</article-title>. <source>Nature</source>
<volume>456</volume>, <fpage>189</fpage>&#x02013;<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1038/nature07448</pub-id><?supplied-pmid 19005546?><pub-id pub-id-type="pmid">19005546</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowenstein</surname><given-names>P. R.</given-names></name><name><surname>Mandel</surname><given-names>R. J.</given-names></name><name><surname>Xiong</surname><given-names>W.-D.</given-names></name><name><surname>Kroeger</surname><given-names>K.</given-names></name><name><surname>Castro</surname><given-names>M. G.</given-names></name></person-group> (<year>2007</year>). <article-title>Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions</article-title>. <source>Curr. Gene Ther.</source>
<volume>7</volume>, <fpage>347</fpage>&#x02013;<lpage>360</lpage>. <pub-id pub-id-type="doi">10.2174/156652307782151498</pub-id><?supplied-pmid 17979681?><pub-id pub-id-type="pmid">17979681</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lumsden</surname><given-names>D. E.</given-names></name><name><surname>Ashmore</surname><given-names>J.</given-names></name><name><surname>Charles-Edwards</surname><given-names>G.</given-names></name><name><surname>Lin</surname><given-names>J.-P.</given-names></name><name><surname>Ashkan</surname><given-names>K.</given-names></name><name><surname>Selway</surname><given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>Accuracy of stimulating electrode placement in paediatric pallidal deep brain stimulation for primary and secondary dystonia</article-title>. <source>Acta Neurochirurg.</source>
<volume>155</volume>, <fpage>823</fpage>&#x02013;<lpage>836</lpage>. <pub-id pub-id-type="doi">10.1007/s00701-013-1629-9</pub-id><?supplied-pmid 23430231?><pub-id pub-id-type="pmid">23430231</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mager</surname><given-names>T.</given-names></name><name><surname>Wood</surname><given-names>P. G.</given-names></name><name><surname>Bamberg</surname><given-names>E.</given-names></name></person-group> (<year>2017</year>). <article-title>Optogenetic control of Ca<sup>2+</sup> and voltage-dependent large conductance (BK) potassium channels</article-title>. <source>J. Mol. Biol</source>. <volume>429</volume>, <fpage>911</fpage>&#x02013;<lpage>921</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2017.02.004</pub-id><?supplied-pmid 28192090?><pub-id pub-id-type="pmid">28192090</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmud</surname><given-names>M.</given-names></name><name><surname>Vassanelli</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Differential modulation of excitatory and inhibitory neurons during periodic stimulation</article-title>. <source>Front. Neurosci.</source>
<volume>10</volume>:<fpage>62</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2016.00062</pub-id><?supplied-pmid 26941602?><pub-id pub-id-type="pmid">26941602</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maimon</surname><given-names>B. E.</given-names></name><name><surname>Zorzos</surname><given-names>A. N.</given-names></name><name><surname>Bendell</surname><given-names>R.</given-names></name><name><surname>Harding</surname><given-names>A.</given-names></name><name><surname>Fahmi</surname><given-names>M.</given-names></name><name><surname>Srinivasan</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Transdermal optogenetic peripheral nerve stimulation</article-title>. <source>J. Neural Eng</source>. <volume>14</volume>:<fpage>034002</fpage>. <pub-id pub-id-type="doi">10.1088/1741-2552/aa5e20</pub-id><?supplied-pmid 28157088?><pub-id pub-id-type="pmid">28157088</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maks</surname><given-names>C. B.</given-names></name><name><surname>Butson</surname><given-names>C. R.</given-names></name><name><surname>Walter</surname><given-names>B. L.</given-names></name><name><surname>Vitek</surname><given-names>J. L.</given-names></name><name><surname>McIntyre</surname><given-names>C. C.</given-names></name></person-group> (<year>2009</year>). <article-title>Deep brain stimulation activation volumes and their association with neurophysiological mapping and therapeutic outcomes</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source>
<volume>80</volume>, <fpage>659</fpage>&#x02013;<lpage>666</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp.2007.126219</pub-id><?supplied-pmid 18403440?><pub-id pub-id-type="pmid">18403440</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malyshev</surname><given-names>A. Y.</given-names></name><name><surname>Roshchin</surname><given-names>M. V.</given-names></name><name><surname>Smirnova</surname><given-names>G. R.</given-names></name><name><surname>Dolgikh</surname><given-names>D. A.</given-names></name><name><surname>Balaban</surname><given-names>P. M.</given-names></name><name><surname>Ostrovsky</surname><given-names>M. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Chloride conducting light activated channel GtACR2 can produce both cessation of firing and generation of action potentials in cortical neurons in response to light</article-title>. <source>Neurosci. Lett.</source>
<volume>640</volume>, <fpage>76</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2017.01.026</pub-id><?supplied-pmid 28093304?><pub-id pub-id-type="pmid">28093304</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manickan</surname><given-names>E.</given-names></name><name><surname>Smith</surname><given-names>J. S.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Eggerman</surname><given-names>T. L.</given-names></name><name><surname>Lozier</surname><given-names>J. N.</given-names></name><name><surname>Muller</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Rapid kupffer cell death after intravenous injection of adenovirus vectors</article-title>. <source>Mol. Ther.</source>
<volume>13</volume>, <fpage>108</fpage>&#x02013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2005.08.007</pub-id><?supplied-pmid 16198149?><pub-id pub-id-type="pmid">16198149</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manno</surname><given-names>C. S.</given-names></name><name><surname>Pierce</surname><given-names>G. F.</given-names></name><name><surname>Arruda</surname><given-names>V. R.</given-names></name><name><surname>Glader</surname><given-names>B.</given-names></name><name><surname>Ragni</surname><given-names>M.</given-names></name><name><surname>Rasko</surname><given-names>J. J.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response</article-title>. <source>Nat. Med.</source>
<volume>12</volume>, <fpage>342</fpage>&#x02013;<lpage>347</lpage>. <pub-id pub-id-type="doi">10.1038/nm1358</pub-id><?supplied-pmid 16474400?><pub-id pub-id-type="pmid">16474400</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantoan Ritter</surname><given-names>L.</given-names></name><name><surname>Golshani</surname><given-names>P.</given-names></name><name><surname>Takahashi</surname><given-names>K.</given-names></name><name><surname>Dufour</surname><given-names>S.</given-names></name><name><surname>Valiante</surname><given-names>T.</given-names></name><name><surname>Kokaia</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>WONOEP appraisal: optogenetic tools to suppress seizures and explore the mechanisms of epileptogenesis</article-title>. <source>Epilepsia</source>
<volume>55</volume>, <fpage>1693</fpage>&#x02013;<lpage>1702</lpage>. <pub-id pub-id-type="doi">10.1111/epi.12804</pub-id><?supplied-pmid 25303540?><pub-id pub-id-type="pmid">25303540</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastakov</surname><given-names>M. Y.</given-names></name><name><surname>Baer</surname><given-names>K.</given-names></name><name><surname>Symes</surname><given-names>C. W.</given-names></name><name><surname>Leichtlein</surname><given-names>C. B.</given-names></name><name><surname>Kotin</surname><given-names>R. M.</given-names></name><name><surname>During</surname><given-names>M. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain</article-title>. <source>J. Virol.</source>
<volume>76</volume>, <fpage>8446</fpage>&#x02013;<lpage>8454</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.76.16.8446-8454.2002</pub-id><?supplied-pmid 12134047?><pub-id pub-id-type="pmid">12134047</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAlinden</surname><given-names>N.</given-names></name><name><surname>Gu</surname><given-names>E.</given-names></name><name><surname>Dawson</surname><given-names>M. D.</given-names></name><name><surname>Sakata</surname><given-names>S.</given-names></name><name><surname>Mathieson</surname><given-names>K.</given-names></name></person-group> (<year>2015</year>). <article-title>Optogenetic activation of neocortical neurons <italic>in vivo</italic> with a sapphire-based micro-scale LED probe</article-title>. <source>Front. Neural Circuits</source>
<volume>9</volume>:<fpage>25</fpage>. <pub-id pub-id-type="doi">10.3389/fncir.2015.00025</pub-id><?supplied-pmid 26074778?><pub-id pub-id-type="pmid">26074778</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCall</surname><given-names>J. G.</given-names></name><name><surname>Qazi</surname><given-names>R.</given-names></name><name><surname>Shin</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Ikram</surname><given-names>M. H.</given-names></name><name><surname>Jang</surname><given-names>K.-I.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Preparation and implementation of optofluidic neural probes for <italic>in vivo</italic> wireless pharmacology and optogenetics</article-title>. <source>Nat. Protoc.</source>
<volume>12</volume>, <fpage>219</fpage>&#x02013;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2016.155</pub-id><?supplied-pmid 28055036?><pub-id pub-id-type="pmid">28055036</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCreery</surname><given-names>D.</given-names></name><name><surname>Lossinsky</surname><given-names>A.</given-names></name><name><surname>Pikov</surname><given-names>V.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name></person-group> (<year>2006</year>). <article-title>Microelectrode array for chronic deep-brain microstimulation and recording</article-title>. <source>IEEE Trans. Biomed. Eng.</source>
<volume>53</volume>, <fpage>726</fpage>&#x02013;<lpage>737</lpage>. <pub-id pub-id-type="doi">10.1109/TBME.2006.870215</pub-id><?supplied-pmid 16602580?><pub-id pub-id-type="pmid">16602580</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCreery</surname><given-names>D. B.</given-names></name><name><surname>Yuen</surname><given-names>T. G.</given-names></name><name><surname>Agnew</surname><given-names>W.</given-names></name><name><surname>F&#x0201e; Bullara</surname><given-names>L. A.</given-names></name></person-group> (<year>1997</year>). <article-title>A characterization of the effects on neuronal excitability due to prolonged microstimulation with chronically implanted microelectrodes</article-title>. <source>IEEE Trans. Biomed. Eng.</source>
<volume>44</volume>, <fpage>931</fpage>&#x02013;<lpage>939</lpage>. <pub-id pub-id-type="doi">10.1109/10.634645</pub-id><?supplied-pmid 9311162?><pub-id pub-id-type="pmid">9311162</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntyre</surname><given-names>C. C.</given-names></name><name><surname>Anderson</surname><given-names>R. W.</given-names></name></person-group> (<year>2016</year>). <article-title>Deep brain stimulation mechanisms: the control of network activity via neurochemistry modulation</article-title>. <source>J. Neurochem.</source>
<volume>139</volume>, <fpage>338</fpage>&#x02013;<lpage>345</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13649</pub-id><?supplied-pmid 27273305?><pub-id pub-id-type="pmid">27273305</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntyre</surname><given-names>C. C.</given-names></name><name><surname>Hahn</surname><given-names>P. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Network perspectives on the mechanisms of deep brain stimulation</article-title>. <source>Neurobiol. Dis.</source>
<volume>38</volume>, <fpage>329</fpage>&#x02013;<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2009.09.022</pub-id><?supplied-pmid 19804831?><pub-id pub-id-type="pmid">19804831</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mingozzi</surname><given-names>F.</given-names></name><name><surname>High</surname><given-names>K. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Immune responses to aav vectors: overcoming barriers to successful gene therapy</article-title>. <source>Blood</source>
<volume>122</volume>, <fpage>23</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2013-01-306647</pub-id><?supplied-pmid 23596044?><pub-id pub-id-type="pmid">23596044</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miocinovic</surname><given-names>S.</given-names></name><name><surname>Lempka</surname><given-names>S. F.</given-names></name><name><surname>Russo</surname><given-names>G. S.</given-names></name><name><surname>Maks</surname><given-names>C. B.</given-names></name><name><surname>Butson</surname><given-names>C. R.</given-names></name><name><surname>Sakaie</surname><given-names>K. E.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Experimental and theoretical characterization of the voltage distribution generated by deep brain stimulation</article-title>. <source>Exp. Neurol.</source>
<volume>216</volume>, <fpage>166</fpage>&#x02013;<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2008.11.024</pub-id><?supplied-pmid 19118551?><pub-id pub-id-type="pmid">19118551</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittelstrass</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>On transdisciplinarity</article-title>. <source>Trames J. Hum. Soc. Sci.</source>
<volume>15</volume>, <fpage>329</fpage>&#x02013;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.3176/tr.2011.4.01</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyagawa</surname><given-names>Y.</given-names></name><name><surname>Marino</surname><given-names>P.</given-names></name><name><surname>Verlengia</surname><given-names>G.</given-names></name><name><surname>Uchida</surname><given-names>H.</given-names></name><name><surname>Goins</surname><given-names>W. F.</given-names></name><name><surname>Yokota</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>112</volume>, <fpage>E1632</fpage>&#x02013;<lpage>E1641</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1423556112</pub-id><?supplied-pmid 25775541?><pub-id pub-id-type="pmid">25775541</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyashita</surname><given-names>T.</given-names></name><name><surname>Shao</surname><given-names>Y. R.</given-names></name><name><surname>Chung</surname><given-names>J.</given-names></name><name><surname>Pourzia</surname><given-names>O.</given-names></name><name><surname>Feldman</surname><given-names>D. E.</given-names></name></person-group> (<year>2013</year>). <article-title>Long-term channelrhodopsin-2 (ChR2) expression can induce abnormal axonal morphology and targeting in cerebral cortex</article-title>. <source>Front. Neural Circuits</source>
<volume>7</volume>:<fpage>8</fpage>. <pub-id pub-id-type="doi">10.3389/fncir.2013.00008</pub-id><?supplied-pmid 23386813?><pub-id pub-id-type="pmid">23386813</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moro</surname><given-names>E.</given-names></name><name><surname>Esselink</surname><given-names>R. J.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Hommel</surname><given-names>M.</given-names></name><name><surname>Benabid</surname><given-names>A. L.</given-names></name><name><surname>Pollak</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>The impact on Parkinson's disease of electrical parameter settings in STN stimulation</article-title>. <source>Neurology</source>
<volume>59</volume>, <fpage>706</fpage>&#x02013;<lpage>713</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.59.5.706</pub-id><?supplied-pmid 12221161?><pub-id pub-id-type="pmid">12221161</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moser</surname><given-names>E. I.</given-names></name><name><surname>Mathiesen</surname><given-names>L.</given-names></name></person-group> (<year>1996</year>). <article-title>Relationship between neuronal activity and brain temperature in rats</article-title>. <source>Neuroreport</source>
<volume>7</volume>:<fpage>1876</fpage>. <pub-id pub-id-type="doi">10.1097/00001756-199607290-00038</pub-id><?supplied-pmid 8905684?><pub-id pub-id-type="pmid">8905684</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muramatsu</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>The current status of gene therapy for parkinson's disease</article-title>. <source>Ann. Neurosci.</source>
<volume>17</volume>, <fpage>92</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.5214/ans.0972-7531.1017209</pub-id><?supplied-pmid 25205879?><pub-id pub-id-type="pmid">25205879</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabavi</surname><given-names>S.</given-names></name><name><surname>Fox</surname><given-names>R.</given-names></name><name><surname>Proulx</surname><given-names>C. D.</given-names></name><name><surname>Lin</surname><given-names>J. Y.</given-names></name><name><surname>Tsien</surname><given-names>R.</given-names></name><name><surname>Malinow</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Engineering a memory with LTD and LTP</article-title>. <source>Nature</source>
<volume>511</volume>, <fpage>348</fpage>&#x02013;<lpage>352</lpage>. <pub-id pub-id-type="doi">10.1038/nature13294</pub-id><?supplied-pmid 24896183?><pub-id pub-id-type="pmid">24896183</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagel</surname><given-names>G.</given-names></name><name><surname>Ollig</surname><given-names>D.</given-names></name><name><surname>Fuhrmann</surname><given-names>M.</given-names></name><name><surname>Kateriya</surname><given-names>S.</given-names></name><name><surname>Musti</surname><given-names>A. M.</given-names></name><name><surname>Bamberg</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Channelrhodopsin-1: a light-gated proton channel in green algae</article-title>. <source>Science</source>
<volume>296</volume>, <fpage>2395</fpage>&#x02013;<lpage>2398</lpage>. <pub-id pub-id-type="doi">10.1126/science.1072068</pub-id><?supplied-pmid 12089443?><pub-id pub-id-type="pmid">12089443</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>T.</given-names></name><name><surname>Mackay</surname><given-names>S. M.</given-names></name><name><surname>Wui Tan</surname><given-names>E.</given-names></name><name><surname>Dani</surname><given-names>K. M.</given-names></name><name><surname>Wickens</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Interfacing with neural activity via femtosecond laser stimulation of drug-encapsulating liposomal nanostructures</article-title>. <source>eNeuro</source> 3:ENEURO.0107-16.2016. <pub-id pub-id-type="doi">10.1523/ENEURO.0107-16.2016</pub-id><?supplied-pmid 27896311?><pub-id pub-id-type="pmid">27896311</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>J.-H.</given-names></name><name><surname>Kim</surname><given-names>J.-H.</given-names></name><name><surname>Jha</surname><given-names>M. K.</given-names></name><name><surname>Jung</surname><given-names>J. Y.</given-names></name><name><surname>Lee</surname><given-names>M.-G.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Reversible induction of pain hypersensitivity following optogenetic stimulation of spinal astrocytes</article-title>. <source>Cell Rep.</source>
<volume>17</volume>, <fpage>3049</fpage>&#x02013;<lpage>3061</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.043</pub-id><?supplied-pmid 27974216?><pub-id pub-id-type="pmid">27974216</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naughton</surname><given-names>J. R.</given-names></name><name><surname>Connolly</surname><given-names>T.</given-names></name><name><surname>Varela</surname><given-names>J. A.</given-names></name><name><surname>Lundberg</surname><given-names>J.</given-names></name><name><surname>Burns</surname><given-names>M. J.</given-names></name><name><surname>Chiles</surname><given-names>T. C.</given-names></name><name><surname>Christianson</surname><given-names>J.</given-names></name><name><surname>Naughton</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Shielded coaxial optrode arrays for neurophysiology</article-title>. <source>Front. Neurosci.</source>
<volume>10</volume>:<fpage>252</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2016.00252</pub-id><?supplied-pmid 27375415?><pub-id pub-id-type="pmid">27375415</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayak</surname><given-names>S.</given-names></name><name><surname>Herzog</surname><given-names>R. W.</given-names></name></person-group> (<year>2009</year>). <article-title>Progress and prospects: immune responses to viral vectors</article-title>. <source>Gene Ther.</source>
<volume>17</volume>, <fpage>295</fpage>&#x02013;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1038/gt.2009.148</pub-id><?supplied-pmid 19907498?><pub-id pub-id-type="pmid">19907498</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>R.</given-names></name><name><surname>Govindasamy</surname><given-names>L.</given-names></name><name><surname>Gurda</surname><given-names>B. L.</given-names></name><name><surname>McKenna</surname><given-names>R.</given-names></name><name><surname>Kozyreva</surname><given-names>O. G.</given-names></name><name><surname>Samulski</surname><given-names>R. J.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Structural characterization of the dual glycan binding adeno-associated virus serotype 6</article-title>. <source>J. Virol.</source>
<volume>84</volume>, <fpage>12945</fpage>&#x02013;<lpage>12957</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01235-10</pub-id><?supplied-pmid 20861247?><pub-id pub-id-type="pmid">20861247</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nghiem</surname><given-names>B. T.</given-names></name><name><surname>Sando</surname><given-names>I. C.</given-names></name><name><surname>Gillespie</surname><given-names>R. B.</given-names></name><name><surname>McLaughlin</surname><given-names>B. L.</given-names></name><name><surname>Gerling</surname><given-names>G. J.</given-names></name><name><surname>Langhals</surname><given-names>N. B.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Providing a sense of touch to prosthetic hands</article-title>. <source>Plast. Reconstr. Surg.</source>
<volume>135</volume>, <fpage>1652</fpage>&#x02013;<lpage>1663</lpage>. <pub-id pub-id-type="doi">10.1097/PRS.0000000000001289</pub-id><?supplied-pmid 26017599?><pub-id pub-id-type="pmid">26017599</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niemeyer</surname><given-names>G. P.</given-names></name><name><surname>Herzog</surname><given-names>R. W.</given-names></name><name><surname>Mount</surname><given-names>J.</given-names></name><name><surname>Arruda</surname><given-names>V. R.</given-names></name><name><surname>Tillson</surname><given-names>D. M.</given-names></name><name><surname>Hathcock</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Long-term correction of inhibitor-prone hemophilia b dogs treated with liver-directed aav2-mediated factor ix gene therapy</article-title>. <source>Blood</source>
<volume>113</volume>, <fpage>797</fpage>&#x02013;<lpage>806</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2008-10-181479</pub-id><?supplied-pmid 18957684?><pub-id pub-id-type="pmid">18957684</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nirenberg</surname><given-names>S.</given-names></name><name><surname>Pandarinath</surname><given-names>C.</given-names></name></person-group> (<year>2012</year>). <article-title>Retinal prosthetic strategy with the capacity to restore normal vision</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A</source>. <volume>109</volume>, <fpage>15012</fpage>&#x02013;<lpage>15017</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1207035109</pub-id><?supplied-pmid 22891310?><pub-id pub-id-type="pmid">22891310</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nomura</surname><given-names>T.</given-names></name><name><surname>Nishimura</surname><given-names>Y.</given-names></name><name><surname>Gotoh</surname><given-names>H.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>Rapid and efficient gene delivery into the adult mouse brain via focal electroporation</article-title>. <source>Sci. Rep.</source>
<volume>6</volume>:<fpage>29817</fpage>. <pub-id pub-id-type="doi">10.1038/srep29817</pub-id><?supplied-pmid 27430903?><pub-id pub-id-type="pmid">27430903</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>B.</given-names></name><name><surname>Patel</surname><given-names>J. C.</given-names></name><name><surname>Rice</surname><given-names>M. E.</given-names></name></person-group> (<year>2017</year>). <article-title>Characterization of optically and electrically evoked dopamine release in striatal slices from digenic knock-in mice with DAT-driven expression of channelrhodopsin</article-title>. <source>ACS Chem. Neurosci.</source>
<volume>8</volume>, <fpage>310</fpage>&#x02013;<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.6b00300</pub-id><?supplied-pmid 28177213?><pub-id pub-id-type="pmid">28177213</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obermeier</surname><given-names>B.</given-names></name><name><surname>Daneman</surname><given-names>R.</given-names></name><name><surname>Ransohoff</surname><given-names>R. M.</given-names></name></person-group> (<year>2013</year>). <article-title>Development, maintenance and disruption of the blood-brain barrier</article-title>. <source>Nat. Med.</source>
<volume>19</volume>, <fpage>1584</fpage>&#x02013;<lpage>1596</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3407</pub-id><?supplied-pmid 24309662?><pub-id pub-id-type="pmid">24309662</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olds</surname><given-names>J.</given-names></name><name><surname>Milner</surname><given-names>P.</given-names></name></person-group> (<year>1954</year>). <article-title>Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain</article-title>. <source>J. Comp. Physiol. Psychol.</source>
<volume>47</volume>, <fpage>419</fpage>&#x02013;<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1037/h0058775</pub-id><?supplied-pmid 13233369?><pub-id pub-id-type="pmid">13233369</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osborne</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Problematizing disciplinarity, transdisciplinary problematics</article-title>. <source>Theory Cult. Soc.</source>
<volume>32</volume>, <fpage>3</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1177/0263276415592245</pub-id><?supplied-pmid 26456992?><pub-id pub-id-type="pmid">26456992</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Suilleabhain</surname><given-names>P. E.</given-names></name><name><surname>Frawley</surname><given-names>W.</given-names></name><name><surname>Giller</surname><given-names>C.</given-names></name><name><surname>Dewey</surname><given-names>R. B.</given-names></name></person-group> (<year>2003</year>). <article-title>Tremor response to polarity, voltage, pulsewidth and frequency of thalamic stimulation</article-title>. <source>Neurology</source>
<volume>60</volume>, <fpage>786</fpage>&#x02013;<lpage>790</lpage>. <pub-id pub-id-type="doi">10.1212/01.WNL.0000044156.56643.74</pub-id><?supplied-pmid 12629234?><pub-id pub-id-type="pmid">12629234</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozden</surname><given-names>I.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>May</surname><given-names>T.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Goo</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>A coaxial optrode as multifunction write-read probe for optogenetic studies in non-human primates</article-title>. <source>J. Neurosci. Methods</source>
<volume>219</volume>, <fpage>142</fpage>&#x02013;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2013.06.011</pub-id><?supplied-pmid 23867081?><pub-id pub-id-type="pmid">23867081</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penrod</surname><given-names>R. D.</given-names></name><name><surname>Wells</surname><given-names>A. M.</given-names></name><name><surname>Carlezon</surname><given-names>W. A.</given-names></name><name><surname>Cowan</surname><given-names>C. W.</given-names></name></person-group> (<year>2015</year>). <article-title>Use of adeno-associated and herpes simplex viral vectors for <italic>in vivo</italic> neuronal expression in mice</article-title>. <source>Curr. Protoc. Neurosci.</source>
<volume>73</volume>, <fpage>4.37.1</fpage>&#x02013;<lpage>4.37.31</lpage>. <pub-id pub-id-type="doi">10.1002/0471142301.ns0437s73</pub-id><?supplied-pmid 26426386?><pub-id pub-id-type="pmid">26426386</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perny</surname><given-names>M.</given-names></name><name><surname>Muri</surname><given-names>L.</given-names></name><name><surname>Dawson</surname><given-names>H.</given-names></name><name><surname>Kleinlogel</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Chronic activation of the D156a point mutant of Channelrhodopsin-2 signals apoptotic cell death: the good and the bad</article-title>. <source>Cell Death Dis.</source>
<volume>7</volume>:<fpage>e2447</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2016.351</pub-id><?supplied-pmid 27809305?><pub-id pub-id-type="pmid">27809305</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisanello</surname><given-names>F.</given-names></name><name><surname>Mandelbaum</surname><given-names>G.</given-names></name><name><surname>Pisanello</surname><given-names>M.</given-names></name><name><surname>Oldenburg</surname><given-names>I. A.</given-names></name><name><surname>Sileo</surname><given-names>L.</given-names></name><name><surname>Markowitz</surname><given-names>J. E.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Dynamic illumination of spatially restricted or large brain volumes via a single tapered optical fiber</article-title>. <source>Nat. Neurosci.</source>
<volume>20</volume>, <fpage>1180</fpage>&#x02013;<lpage>1188</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4591</pub-id><?supplied-pmid 28628101?><pub-id pub-id-type="pmid">28628101</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisanello</surname><given-names>F.</given-names></name><name><surname>Sileo</surname><given-names>L.</given-names></name><name><surname>De Vittorio</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Micro- and nanotechnologies for optical neural interfaces</article-title>. <source>Front. Neurosci.</source>
<volume>10</volume>:<fpage>70</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2016.00070</pub-id><pub-id pub-id-type="pmid">27013939</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prodanov</surname><given-names>D.</given-names></name><name><surname>Delbeke</surname><given-names>J.</given-names></name></person-group> (<year>2016a</year>). <article-title>Mechanical and biological interactions of implants with the brain and their impact on implant design</article-title>. <source>Front. Neurosci.</source>
<volume>10</volume>:<fpage>11</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2016.00011</pub-id><?supplied-pmid 26903786?><pub-id pub-id-type="pmid">26903786</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prodanov</surname><given-names>D.</given-names></name><name><surname>Delbeke</surname><given-names>J.</given-names></name></person-group> (<year>2016b</year>). <article-title>A model of space-fractional-order diffusion in the glial scar</article-title>. <source>J. Theor. Biol.</source>
<volume>403</volume>, <fpage>97</fpage>&#x02013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtbi.2016.04.031</pub-id><?supplied-pmid 27179458?><pub-id pub-id-type="pmid">27179458</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qing</surname><given-names>K.</given-names></name><name><surname>Mah</surname><given-names>C.</given-names></name><name><surname>Hansen</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Dwarki</surname><given-names>V.</given-names></name><name><surname>Srivastava</surname><given-names>A.</given-names></name></person-group> (<year>1999</year>). <article-title>Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2</article-title>. <source>Nat. Med.</source>
<volume>5</volume>, <fpage>71</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1038/8526</pub-id><?supplied-pmid 9883842?><pub-id pub-id-type="pmid">9883842</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabinowitz</surname><given-names>J. E.</given-names></name><name><surname>Rolling</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Conrath</surname><given-names>H.</given-names></name><name><surname>Xiao</surname><given-names>W.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Cross-packaging of a single adeno-associated virus (aav) type 2 vector genome into multiple aav serotypes enables transduction with broad specificity</article-title>. <source>J. Virol.</source>
<volume>76</volume>, <fpage>791</fpage>&#x02013;<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.76.2.791-801.2002</pub-id><?supplied-pmid 11752169?><pub-id pub-id-type="pmid">11752169</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajguru</surname><given-names>S. M.</given-names></name><name><surname>Matic</surname><given-names>A. I.</given-names></name><name><surname>Robinson</surname><given-names>A. M.</given-names></name><name><surname>Fishman</surname><given-names>A. J.</given-names></name><name><surname>Moreno</surname><given-names>L. E.</given-names></name><name><surname>Bradley</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Optical cochlear implants: evaluation of surgical approach and laser parameters in cats</article-title>. <source>Hear. Res.</source>
<volume>269</volume>, <fpage>102</fpage>&#x02013;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/j.heares.2010.06.021</pub-id><?supplied-pmid 20603207?><pub-id pub-id-type="pmid">20603207</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranck</surname><given-names>J. B.</given-names><suffix>Jr.</suffix></name></person-group> (<year>1975</year>). <article-title>Which elements are excited in electrical stimulation of mammalian central nervous system: a review</article-title>. <source>Brain Res.</source>
<volume>98</volume>, <fpage>417</fpage>&#x02013;<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1016/0006-8993(75)90364-9</pub-id><?supplied-pmid 1102064?><pub-id pub-id-type="pmid">1102064</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>R. T.</given-names></name><name><surname>Thompson</surname><given-names>A. C.</given-names></name><name><surname>Wise</surname><given-names>A. K.</given-names></name><name><surname>Needham</surname><given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>Challenges for the application of optical stimulation in the cochlea for the study and treatment of hearing loss</article-title>. <source>Exp. Opin. Biol. Ther.</source>
<volume>17</volume>, <fpage>213</fpage>&#x02013;<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1080/14712598.2017.1271870</pub-id><?supplied-pmid 27960585?><pub-id pub-id-type="pmid">27960585</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>V. M.</given-names></name><name><surname>Gao</surname><given-names>G.-P.</given-names></name><name><surname>Grant</surname><given-names>R. L.</given-names></name><name><surname>Schnell</surname><given-names>M. A.</given-names></name><name><surname>Zoltick</surname><given-names>P. W.</given-names></name><name><surname>Rozamus</surname><given-names>L. W.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Long-term pharmacologically regulated expression of erythropoietin in primates following aav-mediated gene transfer</article-title>. <source>Blood</source>
<volume>105</volume>, <fpage>1424</fpage>&#x02013;<lpage>1430</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2004-06-2501</pub-id><?supplied-pmid 15507527?><pub-id pub-id-type="pmid">15507527</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>C. J. D.</given-names></name><name><surname>Twisk</surname><given-names>J.</given-names></name><name><surname>Bakker</surname><given-names>A. C.</given-names></name><name><surname>Miao</surname><given-names>F.</given-names></name><name><surname>Verbart</surname><given-names>D.</given-names></name><name><surname>Rip</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation</article-title>. <source>Hum. Gene. Ther.</source>
<volume>17</volume>, <fpage>487</fpage>&#x02013;<lpage>499</lpage>. <pub-id pub-id-type="doi">10.1089/hum.2006.17.487</pub-id><?supplied-pmid 16716106?><pub-id pub-id-type="pmid">16716106</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>M. A.</given-names></name><name><surname>Go</surname><given-names>V.</given-names></name><name><surname>Murphy</surname><given-names>T.</given-names></name><name><surname>Fu</surname><given-names>Q.</given-names></name><name><surname>Morizio</surname><given-names>J.</given-names></name><name><surname>Yin</surname><given-names>H.</given-names></name></person-group> (<year>2015</year>). <article-title>A wirelessly controlled implantable LED system for deep brain optogenetic stimulation</article-title>. <source>Front. Integr. Neurosci.</source>
<volume>9</volume>:<fpage>8</fpage>. <pub-id pub-id-type="doi">10.3389/fnint.2015.00008</pub-id><?supplied-pmid 25713516?><pub-id pub-id-type="pmid">25713516</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>P. J.</given-names></name><name><surname>Gunduz</surname><given-names>A.</given-names></name><name><surname>Judy</surname><given-names>J.</given-names></name><name><surname>Wilson</surname><given-names>L.</given-names></name><name><surname>Machado</surname><given-names>A.</given-names></name><name><surname>Giordano</surname><given-names>J. J.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies</article-title>. <source>Front. Neurosci.</source>
<volume>10</volume>:<fpage>119</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2016.00119</pub-id><?supplied-pmid 27092042?><pub-id pub-id-type="pmid">27092042</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubehn</surname><given-names>B.</given-names></name><name><surname>Wolff</surname><given-names>S. B.</given-names></name><name><surname>Tovote</surname><given-names>P.</given-names></name><name><surname>Luthi</surname><given-names>A.</given-names></name><name><surname>Stieglitz</surname><given-names>T.</given-names></name></person-group> (<year>2013</year>). <article-title>A polymer-based neural microimplant for optogenetic applications: design and first <italic>in vivo</italic> study</article-title>. <source>Lab Chip.</source>
<volume>13</volume>, <fpage>579</fpage>&#x02013;<lpage>588</lpage>. <pub-id pub-id-type="doi">10.1039/c2lc40874k</pub-id><?supplied-pmid 23306183?><pub-id pub-id-type="pmid">23306183</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salanova</surname><given-names>V.</given-names></name><name><surname>Witt</surname><given-names>T.</given-names></name><name><surname>Worth</surname><given-names>R.</given-names></name><name><surname>Henry</surname><given-names>T. R.</given-names></name><name><surname>Gross</surname><given-names>R. E.</given-names></name><name><surname>Nazzaro</surname><given-names>J. M.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy</article-title>. <source>Neurology</source>
<volume>84</volume>, <fpage>1017</fpage>&#x02013;<lpage>1025</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000001334</pub-id><?supplied-pmid 25663221?><pub-id pub-id-type="pmid">25663221</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salinas</surname><given-names>F.</given-names></name><name><surname>Rojas</surname><given-names>V.</given-names></name><name><surname>Delgado</surname><given-names>V.</given-names></name><name><surname>Agosin</surname><given-names>E.</given-names></name><name><surname>Larrondo</surname><given-names>L. F.</given-names></name></person-group> (<year>2017</year>). <article-title>Optogenetic switches for light-controlled gene expression in yeast</article-title>. <source>Appl. Microb. Biotechnol</source>. <volume>101</volume>, <fpage>2629</fpage>&#x02013;<lpage>2640</lpage>. <pub-id pub-id-type="doi">10.1007/s00253-017-8178-8</pub-id><?supplied-pmid 28210796?><pub-id pub-id-type="pmid">28210796</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scallan</surname><given-names>C. D.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Patarroyo-White</surname><given-names>S.</given-names></name><name><surname>Sommer</surname><given-names>J. M.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Human immunoglobulin inhibits liver transduction byAAV vectors at low AAV2 neutralizing titers in SCID mice</article-title>. <source>Blood</source>
<volume>107</volume>, <fpage>1810</fpage>&#x02013;<lpage>1817</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2005-08-3229</pub-id><?supplied-pmid 16249376?><pub-id pub-id-type="pmid">16249376</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholl</surname><given-names>H. P.</given-names></name><name><surname>Strauss</surname><given-names>R. W.</given-names></name><name><surname>Singh</surname><given-names>M. S.</given-names></name><name><surname>Dalkara</surname><given-names>D.</given-names></name><name><surname>Roska</surname><given-names>B.</given-names></name><name><surname>Picaud</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Emerging therapies for inherited retinal degeneration</article-title>. <source>Sci. Transl. Med.</source>
<volume>8</volume>:<fpage>368r</fpage>v6. <pub-id pub-id-type="doi">10.1126/scitranslmed.aaf2838</pub-id><?supplied-pmid 27928030?><pub-id pub-id-type="pmid">27928030</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultheis</surname><given-names>C.</given-names></name><name><surname>Liewald</surname><given-names>J. F.</given-names></name><name><surname>Bamberg</surname><given-names>E.</given-names></name><name><surname>Nagel</surname><given-names>G.</given-names></name><name><surname>Gottschalk</surname><given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>Optogenetic long-term manipulation of behavior and animal development</article-title>. <source>PLoS ONE</source>
<volume>6</volume>:<fpage>e18766</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0018766</pub-id><?supplied-pmid 21533086?><pub-id pub-id-type="pmid">21533086</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segev</surname><given-names>E.</given-names></name><name><surname>Reimer</surname><given-names>J.</given-names></name><name><surname>Moreaux</surname><given-names>L. C.</given-names></name><name><surname>Fowler</surname><given-names>T. M.</given-names></name><name><surname>Chi</surname><given-names>D.</given-names></name><name><surname>Sacher</surname><given-names>W. D.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Patterned photostimulation via visible-wavelength photonic probes for deep brain optogenetics</article-title>. <source>Neurophotonics</source>
<volume>4</volume>:<fpage>011002</fpage>. <pub-id pub-id-type="doi">10.1117/1.NPh.4.1.011002</pub-id><?supplied-pmid 27990451?><pub-id pub-id-type="pmid">27990451</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>A.</given-names></name><name><surname>Chaffiol</surname><given-names>A.</given-names></name><name><surname>Mace</surname><given-names>E.</given-names></name><name><surname>Caplette</surname><given-names>R.</given-names></name><name><surname>Desrosiers</surname><given-names>M.</given-names></name><name><surname>Lampic</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Red-shifted channelrhodopsin stimulation restores light responses in blind mice, macaque retina, and human retina</article-title>. <source>EMBO Mol. Med.</source>
<volume>8</volume>, <fpage>1248</fpage>&#x02013;<lpage>1264</lpage>. <pub-id pub-id-type="doi">10.15252/emmm.201505699</pub-id><?supplied-pmid 27679671?><pub-id pub-id-type="pmid">27679671</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>M. G.</given-names></name><name><surname>Homma</surname><given-names>K.</given-names></name><name><surname>Villarreal</surname><given-names>S.</given-names></name><name><surname>Richter</surname><given-names>C.-P.</given-names></name><name><surname>Bezanilla</surname><given-names>F.</given-names></name></person-group> (<year>2012</year>). <article-title>Infrared light excites cells by changing their electrical capacitance</article-title>. <source>Nat. Commun.</source>
<volume>3</volume>:<fpage>736</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms1742</pub-id><?supplied-pmid 22415827?><pub-id pub-id-type="pmid">22415827</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shayakhmetov</surname><given-names>D. M.</given-names></name><name><surname>Di Paolo</surname><given-names>N. C.</given-names></name><name><surname>Mossman</surname><given-names>K. L.</given-names></name></person-group> (<year>2010</year>). <article-title>Recognition of virus infection and innate host responses to viral gene therapy vectors</article-title>. <source>Mol. Ther.</source>
<volume>18</volume>, <fpage>1422</fpage>&#x02013;<lpage>1429</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2010.124</pub-id><?supplied-pmid 20551916?><pub-id pub-id-type="pmid">20551916</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>S.</given-names></name><name><surname>Bryant</surname><given-names>K. D.</given-names></name><name><surname>Brown</surname><given-names>S. M.</given-names></name><name><surname>Randell</surname><given-names>S. H.</given-names></name><name><surname>Asokan</surname><given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>Terminal n-linked galactose is the primary receptor for adeno-associated virus 9</article-title>. <source>J. Biol. Chem.</source>
<volume>286</volume>, <fpage>13532</fpage>&#x02013;<lpage>13540</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.210922</pub-id><?supplied-pmid 21330365?><pub-id pub-id-type="pmid">21330365</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>D.</given-names></name><name><surname>Samoilova</surname><given-names>M.</given-names></name><name><surname>Cotic</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Brotchie</surname><given-names>J.</given-names></name><name><surname>Carlen</surname><given-names>P.</given-names></name></person-group> (<year>2007</year>). <article-title>High frequency stimulation or elevated K+ depresses neuronal activity in the rat entopeduncular nucleus</article-title>. <source>Neuroscience</source>
<volume>149</volume>, <fpage>68</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.06.055</pub-id><?supplied-pmid 17826920?><pub-id pub-id-type="pmid">17826920</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>Y.</given-names></name><name><surname>Yoo</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>H. S.</given-names></name><name><surname>Nam</surname><given-names>S. K.</given-names></name><name><surname>Kim</surname><given-names>H. I.</given-names></name><name><surname>Lee</surname><given-names>S. K.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Characterization of fiber-optic light delivery and light-induced temperature changes in a rodent brain for precise optogenetic neuromodulation</article-title>. <source>Biomed. Opt. Exp.</source>
<volume>7</volume>, <fpage>4450</fpage>&#x02013;<lpage>4471</lpage>. <pub-id pub-id-type="doi">10.1364/BOE.7.004450</pub-id><?supplied-pmid 27895987?><pub-id pub-id-type="pmid">27895987</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiri</surname><given-names>Z.</given-names></name><name><surname>L&#x000e9;vesque</surname><given-names>M.</given-names></name><name><surname>Etter</surname><given-names>G.</given-names></name><name><surname>Manseau</surname><given-names>F.</given-names></name><name><surname>Williams</surname><given-names>S.</given-names></name><name><surname>Avoli</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Optogenetic low-frequency stimulation of specific neuronal populations abates ictogenesis</article-title>. <source>J. Neurosci</source>. <volume>37</volume>, <fpage>2999</fpage>&#x02013;<lpage>3008</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2244-16.2017</pub-id><?supplied-pmid 28209738?><pub-id pub-id-type="pmid">28209738</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>S.</given-names></name><name><surname>Basser</surname><given-names>P. J.</given-names></name><name><surname>Miranda</surname><given-names>P. C.</given-names></name></person-group> (<year>2007</year>). <article-title>The activation function of TMS on a finite element model of a cortical sulcus</article-title>. <source>Conf. Proc. IEEE Eng. Med. Biol. Soc.</source>
<volume>2007</volume>, <fpage>6657</fpage>&#x02013;<lpage>6660</lpage>. <pub-id pub-id-type="doi">10.1109/IEMBS.2007.4353886</pub-id><?supplied-pmid 18003552?><pub-id pub-id-type="pmid">18003552</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinnen</surname><given-names>B. L.</given-names></name><name><surname>Bowen</surname><given-names>A. B.</given-names></name><name><surname>Forte</surname><given-names>J. S.</given-names></name><name><surname>Hiester</surname><given-names>B. G.</given-names></name><name><surname>Crosby</surname><given-names>K. C.</given-names></name><name><surname>Gibson</surname><given-names>E. S.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Optogenetic control of synaptic composition and function</article-title>. <source>Neuron</source>
<volume>93</volume>, <fpage>646</fpage>&#x02013;<lpage>660</lpage>.e5. <pub-id pub-id-type="doi">10.1016/j.neuron.2016.12.037</pub-id><?supplied-pmid 28132827?><pub-id pub-id-type="pmid">28132827</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sironi</surname><given-names>V. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Origin and evolution of deep brain stimulation</article-title>. <source>Front. Integr. Neurosci.</source>
<volume>5</volume>:<fpage>42</fpage>. <pub-id pub-id-type="doi">10.3389/fnint.2011.00042</pub-id><?supplied-pmid 21887135?><pub-id pub-id-type="pmid">21887135</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smedemark-Margulies</surname><given-names>N.</given-names></name><name><surname>Trapani</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>Tools, methods, and applications for optophysiology in neuroscience</article-title>. <source>Front. Mol. Neurosci.</source>
<volume>6</volume>:<fpage>18</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2013.00018</pub-id><?supplied-pmid 23882179?><pub-id pub-id-type="pmid">23882179</pub-id></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>R. H.</given-names></name></person-group> (<year>2008</year>). <article-title>Adeno-associated virus integration: virus versus vector</article-title>. <source>Gene Ther.</source>
<volume>15</volume>, <fpage>817</fpage>&#x02013;<lpage>822</lpage>. <pub-id pub-id-type="doi">10.1038/gt.2008.55</pub-id><?supplied-pmid 18401436?><pub-id pub-id-type="pmid">18401436</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soltan</surname><given-names>A.</given-names></name><name><surname>McGovern</surname><given-names>B.</given-names></name><name><surname>Drakakis</surname><given-names>E.</given-names></name><name><surname>Neil</surname><given-names>M.</given-names></name><name><surname>Maaskant</surname><given-names>P.</given-names></name><name><surname>Akhter</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>High density, high radiance &#x003bc;LED matrix for optogenetic retinal prostheses and planar neural stimulation</article-title>. <source>IEEE Trans. Biomed. circuits Syst</source>. <volume>11</volume>, <fpage>347</fpage>&#x02013;<lpage>359</lpage>. <pub-id pub-id-type="doi">10.1109/TBCAS.2016.2623949</pub-id><pub-id pub-id-type="pmid">28212099</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorokin</surname><given-names>J. M.</given-names></name><name><surname>Davidson</surname><given-names>T. J.</given-names></name><name><surname>Frechette</surname><given-names>E.</given-names></name><name><surname>Abramian</surname><given-names>A. M.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Bidirectional control of generalized epilepsy networks via rapid real-time switching of firing mode</article-title>. <source>Neuron</source>
<volume>93</volume>, <fpage>194</fpage>&#x02013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2016.11.026</pub-id><?supplied-pmid 27989462?><pub-id pub-id-type="pmid">27989462</pub-id></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>E.</given-names></name><name><surname>Koos</surname><given-names>T.</given-names></name><name><surname>Buzsaki</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Diode probes for spatiotemporal optical control of multiple neurons in freely moving animals</article-title>. <source>J. Neurophysiol.</source>
<volume>108</volume>, <fpage>349</fpage>&#x02013;<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00153.2012</pub-id><?supplied-pmid 22496529?><pub-id pub-id-type="pmid">22496529</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starr</surname><given-names>P. A.</given-names></name><name><surname>Vitek</surname><given-names>J. L.</given-names></name><name><surname>Bakay</surname><given-names>R. A.</given-names></name></person-group> (<year>1998</year>). <article-title>Ablative surgery and deep brain stimulation for parkinson's disease</article-title>. <source>Neurosurgery</source>
<volume>43</volume>, <fpage>989</fpage>&#x02013;<lpage>1013</lpage>. discussion: 1013&#x02013;1015. <pub-id pub-id-type="doi">10.1097/00006123-199811000-00001</pub-id><?supplied-pmid 9802843?><pub-id pub-id-type="pmid">9802843</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stensaas</surname><given-names>S. S.</given-names></name><name><surname>Stensaas</surname><given-names>L. J.</given-names></name></person-group> (<year>1976</year>). <article-title>The reaction of the cerebral cortex to chronically implanted plastic needles</article-title>. <source>Acta Neuropathol.</source>
<volume>35</volume>, <fpage>187</fpage>&#x02013;<lpage>203</lpage>. <?supplied-pmid 782142?><pub-id pub-id-type="pmid">782142</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephanova</surname><given-names>D. I.</given-names></name><name><surname>Bostock</surname><given-names>H.</given-names></name></person-group> (<year>1995</year>). <article-title>A distributed-parameter model of the myelinated human motor nerve fibre: temporal and spatial distributions of action potentials and ionic currents</article-title>. <source>Biol. Cybern.</source>
<volume>73</volume>, <fpage>275</fpage>&#x02013;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1007/BF00201429</pub-id><?supplied-pmid 7548315?><pub-id pub-id-type="pmid">7548315</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stujenske</surname><given-names>J. M.</given-names></name><name><surname>Spellman</surname><given-names>T.</given-names></name><name><surname>Gordon</surname><given-names>J. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Modeling the spatiotemporal dynamics of light and heat propagation for <italic>in vivo</italic> optogenetics</article-title>. <source>Cell Rep.</source>
<volume>12</volume>, <fpage>525</fpage>&#x02013;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2015.06.036</pub-id><?supplied-pmid 26166563?><pub-id pub-id-type="pmid">26166563</pub-id></mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Summerford</surname><given-names>C.</given-names></name><name><surname>Samulski</surname><given-names>R. J.</given-names></name></person-group> (<year>1998</year>). <article-title>Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions</article-title>. <source>J. Virol.</source>
<volume>72</volume>, <fpage>1438</fpage>&#x02013;<lpage>1445</lpage>. <?supplied-pmid 9445046?><pub-id pub-id-type="pmid">9445046</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>G.-R.</given-names></name><name><surname>Kong</surname><given-names>L.</given-names></name><name><surname>Holmes</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Correction of a rat model of parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector</article-title>. <source>Hum. Gene Ther.</source>
<volume>14</volume>, <fpage>415</fpage>&#x02013;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.1089/104303403321467180</pub-id><?supplied-pmid 12691607?><pub-id pub-id-type="pmid">12691607</pub-id></mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutton</surname><given-names>A. C.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Calos</surname><given-names>M. E.</given-names></name><name><surname>Mueller</surname><given-names>L. E.</given-names></name><name><surname>Berk</surname><given-names>M.</given-names></name><name><surname>Shim</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat</article-title>. <source>Eur. J. Neurosci.</source>
<volume>37</volume>, <fpage>231</fpage>&#x02013;<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1111/ejn.12040</pub-id><?supplied-pmid 23121286?><pub-id pub-id-type="pmid">23121286</pub-id></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tass</surname><given-names>P. A.</given-names></name><name><surname>Qin</surname><given-names>L.</given-names></name><name><surname>Hauptmann</surname><given-names>C.</given-names></name><name><surname>Dovero</surname><given-names>S.</given-names></name><name><surname>Bezard</surname><given-names>E.</given-names></name><name><surname>Boraud</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Coordinated reset has sustained aftereffects in parkinsonian monkeys</article-title>. <source>Ann. Neurol.</source>
<volume>72</volume>, <fpage>816</fpage>&#x02013;<lpage>820</lpage>. <pub-id pub-id-type="doi">10.1002/ana.23663</pub-id><?supplied-pmid 23280797?><pub-id pub-id-type="pmid">23280797</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Smith</surname><given-names>J. S.</given-names></name><name><surname>Hofherr</surname><given-names>S. E.</given-names></name><name><surname>Barry</surname><given-names>M. A.</given-names></name><name><surname>Byrnes</surname><given-names>A. P.</given-names></name></person-group> (<year>2009</year>). <article-title>Adenovirus activates complement by distinctly different mechanisms <italic>in vitro</italic> and <italic>in vivo</italic>: indirect complement activation by virions <italic>in vivo</italic></article-title>. <source>J. Virol.</source>
<volume>83</volume>, <fpage>5648</fpage>&#x02013;<lpage>5658</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00082-09</pub-id><?supplied-pmid 19321608?><pub-id pub-id-type="pmid">19321608</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toromanoff</surname><given-names>A.</given-names></name><name><surname>Adjali</surname><given-names>O.</given-names></name><name><surname>Larcher</surname><given-names>T.</given-names></name><name><surname>Hill</surname><given-names>M.</given-names></name><name><surname>Guigand</surname><given-names>L.</given-names></name><name><surname>Chenuaud</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle</article-title>. <source>Mol. Ther.</source>
<volume>18</volume>, <fpage>151</fpage>&#x02013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2009.251</pub-id><?supplied-pmid 19888197?><pub-id pub-id-type="pmid">19888197</pub-id></mixed-citation></ref><ref id="B209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Towne</surname><given-names>C.</given-names></name><name><surname>Thompson</surname><given-names>K. R.</given-names></name></person-group> (<year>2016</year>). <article-title>Overview on research and clinical applications of optogenetics</article-title>. <source>Curr. Protoc. Pharmacol.</source>
<volume>75</volume>, <fpage>11.19.1</fpage>&#x02013;<lpage>11.19.21</lpage>. <pub-id pub-id-type="doi">10.1002/cpph.13</pub-id><?supplied-pmid 27960028?><pub-id pub-id-type="pmid">27960028</pub-id></mixed-citation></ref><ref id="B210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>J. N.</given-names></name><name><surname>Shain</surname><given-names>W.</given-names></name><name><surname>Szarowski</surname><given-names>D. H.</given-names></name><name><surname>Andersen</surname><given-names>M.</given-names></name><name><surname>Martins</surname><given-names>S.</given-names></name><name><surname>Isaacson</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>1999</year>). <article-title>Cerebral astrocyte response to micromachined silicon implants</article-title>. <source>Exp. Neurol.</source>
<volume>156</volume>, <fpage>33</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1006/exnr.1998.6983</pub-id><?supplied-pmid 10192775?><pub-id pub-id-type="pmid">10192775</pub-id></mixed-citation></ref><ref id="B211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valon</surname><given-names>L.</given-names></name><name><surname>Mar&#x000ed;n-Llaurad&#x000f3;</surname><given-names>A.</given-names></name><name><surname>Wyatt</surname><given-names>T.</given-names></name><name><surname>Charras</surname><given-names>G.</given-names></name><name><surname>Trepat</surname><given-names>X.</given-names></name></person-group> (<year>2017</year>). <article-title>Optogenetic control of cellular forces and mechanotransduction</article-title>. <source>Nat. Commun.</source>
<volume>8</volume>:<fpage>14396</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms14396</pub-id><?supplied-pmid 28186127?><pub-id pub-id-type="pmid">28186127</pub-id></mixed-citation></ref><ref id="B212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valtcheva</surname><given-names>M.</given-names></name><name><surname>Copits</surname><given-names>B. A.</given-names></name><name><surname>Davidson</surname><given-names>S.</given-names></name><name><surname>Sheahan</surname><given-names>T. D.</given-names></name><name><surname>Pullen</surname><given-names>M. Y.</given-names></name><name><surname>McCall</surname><given-names>J. M.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Surgical extraction of human dorsal root ganglia from organ donors and preparation of primary sensory neuron cultures</article-title>. <source>Nat. Protoc.</source>
<volume>11</volume>, <fpage>1877</fpage>&#x02013;<lpage>1888</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2016.111</pub-id><?supplied-pmid 27606776?><pub-id pub-id-type="pmid">27606776</pub-id></mixed-citation></ref><ref id="B213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkataramani</surname><given-names>S.</given-names></name><name><surname>Davitt</surname><given-names>K. M.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>Y. K.</given-names></name><name><surname>Connors</surname><given-names>B. W.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Semiconductor ultra-violet light-emitting diodes for flash photolysis</article-title>. <source>J. Neurosci. Methods</source>
<volume>160</volume>, <fpage>5</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2006.08.004</pub-id><?supplied-pmid 17000008?><pub-id pub-id-type="pmid">17000008</pub-id></mixed-citation></ref><ref id="B214"><mixed-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Vo-Dinh</surname><given-names>T.</given-names></name></person-group> (ed.). (<year>2003</year>). <source>Biomedical Photonics Handbook</source>, <volume>vol. 9</volume>
<publisher-name>CRC Press</publisher-name>.</mixed-citation></ref><ref id="B215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkmann</surname><given-names>J.</given-names></name><name><surname>Herzog</surname><given-names>J.</given-names></name><name><surname>Kopper</surname><given-names>F.</given-names></name><name><surname>Geuschl</surname><given-names>G.</given-names></name></person-group> (<year>2002</year>). <article-title>Introduction to the programming of deep brain stimulators</article-title>. <source>Mov. Disord.</source>
<volume>17</volume> (<issue>Suppl. 3</issue>), <fpage>S181</fpage>&#x02013;<lpage>S187</lpage>. <pub-id pub-id-type="doi">10.1002/mds.10162</pub-id><?supplied-pmid 11948775?><pub-id pub-id-type="pmid">11948775</pub-id></mixed-citation></ref><ref id="B216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>A. J.</given-names></name><name><surname>Tolstykh</surname><given-names>G. P.</given-names></name><name><surname>Martens</surname><given-names>S.</given-names></name><name><surname>Ibey</surname><given-names>B. L.</given-names></name><name><surname>Beier</surname><given-names>H. T.</given-names></name></person-group> (<year>2016</year>). <article-title>Action potential block in neurons by infrared light</article-title>. <source>Neurophotonics</source>
<volume>3</volume>:<fpage>040501</fpage>. <pub-id pub-id-type="doi">10.1117/1.NPh.3.4.040501</pub-id><?supplied-pmid 27990450?><pub-id pub-id-type="pmid">27990450</pub-id></mixed-citation></ref><ref id="B217"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>R. W.</given-names></name><name><surname>Yi</surname><given-names>S. M.</given-names></name><name><surname>Keshavjee</surname><given-names>S.</given-names></name><name><surname>Brown</surname><given-names>K. E.</given-names></name><name><surname>Welsh</surname><given-names>M. J.</given-names></name><name><surname>Chiorini</surname><given-names>J. A.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer</article-title>. <source>J. Biol. Chem.</source>
<volume>276</volume>, <fpage>20610</fpage>&#x02013;<lpage>20616</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M101559200</pub-id><?supplied-pmid 11262413?><pub-id pub-id-type="pmid">11262413</pub-id></mixed-citation></ref><ref id="B218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Peca</surname><given-names>J.</given-names></name><name><surname>Matsuzaki</surname><given-names>M.</given-names></name><name><surname>Matsuzaki</surname><given-names>K.</given-names></name><name><surname>Noguchi</surname><given-names>J.</given-names></name><name><surname>Qiu</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>High-speed mapping of synaptic connectivity using photostimulation in Channelrhodopsin-2 transgenic mice</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>104</volume>, <fpage>8143</fpage>&#x02013;<lpage>8148</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0700384104</pub-id><?supplied-pmid 17483470?><pub-id pub-id-type="pmid">17483470</pub-id></mixed-citation></ref><ref id="B219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wagner</surname><given-names>F.</given-names></name><name><surname>Borton</surname><given-names>D. A.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Ozden</surname><given-names>I.</given-names></name><name><surname>Burwell</surname><given-names>R. D.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Integrated device for combined optical neuromodulation and electrical recording for chronic <italic>in vivo</italic> applications</article-title>. <source>J. Neural Eng.</source>
<volume>9</volume>, <fpage>2</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1088/1741-2560/9/1/016001</pub-id><?supplied-pmid 22156042?><pub-id pub-id-type="pmid">22156042</pub-id></mixed-citation></ref><ref id="B220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Kugelman</surname><given-names>T.</given-names></name><name><surname>Buch</surname><given-names>A.</given-names></name><name><surname>Herman</surname><given-names>M.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Karakatsani</surname><given-names>M. E.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Non-invasive, focused ultrasound-facilitated gene delivery for optogenetics</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>:<fpage>39955</fpage>. <pub-id pub-id-type="doi">10.1038/srep39955</pub-id><?supplied-pmid 28059117?><pub-id pub-id-type="pmid">28059117</pub-id></mixed-citation></ref><ref id="B221"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weible</surname><given-names>A. P.</given-names></name><name><surname>Piscopo</surname><given-names>D. M.</given-names></name><name><surname>Rothbart</surname><given-names>M. K.</given-names></name><name><surname>Posner</surname><given-names>M. I.</given-names></name><name><surname>Niell</surname><given-names>C. M.</given-names></name></person-group> (<year>2017</year>). <article-title>Rhythmic brain stimulation reduces anxiety-related behavior in a mouse model based on meditation training</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>114</volume>, <fpage>2532</fpage>&#x02013;<lpage>2537</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1700756114</pub-id><?supplied-pmid 28223484?><pub-id pub-id-type="pmid">28223484</pub-id></mixed-citation></ref><ref id="B222"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weitzman</surname><given-names>M. D.</given-names></name><name><surname>Linden</surname><given-names>R. M.</given-names></name></person-group> (<year>2011</year>). <article-title>Adeno-associated virus biology</article-title>. <source>Adeno Associated Virus</source>. <volume>807</volume>, <fpage>1</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-61779-370-7_1</pub-id><?supplied-pmid 22034024?><pub-id pub-id-type="pmid">22034024</pub-id></mixed-citation></ref><ref id="B223"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weller</surname><given-names>M. L.</given-names></name><name><surname>Amornphimoltham</surname><given-names>P.</given-names></name><name><surname>Schmidt</surname><given-names>M.</given-names></name><name><surname>Wilson</surname><given-names>P. A.</given-names></name><name><surname>Gutkind</surname><given-names>J. S.</given-names></name><name><surname>Chiorini</surname><given-names>J. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6</article-title>. <source>Nat. Med.</source>
<volume>16</volume>, <fpage>662</fpage>&#x02013;<lpage>664</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2145</pub-id><?supplied-pmid 20473307?><pub-id pub-id-type="pmid">20473307</pub-id></mixed-citation></ref><ref id="B224"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wietek</surname><given-names>J.</given-names></name><name><surname>Prigge</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Enhancing channelrhodopsins: an overview</article-title>. <source>Methods Mol. Biol.</source>
<volume>1408</volume>, <fpage>141</fpage>&#x02013;<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-3512-3_10</pub-id><?supplied-pmid 26965121?><pub-id pub-id-type="pmid">26965121</pub-id></mixed-citation></ref><ref id="B225"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witt</surname><given-names>A.</given-names></name><name><surname>Palmigiano</surname><given-names>A.</given-names></name><name><surname>Neef</surname><given-names>A.</given-names></name><name><surname>El Hady</surname><given-names>A.</given-names></name><name><surname>Wolf</surname><given-names>F.</given-names></name><name><surname>Battaglia</surname><given-names>D.</given-names></name></person-group> (<year>2013</year>). <article-title>Controlling the oscillation phase through precisely timed closed-loop optogenetic stimulation: a computational study</article-title>. <source>Front. Neural Circuits</source>
<volume>7</volume>:<fpage>49</fpage>. <pub-id pub-id-type="doi">10.3389/fncir.2013.00049</pub-id><?supplied-pmid 23616748?><pub-id pub-id-type="pmid">23616748</pub-id></mixed-citation></ref><ref id="B226"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>N.</given-names></name><name><surname>Watkins</surname><given-names>S. C.</given-names></name><name><surname>Schaffer</surname><given-names>P. A.</given-names></name><name><surname>DeLuca</surname><given-names>N. A.</given-names></name></person-group> (<year>1996</year>). <article-title>Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding icp4, icp27, and icp22</article-title>. <source>J. Virol.</source>
<volume>70</volume>, <fpage>6358</fpage>&#x02013;<lpage>6369</lpage>. <?supplied-pmid 8709264?><pub-id pub-id-type="pmid">8709264</pub-id></mixed-citation></ref><ref id="B227"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Miller</surname><given-names>E.</given-names></name><name><surname>Agbandje-McKenna</surname><given-names>M.</given-names></name><name><surname>Samulski</surname><given-names>R. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Alpha2,3 and alpha2,6 n-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6</article-title>. <source>J. Virol.</source>
<volume>80</volume>, <fpage>9093</fpage>&#x02013;<lpage>9103</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00895-06</pub-id><?supplied-pmid 16940521?><pub-id pub-id-type="pmid">16940521</pub-id></mixed-citation></ref><ref id="B228"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wykes</surname><given-names>R. C.</given-names></name><name><surname>Kullmann</surname><given-names>D. M.</given-names></name><name><surname>Pavlov</surname><given-names>I.</given-names></name><name><surname>Magloire</surname><given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Optogenetic approaches to treat epilepsy</article-title>. <source>J. Neuroscie. Methods</source>
<volume>260</volume>, <fpage>215</fpage>&#x02013;<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2015.06.004</pub-id><?supplied-pmid 26072246?><pub-id pub-id-type="pmid">26072246</pub-id></mixed-citation></ref><ref id="B229"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>W.</given-names></name><name><surname>Chirmule</surname><given-names>N.</given-names></name><name><surname>Berta</surname><given-names>S. C.</given-names></name><name><surname>McCullough</surname><given-names>B.</given-names></name><name><surname>Gao</surname><given-names>G.</given-names></name><name><surname>Wilson</surname><given-names>J. M.</given-names></name></person-group> (<year>1999</year>). <article-title>Gene therapy vectors based on adeno-associated virus type 1</article-title>. <source>J. Virol.</source>
<volume>73</volume>, <fpage>3994</fpage>&#x02013;<lpage>4003</lpage>. <?supplied-pmid 10196295?><pub-id pub-id-type="pmid">10196295</pub-id></mixed-citation></ref><ref id="B230"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Smith</surname><given-names>J. S.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Byrnes</surname><given-names>A. P.</given-names></name></person-group> (<year>2010</year>). <article-title>Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor</article-title>. <source>Mol. Ther.</source>
<volume>18</volume>, <fpage>609</fpage>&#x02013;<lpage>616</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2009.279</pub-id><?supplied-pmid 19953082?><pub-id pub-id-type="pmid">19953082</pub-id></mixed-citation></ref><ref id="B231"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Entorhinal principal neurons mediate brain-stimulation treatments for epilepsy</article-title>. <source>EBioMedicine</source>
<volume>14</volume>, <fpage>148</fpage>&#x02013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2016.11.027</pub-id><?supplied-pmid 27908611?><pub-id pub-id-type="pmid">27908611</pub-id></mixed-citation></ref><ref id="B232"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Cumberbatch</surname><given-names>D.</given-names></name><name><surname>Centanni</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>S. Q.</given-names></name><name><surname>Winder</surname><given-names>D.</given-names></name><name><surname>Webb</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Coupling optogenetic stimulation with NanoLuc-based luminescence (BRET) Ca(++) sensing</article-title>. <source>Nat. Commun.</source>
<volume>7</volume>:<fpage>13268</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms13268</pub-id><?supplied-pmid 27786307?><pub-id pub-id-type="pmid">27786307</pub-id></mixed-citation></ref><ref id="B233"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yekhlef</surname><given-names>L.</given-names></name><name><surname>Breschi</surname><given-names>G. L.</given-names></name><name><surname>Taverna</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Optogenetic activation of VGLUT2-expressing excitatory neurons blocks epileptic seizure-like activity in the mouse entorhinal cortex</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>:<fpage>43230</fpage>. <pub-id pub-id-type="doi">10.1038/srep43230</pub-id><?supplied-pmid 28230208?><pub-id pub-id-type="pmid">28230208</pub-id></mixed-citation></ref><ref id="B234"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yizhar</surname><given-names>O.</given-names></name><name><surname>Fenno</surname><given-names>L. E.</given-names></name><name><surname>Davidson</surname><given-names>T. J.</given-names></name><name><surname>Mogri</surname><given-names>M.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group> (<year>2011</year>). <article-title>Optogenetics in neural systems</article-title>. <source>Neuron</source>
<volume>71</volume>, <fpage>9</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2011.06.004</pub-id><?supplied-pmid 21745635?><pub-id pub-id-type="pmid">21745635</pub-id></mixed-citation></ref><ref id="B235"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>H. H.</given-names></name><name><surname>Min</surname><given-names>J.</given-names></name><name><surname>Hwang</surname><given-names>E.</given-names></name><name><surname>Lee</surname><given-names>C. J.</given-names></name><name><surname>Suh</surname><given-names>J. K.</given-names></name><name><surname>Hwang</surname><given-names>O.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Optogenetic inhibition of the subthalamic nucleus reduces levodopa-induced dyskinesias in a rat model of Parkinson's disease</article-title>. <source>Stereotact. Funct. Neurosurg.</source>
<volume>94</volume>, <fpage>41</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1159/000442891</pub-id><?supplied-pmid 26962855?><pub-id pub-id-type="pmid">26962855</pub-id></mixed-citation></ref><ref id="B236"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>H. H.</given-names></name><name><surname>Park</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>Y. H.</given-names></name><name><surname>Min</surname><given-names>J.</given-names></name><name><surname>Hwang</surname><given-names>E.</given-names></name><name><surname>Lee</surname><given-names>C. J.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Optogenetic inactivation of the subthalamic nucleus improves forelimb akinesia in a rat model of Parkinson disease</article-title>. <source>Neurosurgery</source>
<volume>74</volume>, <fpage>533</fpage>&#x02013;<lpage>541</lpage>. <pub-id pub-id-type="doi">10.1227/NEU.0000000000000297</pub-id><?supplied-pmid 24463495?><pub-id pub-id-type="pmid">24463495</pub-id></mixed-citation></ref><ref id="B237"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname><given-names>S. H.</given-names></name><name><surname>Kwok</surname><given-names>S. J. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Light in diagnosis, therapy and surgery</article-title>. <source>Nat. Biomed. Eng.</source>
<volume>1</volume>:<fpage>0008</fpage>. <?supplied-pmid 28649464?><pub-id pub-id-type="pmid">28649464</pub-id></mixed-citation></ref><ref id="B238"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G. R.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>T.</given-names></name><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2000</year>). <article-title>A tyrosine hydroxylase-neurofilament chimeric promoter enhances long-term expression in rat forebrain neurons from helper virus-free hsv-1 vectors</article-title>. <source>Brain Res.</source>
<volume>84</volume>, <fpage>17</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/S0169-328X(00)00197-2</pub-id><?supplied-pmid 11113528?><pub-id pub-id-type="pmid">11113528</pub-id></mixed-citation></ref><ref id="B239"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.-P.</given-names></name><name><surname>Oertner</surname><given-names>T. G.</given-names></name></person-group> (<year>2007</year>). <article-title>Optical induction of synaptic plasticity using a light-sensitive channel</article-title>. <source>Nat. Methods</source>
<volume>4</volume>, <fpage>139</fpage>&#x02013;<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth988</pub-id><?supplied-pmid 17195846?><pub-id pub-id-type="pmid">17195846</pub-id></mixed-citation></ref><ref id="B240"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>D. R.</given-names></name><name><surname>Dours-Zimmermann</surname><given-names>M. T.</given-names></name></person-group> (<year>2008</year>). <article-title>Extracellular matrix of the central nervous system: from neglect to challenge</article-title>. <source>Histochem. Cell Biol.</source>
<volume>130</volume>, <fpage>635</fpage>&#x02013;<lpage>653</lpage>. <pub-id pub-id-type="doi">10.1007/s00418-008-0485-9</pub-id><?supplied-pmid 18696101?><pub-id pub-id-type="pmid">18696101</pub-id></mixed-citation></ref><ref id="B241"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zorzos</surname><given-names>A. N.</given-names></name><name><surname>Boyden</surname><given-names>E. S.</given-names></name><name><surname>Fonstad</surname><given-names>C. G.</given-names></name></person-group> (<year>2010</year>). <article-title>Multiwaveguide implantable probe for light delivery to sets of distributed brain targets</article-title>. <source>Opt. Lett.</source>
<volume>35</volume>, <fpage>4133</fpage>&#x02013;<lpage>4135</lpage>. <pub-id pub-id-type="doi">10.1364/OL.35.004133</pub-id><?supplied-pmid 21165114?><pub-id pub-id-type="pmid">21165114</pub-id></mixed-citation></ref><ref id="B242"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zrenner</surname><given-names>C.</given-names></name><name><surname>Belardinelli</surname><given-names>P.</given-names></name><name><surname>M&#x000fc;ller-Dahlhaus</surname><given-names>F.</given-names></name><name><surname>Ziemann</surname><given-names>U.</given-names></name></person-group> (<year>2016</year>). <article-title>Closed-loop neuroscience and non-invasive brain stimulation: a tale of two loops</article-title>. <source>Front. Cell. Neurosci.</source>
<volume>10</volume>:<fpage>92</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2016.00092</pub-id><?supplied-pmid 27092055?><pub-id pub-id-type="pmid">27092055</pub-id></mixed-citation></ref></ref-list></back></article>